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Abstract 
  
Breast cancer (BC) is the most frequently diagnosed cancer and a leading cause of 
death among women worldwide. Early BC is potentially curable, nevertheless, the 
mortality rates still observed among BC patients, demonstrates the urgent need of 
novel and more effective diagnostic and therapeutic options.  
Limitless self-renewal is a hallmark of cancer governed by telomere maintenance. In 
around 95% of BC cases, this process is achieved by telomerase reactivation through 
upregulation of human Telomerase Reverse Transcriptase (hTERT). The 
hypermethylation of a specific region within hTERT promoter, termed TERT 
Hypermethylated Oncological Region (THOR) has been associated with increased 
hTERT expression in cancer. However, its biological role and clinical potential in BC 
has never been studied. Therefore, we aimed to investigate the role of THOR as a 
biomarker, explore the functional impact of THOR in hTERT upregulation, and also 
identify other potential DNA methylation-based markers in BC.  
Firstly, we demonstrated that THOR is significantly hypermethylated in malignant 
breast tissue when compared to benign tissue (40.23% vs. 12.81%), representing a 
potential candidate biomarker for future application in BC screening and early 
diagnosis. Importantly, as DNA methylation marks can be determined from blood 
samples, assessing THOR methylation status may constitute a non-invasive assay to 
help in BC management.  
Next, using a reporter assay, we revealed that THOR acts as a repressive regulatory 
element of hTERT, and that THOR hypermethylation might be relevant for hTERT 
upregulation in BC. To further investigate its biological impact on hTERT transcription, 
targeted THOR demethylation was performed using the CRISPR-dCas9 system. 
Although, THOR demethylation was achieved, hTERT mRNA levels were not 
significantly reduced. Surprisingly, cells previously demethylated on THOR region led 
to a remarkable reduction in tumor development in vivo. Therefore, additional studies 
are required to validate these observations and to unravel the causality between 
THOR hypermethylation and hTERT upregulation in BC. 
Finally, through a genome-wide methylation analysis, we identified three novel DNA 
methylation markers, located on the PRAC2, TDRD10 and TMEM132C genes that 
showed diagnostic and prognostic value in BC, as well as in other cancer types. 
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This work evidences the importance of DNA methylation in breast tumorigenesis and, 
more importantly, their clinical value as promising diagnostic, prognostic and 
therapeutic targets in BC.  
 
 
Keywords: Breast cancer, Telomerase, hTERT, THOR, DNA methylation, 
Biomarkers. 
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Resumo 
 
O cancro da mama (CM) é o tumor maligno mais frequentemente diagnosticado, e 
uma das principais causas de morte entre as mulheres, em todo o mundo. Em 2018, 
cerca de 2,1 milhões de novos casos foram diagnosticados e 626.679 pessoas 
morreram por CM, em todo o mundo. No geral, o CM é o segundo tipo de cancro mais 
comum, a seguir ao cancro do pulmão, sendo considerada a quinta causa mais 
comum de morte devido a cancro. 
O CM consiste numa doença altamente heterogénea, que compreende diversos 
subtipos histológicos e moleculares, os quais diferem em termos de resposta à 
terapêutica e prognóstico da doença. A deteção precoce e os avanços no tratamento 
conduziram a uma melhoria significativa na sobrevivência e qualidade de vida dos 
pacientes, no entanto, o CM ainda está entre as principais causas de morte por 
cancro. Atualmente, quando detetado numa fase inicial da doença, é potencialmente 
curável mas as taxas de mortalidade ainda observadas entre os pacientes, 
demonstram a necessidade urgente de novas e mais eficazes opções de diagnóstico 
e terapêutica. 
A capacidade de autorrenovação ilimitada das células cancerígenas é uma 
característica fundamental do cancro, sendo alcançada pela manutenção dos 
telómeros. Em cerca de 95% dos casos de CM, este processo depende da reativação 
da enzima telomerase. A telomerase consiste num complexo ribonucleoproteico, 
constituído por uma subunidade catalítica, a transcriptase reversa da telomerase 
humana (hTERT) e uma subunidade de RNA, conhecida como componente de RNA 
da telomerase humana (hTERC). Tem sido proposto que a atividade da telomerase é 
determinada principalmente pela re-expressão da sua subunidade catalítica, a hTERT 
e, visto que, quer a atividade da telomerase, como a expressão da hTERT, estão 
aumentadas na maioria dos tumores malignos da mama, e ausentes na maioria dos 
tecidos somáticos normais, a telomerase/hTERT, bem como os seus mecanismos 
regulatórios, são considerados potenciais biomarcadores de cancro com implicações 
relevantes na prática clínica. 
Até à data, diversos mecanismos genéticos e epigenéticos demonstraram ser 
responsáveis pela regulação da hTERT, no entanto, a complexidade por trás da sua 
regulação no cancro não é ainda totalmente compreendida. Um dos mecanismos 
associados à expressão da hTERT no cancro é a hipermetilação de uma região 
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específica do seu promotor, denominada como Região Oncológica Hipermetilada da 
hTERT (em inglês, THOR). Esta região demonstrou estar associada à progressão 
tumoral e à sobrevivência dos pacientes em diversos tipos de cancro, tais como, 
cancro da próstata, bexiga e pâncreas. No entanto, o seu papel biológico na ativação 
da transcrição da hTERT, bem como o seu potencial clínico no CM não foi ainda 
investigado.  
Deste modo, o principal objetivo do presente estudo, foi investigar o papel do THOR 
como biomarcador de doença em CM, bem como explorar o mecanismo pelo qual a 
hipermetilação do THOR contribui para a regulação positiva da hTERT. 
Adicionalmente, uma vez que vários estudos têm demonstrado que a metilação do 
DNA desempenha um papel relevante na patogénese do CM, pretendeu-se também 
identificar novos potenciais biomarcadores de diagnóstico e/ou prognóstico baseados 
em alterações nos padrões de metilação do DNA.  
Inicialmente, para avaliar o potencial do THOR como biomarcador clínico em CM, o 
seu nível de metilação foi analisado na coorte de carcinoma invasivo da mama 
disponível na plataforma de acesso público, The Cancer Genome Atlas (TCGA). 
Posteriormente, confirmaram-se os resultados utilizando duas coortes compostas por 
amostras de tecido de carcinoma invasivo de mama provenientes de mulheres 
diagnosticadas com CM no Centro Hospitalar Universitário do Algarve (CHUAlgarve, 
Faro, Portugal). Todas as coortes (TCGA e CHUAlgarve) revelaram que o THOR está 
significativamente hipermetilado no tecido mamário maligno quando comparado com 
o tecido benigno. A análise de metilação do THOR permitiu diferenciar cancro de 
tecido normal a partir do estádio mais inicial da doença (AUC> 0,9574, p <0,0001), 
evidenciando assim o seu potencial como biomarcador para deteção precoce do CM. 
Para além disso, quando comparado com os biomarcadores séricos, CEA e CA 15-3, 
o estado da metilação do THOR demonstrou ser mais representativo do estado atual 
do tumor do que os biomarcadores acima mencionados e, portanto, poderia ser usado 
no futuro como uma ferramenta valiosa para acompanhamento dos pacientes com 
CM. É importante ressaltar que, apesar de no presente estudo a hipermetilação do 
THOR ter sido determinada em amostras de tecido, esta pode constituir a base para 
o desenvolvimento de um ensaio não invasivo, e assim, melhorar a prática clínica. Os 
resultados obtidos revelam também que os pacientes com o THOR hipermetilado 
apresentam níveis mais elevados de expressão da hTERT, sugerindo assim que a 
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metilação do THOR atua como um mecanismo de regulação positiva da ativação 
transcricional da hTERT. 
Neste sentido, de forma a investigar o papel funcional da hipermetilação do THOR na 
regulação génica da hTERT, foram realizados ensaios repórter de luciferase e a 
desmetilação direcionada do THOR com recurso ao sistema CRISPR-dCas9 em 
linhas celulares de CM. Os ensaios repórter revelaram que a região THOR atua como 
um elemento regulador repressivo da hTERT e que a sua hipermetilação pode ser 
relevante para a regulação positiva da hTERT no CM. Assim, para testar essa 
hipótese, utilizou-se o sistema CRISPR-dCas9 fundido com a enzima TET1 
desmetilase, para avaliar se a desmetilação direcionada do THOR poderia reverter a 
regulação positiva de hTERT. Os resultados obtidos revelaram que a desmetilação 
específica da região THOR, foi conseguida, tendo-se obtido uma redução nos níveis 
de metilação de 15 a 70%, em determinadas CpGs. No entanto, apesar de se ter 
observado uma redução significativa na metilação do THOR, os níveis de mRNA da 
hTERT não foram significativamente reduzidos. Portanto, o presente estudo não nos 
permite estabelecer um efeito de causalidade entre a desmetilação do THOR e a 
inativação da transcrição da hTERT, sendo necessários estudos adicionais para 
desvendar esta hipótese. Porém, surpreendentemente, as células previamente 
desmetiladas na região THOR conduziram a uma notável redução no 
desenvolvimento de tumors in vivo, sendo essencial no futuro validar e determinar a 
razão biológica para estas observações. 
Por último, pretendeu-se destacar a importância das alterações epigenéticas na 
patogénese do CM e identificar novos biomarcadores de CM baseados na metilação 
do DNA. Para tal, realizou-se uma análise genómica dos padrões de metilação do 
DNA em CM e, avaliou-se o seu impacto na expressão génica. Estas análises foram 
efetuadas com recurso aos dados de metilação do DNA e de expressão génica, 
disponíveis nas bases de dados TCGA e METABRIC. De acordo com os resultados 
obtidos, foram identificados sete novos genes associados ao CM. Destes, os genes, 
PRAC2, TDRD10 e TMEM132C, apresentaram marcas de metilação do DNA com 
valor diagnóstico e prognóstico. Estes três novos biomarcadores baseados na 
metilação do DNA foram analisados em outras coortes de cancro disponíveis no 
TCGA e demonstraram ter também potencial diagnóstico e prognóstico noutros tipos 
de cancro.  
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Em suma, o presente trabalho evidencia a importância dos padrões de metilação do 
DNA na patogénese do cancro da mama e destaca o seu potencial valor clínico. 
Particularmente, a hipermetilação do THOR é proposta como um alvo de diagnóstico 
e de terapêutica promissor para o CM. 
 
Palavras-chave: Cancro da mama, Telomerase, hTERT, THOR, metilação de DNA, 
biomarcadores. 
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1.1 Breast Cancer 
 
1.1.1 Epidemiology and risk factors 
 
Cancer is a major public health problem in the world, accounting for 18.1 million new 
cancer cases and 9.6 million deaths in 2018 (Bray et al., 2018). Given the rapid growth 
and aging of population worldwide, cancer is nearly replacing cardiovascular diseases 
as the leading cause of death worldwide. And, according to WHO (2015), cancer 
already ranks as the first leading cause of premature mortality (0-69 years) in North 
America, parts of South America, Oceania and Europe (Bray et al., 2018; Torre et al., 
2015). 
Breast cancer (BC) is the most frequently diagnosed cancer and a leading cause of 
death among women worldwide, with an estimated 2.1 million new cases and 626.679 
deaths in 2018. Overall, this disease is the second most common cancer in the world, 
following lung cancer, and ranks as the 5th most common cause of cancer-related 
death (Bray et al., 2018). Currently, breast cancer incidence rates are higher in 
Australia/New Zealand, Western and Northern Europe, and Northern America, while 
the lower incidence rates are observed in Africa and Asia (Figure 1.1A) (Bray et al., 
2018). This variation in breast cancer incidence is mainly related to differences in 
access to breast cancer screening programmes across the world, as well as higher 
exposure to known risk factors in the high-income countries (Torre et al., 2016). In 
terms of mortality, the highest mortality rates are found in Melanesia, whereas the 
lowest are in Eastern Asia countries (Figure 1.1A).  
In Portugal, according to the latest estimates from Globocan (2018), BC is the most 
incident cancer type and the third cause of cancer-related death (first among women) 
(Figure 1.1B). There are around 6974 new cases every year, with an incidence rate of 
70.7 cases per 100.000 people (Figure1.1B), while mortality rates are in the order of 
11.3 cases per 100.000 people, corresponding to 1748 deaths per year, with both the 
estimate age-standardized  (ASR) incidence and mortality rates being lower than the 
European ratio (Bray et al., 2018). According to Lacerda et al, between 1998 and 2011, 
BC incidence rates increased at all ages and in all portuguese geographic regions, 
with the south (including Lisbon) presenting the highest incidence rate (Lacerda et al., 
2018). This fact has turned BC into one of the major interests in the national cancer 
research community, which has contributed to the progress in early diagnosis, 
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improved treatment, and a greater investment in education for disease prevention and 
early detection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Epidemiologic cancer data in the world and in Portugal. A. Breast cancer 
estimated age-standardised incidence and mortality rates in the World per 100 000 people. B. 
Incidence and mortality rates of the Top 10 most common types of cancer in Portugal – 
estimates presented for the year 2018. Source: Globocan 2018. 
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The majority of breast cancers are sporadic and the etiology is still not completely 
understood. Nevertheless, it is known that a combination of several factors may 
increase or decrease breast cancer risk (Subramani & Lakshmanaswamy, 2017). 
Besides being female, increasing age is the most relevant risk factor since BC 
incidence doubles about every ten years. Most breast cancers are diagnosed in 
women older than 50 years old. Although male breast cancer is rare, about 1% of all 
breast carcinomas occur in men (Fentiman, Fourquet, & Hortobagyi, 2006; Subramani 
& Lakshmanaswamy, 2017). 
Other important risk factors include reproductive and hormonal factors such as 
nulliparity and late pregnancy (after 30), early menarche (before 12 years of age), late 
menopause (after 55 years old) and use of hormonal contraceptives, since these 
increase the breast exposure to elevated levels of oestrogen. Additionally, certain 
breast alterations such as atypical mammary hyperplasia, previous history of 
preneoplastic or neoplastic breast lesions as well as genetic predisposition contribute 
to a higher risk of developing breast cancer. Specifically, inherited germline mutations 
in BC susceptibility genes, like BRCA1 and BRCA2, are also major predetermining 
factors, increasing to 65% and 45% the chance of a carrier to develop the disease in 
their lifetime, respectively. However, these inherited mutations only account for 5-10% 
of all breast cancer cases (Balmana et al., 2011; Subramani & Lakshmanaswamy, 
2017). Other factors such as exposure to ionising radiation, a sedentary life style, post-
menopausal weight gain, dietary fat, alcohol consumption and menopausal hormone 
therapy also contribute to increased BC risk (Senkus et al., 2015; Torre et al., 2015). 
On the other hand, maintaining a healthy body weight, increasing physical activity, 
childbearing and breastfeeding seems to reduce the risk, with higher protection for 
early first birth and a larger number of births (Subramani & Lakshmanaswamy, 2017). 
 
1.1.2 Histopathologic and molecular classification 
 
Breast cancer is considered a heterogeneous disease, encompassing several 
histological and molecular subtypes associated with diverse therapeutic responses 
and clinical outcomes (Malhotra et al., 2010; Zardavas et al., 2015). 
The majority of BC are epithelial tumors, particularly adenocarcinomas that originate 
in the mammary ducts or lobules (Subramani & Lakshmanaswamy, 2017). According 
to the histological classification, BC can range from carcinoma in situ (Stage 0) to 
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invasive (infiltrating) breast carcinoma of several stages (I to IV) (American cancer 
society, 2013). Carcinoma in situ is sub-classified in two major non-invasive 
premalignant lesions, ductal (DCIS) and lobular (LCIS), and based on the architectural 
features of the tumor, DCIS, which is more common than LCIS, is further differentiated 
into five subtypes: comedo, cribiform, micropapillary, papillary and solid (Malhotra et 
al., 2010). Similarly, invasive carcinomas are also sub-classified in different 
histological subtypes, including infiltrating ductal (IDC), which account for around 65-
80% of all breast carcinomas, invasive lobular (ILC), ductal/lobular mixed histology, 
mucinous (colloid), tubular, medullary and papillary carcinomas (Malhotra et al., 2010; 
Weigelt, Geyer, & Reis-filho, 2010). Additionally, based on the levels of nuclear 
pleomorphism, glandular/tubule formation and mitotic index, invasive carcinomas are 
further classified into grade 1 (well-differentiated), grade 2 (moderately) or grade 3 
(poorly differentiated) tumors (Malhotra et al., 2010).  
Over time, several classification systems incorporating molecular markers, such as 
the estrogen receptor (ER), progesterone receptor (PR) and the human epidermal 
growth factor receptor 2 (HER2) have been generated (Rakha & Green, 2017). In 
general, breast tumors are divided in hormone receptor positive or negative. In the first 
ones, breast cancer cells express ER and/or PR, being eligible for targeted therapies 
using aromatase inhibitors (anastrozole) or ER modulators (tamoxifen). These are 
more commonly diagnosed in postmenopausal women and present a better prognosis. 
By contrast, the hormone receptor-negative cancers do not express ER or PR and for 
this reason hormonal therapy is not feasible. These cancers tend to grow faster than 
the hormone receptor-positives, and therefore are associated with a worst prognosis 
(Rakha & Green, 2017; Subramani & Lakshmanaswamy, 2017). Regarding HER2, this 
protein is usually overexpressed in hormone receptor–negative cancers. Targeted 
therapy is available to treat this type of BC through the use of trastuzumab (Herceptin), 
nevertheless patients’ prognosis is usually poor (Makki, 2015). 
The assessment of these proteins is extremely important, as ER and HER2 are 
considered main determinants of BC biology and can be used as prognostic and 
predictive markers, allowing to select the patients more likely to respond to therapy 
(Rakha & Green, 2017). 
Recently, gene expression profiling has enabled a more comprehensive view of the 
molecular identity of breast cancer. Five major molecular and outcome-related BC 
subtypes, known as PAM50 subtypes, were identified based on genome-wide 
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expression analyses: Luminal-A, Luminal-B, HER-2 (ERBB2), Normal-like and Basal-
like (Figure 1.2) (Sørlie et al., 2001; TCGA Network, 2012). Breast cancer 
classification based on PAM50 subtypes and risk of recurrence (ROR) score have 
shown to significantly contribute to prognostic assessment and to facilitate more 
precise therapeutic decisions (Ohnstad et al., 2017).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Hierarchical clustering of 85 breast tissue samples into five subgroups based 
on gene expression. Luminal subtype A- dark blue; luminal subtype B - yellow; normal 
breast-like - green; basal-like - red and ERBB2 - pink. Adapted from (Sørlie et al., 2001). 
 
 
The luminal types represent the majority of breast carcinomas (60-70%), are usually 
ER and PR positive, HER-2 positive or negative, and are considered the most 
heterogeneous molecular group in terms of gene expression and clinical outcome 
(Makki, 2015; TCGA Network, 2012). Within this molecular group, Ki-67 (proliferation 
Lower                                     Higher 
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marker) assessment is particularly important to distinguish Luminal A carcinomas from 
Luminal B, in which a higher score combined with HER2 overexpression defines 
Luminal B tumors with a worse prognosis than Luminal A (Weigelt et al., 2010). 
HER2 tumors are generally both hormone receptor negative and HER2 positive and 
account for about 15% of all mammary tumors (Makki, 2015). HER2 overexpression 
and associated genes occurs by amplification of a DNA segment on 17q12 amplicon. 
These tumors are usually poorly differentiated and the patients display an aggressive 
clinical behaviour (Weigelt et al., 2010). 
The basal-like subtype comprises about 15-20% of all BC and is most likely both 
hormone receptor and HER2 negative, being called for this reason as triple-negative 
breast cancer (TNBC) (Schnitt 2010; TCGA Network 2012). Basal-like carcinomas are 
particularly prevalent in young women of African and Hispanic descent, being 
characterized as high grade tumors with a high proliferation index and expression of 
genes associated with cell invasion and metastasis, which might explain the poor 
clinical outcome, shortest patient survival and high mortality rates (Gazinska et al., 
2013; Schnitt, 2010).  
Apart from basal-like subtype, other two minor subtypes are classified as TNBC, 
namely, the Normal-like and Claudin-low carcinomas. The Normal-like BC are still 
poorly characterized, however they cluster together with benign breast lesions and are 
generally associated with a good prognosis. These tumors exhibit a gene signature of 
adipose tissue and basal epithelial cells, presenting low expression of luminal cell-
associated genes (Sørlie et al., 2001; Yersal & Barutca, 2014). Lastly, Claudin-low 
tumors are characterized by downregulation of genes involved in cell-cell adhesion, 
including the genes encoding Claudin 3, 4, and 7, Occludin and E-cadherin, and high 
enrichment of epithelial-to-mesenchymal transition genes, such as vimentin-encoding 
gene, immune system response genes and cancer stem cell features. Clinically, 
patients with this subtype of tumors have a poor prognosis (Prat et al., 2010). 
 
1.1.3 Screening, diagnostic and prognostic markers in clinical use 
 
Mammography is the most widely used screening method for detection of breast 
cancer at a pre-clinical stage. It is recommended mammography screening, every 2 
years, in women aged 50-69 years (Senkus et al., 2015). For women at higher risk, 
with familial BC or BRCA mutations, it is recommended a yearly mammography 
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concomitantly with a magnetic resonance imaging of the breast (Balmana et al., 2011). 
The adoption of BC screening programmes has contributed to a reduction in BC 
mortality and effectiveness of the treatment.  
Surgical intervention is considered the gold standard for diagnosis and treatment of 
BC (National Cancer Institute, 2014). After surgery, pathological assessment is based 
on a tissue biopsy with determination of histology, grade, immunohistochemical (IHC) 
evaluation of ER, PR, HER2 and the cell proliferation marker Ki-67, which in 
association with tumor size and regional lymph nodes status represent the most 
important prognostic factors in BC (Senkus et al., 2015). In clinical practice, Ki-67 
assessment is particularly important to differentiate the luminal group into luminal A 
and B. Tumors with a Ki-67 index lower than 14% have been defined as low 
proliferative tumors, and those with a higher index as highly proliferative, representing 
the luminal A and luminal B subtypes, respectively (Bustreo et al., 2016; Feeley et al., 
2014). However, there is some controversy regarding the Ki-67 cut-off that should be 
considered. According to the 2015 Saint Gallen Conference, the majority of panellists 
voted that a threshold of 20% for Ki-67 was the optimal indicator of poor prognosis 
and thus should be used to stratify the high-risk patients with luminal breast cancer 
(Bustreo et al., 2016; Gnant, Thomssen, & Harbeck, 2015). 
Currently, the treatment guidelines are based on these pathological features and 
disease stage, which is determined according to the TNM staging system (tumor size, 
regional lymph node status and metastases) (Edge et al., 2010; Khatcheressian et al., 
2013; Senkus et al., 2015). The BC treatment may include combinations of surgery 
(mastectomy or breast-conserving surgery), radiotherapy, chemotherapy, hormonal 
therapy (tamoxifen and/or aromatase inhibitors) or targeted therapy (trastuzumab, 
anti-HER2) (Figure 1.3). Furthermore, in some cases, when breast-conserving surgery 
is desired neoadjuvant therapy can be required in order to promote down staging 
(Schnitt, 2010; Senkus et al., 2015). 
Early detection and improved treatment have led to an increase in overall survival, 
ranging from 70% to 80% the 5-year survival in the European Countries (Coleman et 
al., 2008; Torre et al., 2015). Nevertheless, the clinical outcome for women with breast 
cancer varies widely. According to the stage of disease the 5-year survival rate for 
women with stage 0 or I is close to 100%, for stage II is about 93%, stage III is around 
72%, while for stage IV or metastatic disease, it decreases drastically to around 22% 
(Howlader et al., 2014). 
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Apart from the clinical features and assessment of the biomarkers described above, 
other markers have been used in clinical routine to monitor and evaluate BC 
prognosis. Despite the intense research in validation of serum-based biomarkers for 
BC, only few were approved by the Food and Drug Administration (FDA) to monitor 
patients, such as CA 15-3 and CEA. However none has been accepted as a standard 
diagnostic/prognostic procedure in routine or in guidelines so far, due to lack of 
sensitivity and specificity (Khatcheressian et al., 2013; Ludwig & Weinstein, 2005; 
Sauter, 2017). Additionally, the CellSearch system was approved by the FDA to detect 
the level of circulating tumor cells (CTCs) based on analysis of EpCAM (Epithelial Cell 
Adhesion Molecule), CD45, Cytokeratins (CK) 8, 18 and 19 to monitor disease 
progression in patients with metastatic BC (Sauter, 2017). Cytokeratin expression can 
also be measured by IHC in breast tissue in order to evaluate disease prognosis. 
Specifically, expression of CK5/6, CK14 and CK20 has been correlated with higher 
tumor grade and worst prognosis (Harbeck & Gnant, 2017; Sauter, 2017). 
In the last decade, several gene expression profiling tests have enabled a more 
comprehensive view of the molecular identity of BC and have been proposed to predict 
clinical outcome and aid in adjuvant therapy decision-making. 
Prosigna test (Nanostring technologies, Seattle, WA), known as PAM50, consists in a 
50 gene signature that has been used for BC molecular classification, as described 
above (Rakha & Green, 2017). Based on the mRNA expression level of these genes 
a risk score (ROR) can be calculated to evaluate patient prognosis and establish more 
precise therapeutic decisions (Ohnstad et al., 2017). Other RNA-based genomic tests, 
such as Mammaprint (Agendia, Huntington Beach, CA) and Oncotype DX (Genomic 
Health, Redwood City, CA) may also be used to provide prognostic and/or predictive 
information in early-stage BC beyond the standard clinicopathological assessment 
and to determine the likelihood of benefit from adjuvant chemotherapy (Figure 1.3) 
(Cardoso et al., 2016; Senkus et al., 2015). Mammaprint is a 70-gene signature that 
classifies the patients into low and high risk group and, based on this, selects the 
patients that should take adjuvant chemotherapy. The clinical utility of Mammaprint 
was recently demonstrated in a randomized prospective trial (MINDACT, 
NCT000433589) (Cardoso et al., 2016). The Oncotype DX is a 21 gene panel assay 
that categorizes the patients into 3 risk of recurrence groups, predicting the risk of 
distant disease recurrence at 10 years following diagnosis. The prognostic impact of 
Oncotype DX has been evaluated through different clinical trials such as TAILORx trial 
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(NCI-2009-00707) and was proven to properly select the patients more likely to benefit 
from adjuvant chemotherapy (Duffy et al., 2017). Prosigna and Oncotype DX tests are 
designed for patients with ER-positive BC only, while the Mammaprint can be applied 
for both ER-positive and negative patients. All of these 3 tests may be used in patients 
lymph node-negative or up to 1-3 metastatic lymph nodes (Duffy et al., 2017). 
 
 
 
Figure 1.3 Schematic representation of therapeutic strategies in early breast cancer. 
The individual therapeutic strategy may differ according to tumor and disease features and 
patients’ preferences. ER - oestrogen receptor; PgR - progesterone receptor. HER2 - human 
epidermal growth factor receptor 2. Adapted from (Harbeck & Gnant, 2017). 
 
 
1.1.4 Limitations of current breast cancer markers 
 
Over the past years major strides have been made in terms of BC management and 
patient survival. Nonetheless, the heterogeneous nature of this disease has 
challenged the development of more effective biomarkers to diagnose and monitor BC 
as well as to guide therapy. 
So far, standard screening for new and recurrent BC is only based on clinical breast 
examination and imaging, which is known to have a limited sensitivity, particularly in 
young women and women with dense breasts (Buist et al., 2004; Tanos & Thierry, 
2018). Apart from being an active area of investigation, there are no FDA approved 
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non-invasive biomarkers for early diagnosis of BC or screening (Sauter, 2017). Liquid 
biopsies could provide useful clinical information from body fluid analysis, such as 
blood, and thus anticipate the diagnosis of an individual before the symptoms appear 
(Tanos & Thierry, 2018). Furthermore, since recurrence is a major clinical 
manifestation of tumor progression and represents the main cause of death from this 
disease, the identification of biomarkers that could predict tumor behaviour is a major 
issue in this pathology (Bidard et al., 2018; Byler et al., 2014; Moody et al., 2005). 
Regarding prognostic assessment, as mentioned above, several multianalyte tests are 
already available to predict clinical outcome in patients with early stage BC. These 
molecular tests (e.g. Oncotype and Mammaprint) were shown to be useful in clinical 
practice since they allow a better stratification of the patients that should be submitted 
to adjuvant chemotherapy, reducing the chemotherapy costs and side effects without 
impairing the long-term outcome (Duffy et al., 2017). Conversely, these multigene 
tests are tissue-based, being the majority RNA-based, which is well known not be the 
best sample source due to poor stability of RNA molecules (Rakha & Green, 2017). 
Furthermore, multianalyte tissue testing is based on primary tumor and, due to 
intratumoral heterogeneity, the phenotypic profiles of its metastasis, or a recurrent 
tumor that may differ from the primary tumor, might turn non representative for long 
term monitoring (Sauter, 2017). In addition, these tests are expensive to perform, and 
while in the United States they are covered by health insurance, in Portugal and in 
Europe that is not the case, only being approved in particular situations (Notícias 
Magazine 2018). 
Promising biomarker approaches include non-invasive tests, such as liquid biopsy for 
both to screen healthy individuals for BC and to monitor individuals after treatment, 
and tissue biomarkers for patients already diagnosed with the disease. 
 
1.1.5 Breast tumorigenesis 
 
Cancer is a group of complex and heterogenous diseases charactherized by the 
abnormal and uncontrolled cellular proliferation that culminate with the invasion of 
surrounding tissues and metastatic dissemination (Du & Elemento, 2015; Hanahan & 
Weinberg, 2011). The transformation of normal cells into a neoplastic state occurs 
through a multistep process in which the cells acquire the ability to overcome the 
normal biological circuits and processes to become tumorigenic and ultimately 
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malignant. As proposed by D. Hanahan and R. Weinberg, this malignant 
transformation involves the acquisition of several hallmark capabilities that are 
transversal to all cancer types, including breast. They include sustaining proliferative 
signalling, evading growth suppressors, resisting cell death, enabling replicative 
immortality, inducing angiogenesis, activating invasion and metastasis, 
reprogramming of energy metabolism, and evading immune destruction (Hanahan & 
Weinberg, 2011). The time required for this carcinogenic process can be variable and 
may involve several decades (Rivenbark, Connor, & Coleman, 2013). 
The most-well established model of breast cancer development points towards a 
stepwise progression from normal breast epithelium to atypical hyperplasia, ductal 
carcinoma in situ (DCIS), followed by invasive breast cancer (Beckmann et al., 1997; 
Rivenbark et al., 2013). The transition from normal breast epithelia to atypical 
hyperplasia is mainly characterized by increased growth and well-differentiated 
histologic and biological features (Allred et al., 2008). By contrast, DCIS is a non-
invasive lesion that may contain both well and poorly differentiated cells, and when 
high-grade is more likely to gradually progress to invasive breast cancer (Rivenbark 
et al., 2013). Although DCIS is considered a precursor for development of invasive 
BC, it is not completely clear whether all DCIS will progress to invasive disease, and 
in fact some studies have reported that some DCIS could spontaneously disappear 
(Cowell et al., 2013; Santpere, Alcaráz-sanabria, & Corrales-sánchez, 2018). Lastly, 
invasive breast cancer is characterized by significant histological and biological 
variability and invasion of cells into surrounding stroma or tumor microenvironment 
(Cowell et al., 2013).  
Multiple genetic and epigenetic alterations (Figure 1.4) are required to promote these 
transitions between the different morphological stages and drive tumor progression 
(Agnantis et al., 2004; Rivenbark et al., 2013). Throughout the tumorigenesis and 
progression, these molecular alterations result in aberrant or abnormal protein 
expression that confers new cellular phenotypes and behaviours, leading to growth 
advantages and ability to invade locally and to distant tissues (Rivenbark et al., 2013). 
Thus, gain-of-function events, such as the activation of proto-oncogenes by mutations, 
rearrangements or amplifications, and loss-of-function events reflecting the 
inactivation of tumor suppressor genes are both the basis of breast tumorigenesis 
(Suter & Marcum, 2007). 
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Figure 1.4 Multistep process of human breast carcinogenesis. Breast cancer develops 
from normal breast epithelial cells that evolve through atypical hyperplasia, DCIS and invasive 
breast cancer. Multiple genetic and epigenetic alterations occur during the process of 
malignant transformation. Adapted from (Agnantis et al., 2004). 
 
 
Some of the cancer pathways mainly altered in breast cancer are the PIK3CA/PTEN, 
RB1, TP53, MAPK, ER signalling, Kinesin, Polo-like kinase and telomere maintenance 
pathways (Feng et al., 2018; Network, 2012; Shi et al., 2017; Suter & Marcum, 2007). 
These pathways are regulated by several genes and according to a study published 
by the Cancer Genome Atlas Network, somatic mutations in TP53, PIK3CA and 
GATA3, occurred with a 10% frequency across all molecular breast cancers subtypes 
(TCGA Network 2012). Additionally, some genetic alterations were more commonly 
found in a specific molecular BC subtype than others. Namely, an enrichment of 
specific mutations in GATA3, PIK3CA and MAP3K1 were observed within the luminal 
A subtype. Also, a higher rate of TP53 mutations (72% to 80%) was associated with 
HER2 and basal-like subtypes, whereas the luminal group showed a lower frequency 
(12% to 29%) of these mutations (TCGA Network, 2012). Thus, the results of this study 
further evidence the heterogeneous pattern behind BC and among the major 
molecular BC subtypes. Copy number alterations, such as gene deletions or 
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amplifications have been also found in various genes and chromosomal regions, 
including amplifications in PIK3CA and ERBB2, and deletions in TP53, MAP2K4, 
PPP2R2A and MTAP (Curtis et al., 2012; Network, 2012).  
Epigenetic modifications or epimutations also play a crucial role in breast cancer 
development and progression. These also serve as prognostic biomarkers (Brock et 
al., 2008; Castelo-Branco et al., 2013; Pérez-Rivas et al., 2014) in cancer and are 
increasingly being investigated as therapeutic targets (Faleiro, Leao, et al., 2017; 
Jones, Issa, & Baylin, 2016). The most well studied epigenetic alterations include DNA 
methylation, histone modifications and non-coding RNAs, such as microRNAs 
(miRNAs) (Byler et al., 2014). DNA methylation alterations are common events in BC, 
being the DNA methylation profile between normal and malignant breast tissue highly 
diverse (Lewis et al., 2005; Mirza et al., 2007; Stefansson & Esteller, 2013). 
Hypermethylation of promoter CpG islands is thought to contribute for gene 
inactivation, however recent studies have shown that gene promoter may correlate 
with either upregulation or downregulation of the associated gene (Bert et al., 2013; 
Brooks et al., 2010; Castelo-Branco et al., 2016; Wu, Sarkissyan, & Vadgama, 2015). 
For example, several studies have reported promoter hypermethylation leading to 
silencing of tumor suppressor genes in BC, including BRCA1 (Zhu et al., 2015), E-
cadherin (Shargh et al., 2014) and TMS1 (Mirza et al., 2007). By contrast, the Wilms’ 
tumor suppressor 1 (WT1) gene is overexpressed in breast tumor tissue despite 
hypermethylation of its promoter (Loeb et al., 2001).  
Additionally, a study by Elsheikh et al., demonstrated that global histone modifications, 
such as histone acetylation and methylation patterns are associated with tumor 
phenotypes and might represent an early sign of BC (Elsheikh et al., 2009). 
Regarding miRNAs, their biological importance has been recognized and associated 
with the pathogenesis of cancer and mechanisms that govern metastatic spread 
(Croce & Calin, 2005). miRNAs are implicated in genome instability, acting as tumour 
suppressors or oncogenic drivers and, according to several studies, these are 
aberrantly expressed in cancer, including breast, when compared to healthy tissue 
(Iorio et al., 2005; Leão et al., 2018; Pérez-Rivas et al., 2014; Volinia et al., 2012). 
Specifically, mir-125b, mir-145, mir-21, and mir-155,  were significantly downregulated 
across multiple BC subtypes (Iorio et al., 2005). Also, let-7g, miR-133a, miR-342-5p 
and miR-491-5p demonstrated to downregulate endogenous telomerase activity and 
inhibit cell proliferation in breast cancer cells by targeting hTERT, implicated in 
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telomere maintenance pathway, and other genes involved in Wnt signaling pathway 
(Hrdlickova et al., 2014). 
Altogether, the studies mentioned above show the complexity behind breast 
tumorigenesis, suggesting that a distinct pattern of genes are regulated by several 
molecular mechanisms, being silenced or re-expressed across all BC subtypes. 
 
 
1.2 The Role of Telomerase/hTERT in Breast Cancer 
 
1.2.1 Replicative immortality: telomeres and telomerase1 
 
As mentioned before, one of the hallmark capabilities acquired by the cells during the 
process of tumorigenesis is the ability of limitless self-renewal. This replicative 
capacity is one of the most critical features of cancer cells, which is attained by 
telomere maintenance (Hanahan & Weinberg, 2011). Telomere maintenance in the 
majority of human cancers (90%), including breast, is governed by telomerase, or less 
frequently via an alternative recombination-based mechanism responsible for 
telomere lengthening (ALT mechanism). Telomerase is a specialized DNA 
polymerase that is reactivated in cancer allowing tumor cells to escape from cellular 
senescence and to proliferate indefinitely. However, its activity is absent in most 
normal somatic tissues. This differential role makes telomerase and its regulatory 
mechanisms attractive cancer biomarkers with relevant implications in clinical practice 
(Poremba et al., 2002; Shay, Wright, & Werbin, 1991). 
Telomeres are centrally involved in the ability of limitless self-renewal since they 
protect the ends of chromosomes from degradation and end-to-end fusions, 
contributing to genomic stability (Hanahan & Weinberg, 2011; Martinez & Blasco, 
2015). The telomere structure was discovered by Muller and Meier in 1938. 
Mammalian telomeres are nucleoprotein complexes composed of multiple tandem 
TTAGGG DNA repeats (5 to 20 kb) that are located at the ends of eukaryotic 
chromosomes (Blackburn, 1991; Meier & Muller, 1938; Moyzis et al., 1988). Telomeric 
DNA repeats are followed by a terminal 3´G-rich single-stranded overhang forming a 
                                                                 
1 Part of this text was published as a manuscript entitled “Mechanisms of human telomerase 
reverse transcriptase (hTERT) regulation: clinical impacts in cancer.” Joana Apolonio; 
Ricardo Leão; Donghyun Lee; Arnaldo Figueiredo; Uri Tabori; Pedro Castelo-Branco. Journal 
of Biomedical Science (2018) 25:22 https://doi.org/10.1186/s12929-018- 0422-8. 
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telomeric loop (T-loop) that provides 3´end protection (de Lange, 2005; Doksani et al., 
2013). Telomeric DNA is associated with the shelterin protein complex and together 
they protect chromosomal ends and maintain genomic and chromosomal integrity by 
preventing nucleolytic degradation, unnecessary recombination, and inter 
chromosomal fusions (de Lange, 2005, 2010; Shay, 2003). The shelterin complex 
consists of a group of six telomere-specific proteins; the following three, telomeric 
repeat binding factor 1 and 2 (TERF1, TERF2) and protection of telomeres protein 1 
(POT1) interact directly with TTAGGG repeats. These proteins are interconnected with 
three others: TERF1 Interacting Nuclear Factor 2 (TINF2), tripeptidylpeptidase 1 
(TPP1), and repressor activator protein 1 (RAP1) (de Lange, 2005; Doksani et al., 
2013; Zimmermann et al., 2014). Telomeric DNA is masked with shelterin protective 
caps and these complexes enable DNA damage repair (DDR) machinery to distinguish 
telomeric DNA from genomic DNA damage (Griffith et al., 1999; van Steensel, 
Smogorzewska, & de Lange, 1998). 
Throughout cellular lifespan, telomeric DNA is shortened after each replicative cycle 
due to the “end-replication problem”, oxidative damage, age and lifestyle (including 
diet, smoking, professional environment and stress) (Harley, 1991; Shammas, 2011; 
Wright & Shay, 1992). Telomere shortening beyond a limit leads to a stage of cell 
growth arrest. At this stage (M1), DNA damage signalling and cellular senescence are 
triggered which constitutes a crucial protective mechanism that prevents progression 
to an oncogenic state (Shay, 2003; Wright, Pereira-Smith, & Shay, 1989). However, 
in some cases, cells surpass this senescence state, avoiding important cell cycle 
checkpoints provided by p16INK4a, TP53 and Rb, and enter in a crisis state (M2) 
(Wright et al., 1989). At this point, cells have very short telomeres and their 
chromosomal ends fuse, leading to chromosome breakage-fusion-bridge cycles, 
genomic instability, and eventually cell apoptosis, known as programmed cell death 
(Hanahan & Weinberg, 2011; Wright et al., 1989). However, in rare situations, cells 
may acquire the ability to continuously divide which may promote malignant 
transformation (Figure 1.5). This process of unlimited self-renewal is mediated by 
telomerase that maintains or lengthens telomeres promoting the cellular 
immortalization process (Hanahan & Weinberg, 2011; Shay et al., 1991; Wright et al., 
1989). 
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Figure 1.5 Telomere length dynamics in different cells over time. Telomeres shorten over 
time. Germ cells and embryonic stem cells have long telomeres that are maintained by 
telomerase activity. Stem cells have shorter telomeres and somatic cells even shorter. After 
multiple cell divisions these cells achieve a senescence state (M1). At M2 stage cells enter 
crisis due to their short telomeres that lead to chromosomal and genomic instability resulting 
in apoptosis. Cancer cells escape from crisis through telomerase activation, reacquire longer 
telomeres and unlimited self-renewal capacity. Adapted from (Leão, Apolónio et al. 2018). 
 
 
Telomerase was discovered in 1985, as an enzyme capable of extending telomeric 
repeat sequences in Tetrahymena extracts. Later, in 1989, telomerase activity was 
reported for the first time (Greider & Blackburn, 1985, 1989; Morin, 1989). However, 
the protein component of telomerase was only identified and functionally characterized 
in 1997, more than a decade after its discovery (Harrington et al., 1997). This enzyme 
consists of a large ribonucleoprotein complex responsible for progressive synthesis of 
telomeric DNA repeats. The two different subunits that constitute telomerase are: a 
functional catalytic protein subunit termed human telomerase reverse transcriptase 
(hTERT) encoded by the hTERT gene, positioned at chromosome 5p15.33; and a 
RNA component known as human telomerase RNA component (hTERC or hTR), 
encoded by the hTERC gene on chromosomal region 3q26 (Cong, Wen, & Bacchetti, 
1999; Feng et al., 1995; MacNeil, Bensoussan, & Autexier, 2016). Other proteins 
including Pontin, Reptin, GAR1, NHP2, and TCAB1 were shown to be associated with 
the telomerase core complex and required for proper telomerase assembly and 
recruitment to chromosomes (Venteicher et al., 2008; Vulliamy et al., 2008). Dyskerin 
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and telomerase protein component (TEP1) have an important role in stabilizing the 
telomerase complex (Cohen et al., 2007; Saito et al., 1997). ES1P and ES3P are 
additional protein subunits (Ku heterodimer) involved in assembly and maturation, 
which also contribute to the telomerase enzymatic complex (Liu et al., 2004). Despite 
extensive research on these proteins, the three-dimensional structure of human 
telomerase is yet to be fully understood (Akincilar, Unal, & Tergaonkar, 2016). 
Importantly, only hTERC and hTERT are necessary for the reestablishment of 
telomerase activity (Beattie et al., 1998; Ishikawa, 1997; Weinrich et al., 1997). 
hTERT mRNA expression is strictly controlled and closely associated with telomerase 
activity, which suggests that hTERT is the primary determinant for the enzyme activity. 
Therefore, the current knowledge proposes that the limiting factor for telomerase 
activity is hTERT expression which is tightly regulated at transcriptional level (Akincilar 
et al., 2016; Avilion et al., 1996; Bodnar et al., 1998; Morales et al., 1999; Yi et al., 
1999). hTERC acts as a template for the synthesis of telomeric DNA, and unlike 
hTERT, is ubiquitously expressed in all tissues. Therefore, it has been considered by 
some authors as a non-limiting factor of telomerase activity (Cong, Wright, & Shay, 
2002; Kyo & Inoue, 2002). However, the study performed in fibrosarcoma-derived 
HT1080 cells, revealed that hTERC is more abundant in tumors than in normal cells 
with its locus amplified, and is essential for telomerase activity and can be a limiting 
factor (Cristofari & Lingner, 2006). 
Telomerase activity has been detected in around 90–95% of invasive breast 
carcinomas (Hiyama et al., 1996; Kulić et al., 2016; Poremba et al., 1998). By contrast, 
no activity has been found in non-malignant breast tissues including healthy breast 
tissue, papilloma and atypical hyperplasia (Kulić et al., 2016; Poremba et al., 1998). 
However, 59% to 70% of ductal in situ carcinomas have detectable telomerase activity, 
suggesting that telomerase reactivation is an early event in breast tumorigenesis and 
may be useful to predict the risk of developing invasive BC in patients with DCIS 
(Poremba et al., 1998; Rivenbark et al., 2013; Umbricht et al., 1999). Using tissue 
microarrays from 611 breast carcinomas, Poremba et al., demonstrated that increased 
expression of both telomerase core components, hTERT and hTERC, were 
associated with a worse BC prognosis, however, in multivariate analysis only hTERT 
protein expression revealed to be a strong independent prognostic factor (Poremba et 
al., 2002). Previous studies have also reported that levels of hTERT mRNA are higher 
in BC than in non-cancerous breast tissue (Elkak et al., 2006; Poremba et al., 2002). 
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Furthermore, higher hTERT expression showed to be strongly associated with a lower 
overall survival in BC patients, suggesting its potential role in breast carcinogenesis 
that could be used as a diagnostic/prognostic marker (Elkak et al., 2006; Lu et al., 
2011; Poremba et al., 2002). Nevertheless, the role of telomerase activity or hTERT 
as prognostic markers has been controversial in breast cancer, since some studies 
have found a significant association with clinicopathological features and disease 
outcome, and others failed to detect this association (Kulić et al., 2016; Lu et al., 2011; 
Poremba et al., 1998; Salhab et al., 2008). For example, in the study published by 
Kulić et al. telomerase activity was positively correlated with tumor size, nodal status, 
grade, HER-2 expression and Ki-67 expression, being also associated with a shorter 
10-year disease-free survival and 10-year overall survival (Kulić et al., 2016). On the 
other hand, Lu et al. reported a significant association between telomerase expression 
and tumor size, but did not find any association with other clinical features or disease 
outcome (Lu et al., 2011). 
It is well known that telomere shortening is present in the majority of in situ and 
invasive breast carcinomas (Meeker et al., 2004). Additionally, as telomerase activity 
and hTERT expression, also telomere shortening has been associated with TNM 
stage, disease aggressiveness and survival (Fordyce et al., 2006; Heaphy, 
Subhawong, Gross, et al., 2011), suggesting that apart from their role in tumor 
initiation, short dysfunctional telomeres may also contribute to disease progression. 
As previously mentioned, about 90-95% of BC cases maintain telomere length through 
telomerase reactivation, while the remaining subset of BC cases demonstrate to 
maintain telomeres through an alternative lengthening of telomeres (ALT) mechanism 
(Heaphy, Subhawong, Hong, et al., 2011; Lu et al., 2011; Poremba et al., 2002). ALT 
involves homologous recombination (HR)-mediated DNA replication, which occurs in 
the absence of telomerase activity (Royle et al., 2008). The mechanisms behind ALT 
activation and how ALT extends the telomeres are still poorly understood, however, it 
is currently known that this alternative process participates in chromosomes end-to-
end fusions and induce breakage-fusion-bridge cycles, resulting in an increased 
number of complex chromosomal rearrangements and genome-wide instability (Min, 
Wright, & Shay, 2017; Royle et al., 2008). The ALT positive cells/tumors are usually 
characterized by heterogeneous telomere lengths, extra-chromosomal circular and 
linear telomeric DNA and the presence of specialized promyelocytic leukemia nuclear 
bodies (PMLs) (Min et al., 2017; Pompili et al., 2017; Subhawong et al., 2009). 
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Therefore, the detection of ALT phenotype in cell lines or tumors can be deduced by 
the co-localization of telomeric DNA with ALT-associated PML bodies using 
fluorescence in situ hybridization (FISH) combined with PML protein 
immunofluorescence (Pompili et al., 2017; Subhawong et al., 2009). The ALT 
mechanism is commonly identified in sarcomas, glioblastomas and germ cell tumors, 
however is very rare in carcinomas, such as breast (Lee et al., 2019; Subhawong et 
al., 2009). In this context, Subhawong et al. were the first to identify the presence of 
ALT in 3 out of 71 invasive ductal breast carcinomas, belonging all the 3 cases to the 
HER2-positive group (Subhawong et al., 2009). Furthermore, in another study it was 
also reported a positive correlation between ALT phenotype and HER2 
overexpression, which suggests that both mechanisms may cooperate for genome 
instability usually observed in HER2 amplified breast carcinomas (Xu, Peng, & Song, 
2014). Interestingly, these authors also observed a co-expression of hTERT and ALT 
phenotype in the same cell of BC tissues, suggesting that both telomere extension 
mechanisms coexist and may work synergically in the same cell in human breast 
carcinoma  (Xu et al., 2014). 
Is important to mention that in recent years several researchers have pointed that 
telomerase and its components also exerts functions independent of telomere 
lengthening that are relevant for many biological processes (Cong & Shay, 2008; 
Hanahan & Weinberg, 2011). Among the non-canonical functions of telomerase, and 
in particular its protein component hTERT, are the regulation of chromatin 
architecture, involvement in DNA damage repair, enhancement of cell proliferation 
and resistance to apoptosis, gene expression regulation and maintenance of 
mitochondrial functionality (Chiodi & Mondello, 2012; Cong & Shay, 2008; Indran, 
Hande, & Pervaiz, 2011). For example, hTERT has been shown to amplify the Wnt-β-
catenin signalling pathway, regulating the expression of Wnt target genes, which play 
a crucial role in development and tumorigenesis (Park et al., 2009). Additionally, 
hTERT has been found associated with different factors/targets at multiple chromatin 
sites along the chromosomes and away from telomeres, thus evidencing the different 
roles and functions of telomerase/hTERT in tumorigenesis (Chiodi & Mondello, 2012; 
Masutomi et al., 2005; Park et al., 2009). 
Hence, telomerase and hTERT play crucial roles in cancer not only through telomere 
maintenance but also due to several functions to which hTERT contributes. hTERT 
regulation is a complex process yet to be fully understood, where both transcriptional 
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and posttranscriptional mechanisms are involved (Cong et al., 2002) and were shown 
to have clinical implications in cancers that rely on hTERT activation. 
 
1.2.2 Regulation of human telomerase reverse transcriptase (hTERT) 
 
It is widely known that in most cases, hTERT expression is closely correlated with 
telomerase activity, being considered the rate-limiting factor for telomerase activation 
in most cells (Cong et al., 2002). 
Telomerase is constitutively activated in germline, hematopoietic, stem and also 
rapidly renewing cells (Broccoli, Young, & de Lange, 1995; Counter et al., 1995). On 
the other hand, telomerase activity is very low or absent in somatic cells mainly due to 
tight hTERT regulation (Cifuentes-Rojas & Shippen, 2012). However, telomerase 
activity was found in normal human blood cells and other normal human cell types that 
are mitotically active, such as proliferative basal skin layer, endometrial tissue (during 
menstrual cycle), proliferative zone of intestinal crypts and hair follicles (Brien et al., 
1997; Broccoli et al., 1995; Counter et al., 1995; Harle-Bachor & Boukamp, 1996; 
Hiyama et al., 1995; Kyo et al., 1997; Ramirez et al., 1997; Saito, Schneider, et al., 
1997). 
Telomere length and telomerase activity diverge between embryonic and adult stem 
cells. While embryonic stem cells fully maintain their telomeres and exhibit telomerase 
activity, adult stem cells have progressive telomere shortening and minimal 
telomerase activity (Figure 1.5). Since hTERT is not expressed in most normal human 
cells, it can be used as a potential cancer biomarker. In fact, there are studies 
suggesting that telomerase activity might be a useful marker for diagnosis to detect 
cancer disease and prognosis as it is associated with stage and disease outcome in 
different cancers (e.g., prostate, breast, bladder, thyroid, colon, gastric and lung) (Ahn 
et al., 1997; Breslow et al., 1997; Carey et al., 1999; Fernandez-Marcelo et al., 2015; 
Glybochko et al., 2014; Graham & Meeker, 2017; Kulić et al., 2016; Lin et al., 1996; 
Tahara et al., 1995; Umbricht et al., 1997; Yoshida, Sugino, Goodison, et al., 1997; 
Yoshida, Sugino, Tahara, et al., 1997). 
hTERT regulation mechanisms have been studied for the last 20 years, and recent 
advances mainly related to the discovery of hTERT promoter mutations have given 
new impetus to better understand the mechanisms involved in hTERT regulation 
(Naderlinger & Holzmann, 2017). However, other alterations were recently reported, 
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and hTERT expression is also up-regulated in tumors via multiple genetic and 
epigenetic mechanisms including hTERT amplifications, hTERT genomic 
rearrangements and epigenetic modifications through hTERT promoter methylation 
(Barthel et al., 2017; Castelo-Branco et al., 2013). Also, pre-mRNA alternative splicing 
of the hTERT gene was found to be involved in the regulation of telomerase activity in 
cancer (Kilian et al., 1997; Liu et al., 2017; Nakamura et al., 1997) and has been 
associated with diagnosis, prognosis and clinical parameters (Liu et al., 2017). 
 
In the next sections of this thesis, the genetic and epigenetic mechanisms mainly 
involved in hTERT regulation are described, with a main focus on those implicated in 
breast cancer. 
 
1.2.2.1 Genetic mechanisms of hTERT regulation in cancer 
 
Several genetic mechanisms have been associated with hTERT reactivation in 
neoplastic cells, including hTERT DNA copy number amplifications, rearrangements, 
hTERT polymorphic variants and hTERT promoter mutations (Gaspar et al., 2018). 
 
1.2.2.1.1 DNA copy number amplifications 
 
Gain or loss of genetic material occurs frequently in cancer where gene amplification 
is an important mechanism for the oncogenic process. Gene amplification results from 
an increase in copy number associated with overexpression of the amplified gene. 
Different models have been proposed for the initiation of amplification including DNA 
replication errors, telomere dysfunction and the existence of chromosomal fragile sites 
(Albertson, 2006). Specifically, hTERT gene amplification can result from telomere 
dysfunction in addition to breakage at fragile sites and formation of chromosomal 
fusions (McClintock, 1942). In a large cohort including 31 different types of cancer, it 
was demonstrated that 3% out of 95% of hTERT expressing tumours presented 
hTERT amplifications (Barthel et al., 2017). Additionally, amplification of 
the hTERT gene was observed in 5 of 19 breast carcinomas (26%) (Zhang et al., 
2000). Furthermore, increased hTERT gene copy number was associated with 
upregulation of hTERT expression, related to acquired drug resistance and correlated 
with worse clinical outcomes in breast cancer (Gay-Bellile et al., 2017; Piscuoglio et 
al., 2016; Zhang et al., 2000). Therefore, hTERT may be a target for amplification 
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during breast tumorigenesis, which contributes to the dysregulation of telomerase 
activity, and may have clinical significance in breast cancer (Gay-Bellile et al., 2017; 
Zhang et al., 2000). 
 
1.2.2.1.2 DNA rearrangements 
 
Another potential mechanisms of hTERT upregulation in tumors are genomic 
rearrangements affecting the hTERT gene locus (5p15.33). Functionally, these 
rearrangements bring active enhancers in proximity to the hTERT gene, and the 
interaction between the promoter and these newly introduced enhancers drives 
hTERT expression (Gaspar et al., 2018; Peifer et al., 2015). So far, hTERT 
rearrangements have only been extensively explored in neuroblastoma, where these 
were associated with increased hTERT expression, poorer patient outcome, and found 
along with other telomere maintenance mechanisms including ALT and MYCN 
amplifications (Kawashima et al., 2016). Further studies are essential to understand 
whether or not hTERT rearrangements are present in different types of cancers, and 
as well their clinical impact. 
 
1.2.2.1.3 hTERT polymorphic variants 
 
hTERT polymorphisms have been consistently associated with susceptibility for 
multiple human tumors. Through genome-wide association studies (GWAS), several 
functional single nucleotide polymorphisms (SNPs) located in hTERT locus have been 
identified (Gaspar et al., 2018; Liu et al., 2018). These SNPs may occur in both intronic 
and exonic regions of hTERT or in its promoter, being called TERT promoter 
polymorphisms (Gaspar et al., 2018). Among the most common hTERT 
polymorphisms associated with cancer susceptibility are rs2736100, rs2736098, 
rs2853676, rs2853669 and rs2735940 (Aydin et al., 2018; Gaspar et al., 2018; Liu et 
al., 2018; Zhou et al., 2018). The relationship between hTERT polymorphisms 
and breast cancer risk has been reported in several publications, however the results 
have been controversial among the different studies. The rs2736098 variant, located 
in the second exon of the TERT gene, has been positively correlated with increased 
susceptibility for many types of cancer, especially lung and bladder cancer (Zhou et 
al., 2018). In a meta-analysis, Li et al. found that this variant is also associated with 
increased risk of developing breast cancer (Li et al., 2016), but in another study no 
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statistical difference was found between rs2736098 polymorphisms and BC risk (Aydin 
et al., 2018). Conflicting data was also observed for the rs2853669 variant, which is 
located in the TERT promoter. On one hand, this SNP has been described as a 
functional variant associated with BC risk (Helbig et al., 2017; Li et al., 2016), although 
other studies demonstrated that there was no significant association (Aydin et al., 
2018; Liu et al., 2018). Therefore, the role of TERT polymorphisms in breast 
tumorigenesis and patient prognosis still constitute an interesting field that should be 
further explored. 
 
1.2.2.1.4 hTERT promoter mutations 
 
In 2013, two pivotal studies reported two recurrent somatic non-coding mutations 
within the hTERT promoter region in both familial and sporadic melanomas (Horn et 
al., 2013; Huang et al., 2013). These two mutations were located at -124 and -146 bp 
upstream from ATG (chr5:1,295,228 G>A and 1,295,250 G>A, C>T on opposite 
strand). After the initial discovery, hTERT promoter mutations (TERTpMut) have been 
identified in multiple and distinct tumor types, such as glioblastoma, bladder and 
thyroid cancer, with different prevalence according to cancer type and histology 
(Vinagre et al., 2013). 
TERTpMut represents a frequent but unique genetic alteration that drives hTERT 
expression and telomerase activation. hTERT core promoter consists of 260 base 
pairs with multiple transcription-factor binding motifs that regulate gene transcription 
and telomerase activation (Kyo et al., 2008). The location of these mutations within 
the promoter creates additional binding sites for the E-twenty-six (ETS) transcription 
factor family, thus constituting a novel mechanism of genetic activation in cancer and 
a possible driver genomic alteration (Fredriksson et al., 2014; Vogelstein et al., 2013). 
The transcriptional control of hTERT gene is complex and includes regulation at 
multiple levels by various positive and negative factors or pathways (Cong et al., 
2002). Recent knowledge has come from the cloning of hTERT promoter and 
identification of various transcription factor binding motifs involved in hTERT 
expression and telomerase regulation by TERTpMut (Aisner, Wright, & Shay, 2002; 
Akincilar et al., 2016; Cong et al., 1999; Kyo & Inoue, 2002; Lewis & Tollefsbol, 2016; 
Wick, Zubov, & Hagen, 1999). TERTpMut modulate transcriptional regulation without 
altering an encoding protein. Functionally, TERTpMut are associated with the formation 
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of consensus binding sequence (CCGGAA) at the E-twenty-six/ternary complex 
(ETS/TCF) transcription factors (Figure 1.6), providing a possible mechanism for 
cancer-specific upregulation of telomerase (Horn et al., 2013; Huang et al., 2013). 
Mechanistically, ETS transcription factor binding to the motifs created by the 
mutations, causes the recruitment of a multimeric ETS family member, the GA-binding 
protein (GABP) that activates hTERT transcription (Bell et al., 2015; Huang et al., 
2013; Stern et al., 2015). These findings were further explored through luciferase 
reporter assays showing increased telomerase activity in cells transfected with mutant 
constructs (Horn et al., 2013; Huang et al., 2015; Huang et al., 2013). In cancer cells 
harboring TERTpMut, the mutant promoter recruits GABPA and exhibits H3K4m2/3, an 
active chromatin mark. On the other hand, control cell lines exhibit the H3K27me3, a 
mark of epigenetic silencing, suggesting that only the mutant promoters are 
transcriptionally active (Stern et al., 2015). Despite both mutations are functionally 
active, the TERTpMut C228T is significantly more frequent than the C250T (Hurst, Platt, 
& Knowles, 2014).  
The wide distribution of TERTpMut across different tumors and high frequency in some 
of them has created an important hub around these genetic alterations (Huang et al., 
2015; Vinagre et al., 2013; Wang et al., 2014). TERTpMut  are particularly recurrent in 
cancers with low rate of self-renewal, such as melanoma, liposarcomas, gliomas, 
squamous cell carcinoma, urothelial carcinomas and thyroid cancer, being associated 
with poor clinical outcomes in those cancer types (Huang et al., 2013; Killela et al., 
2013; Melo et al., 2014; Vinagre et al., 2013). Bladder, thyroid, cutaneous melanoma, 
basal cell and squamous carcinoma and oligodendrogliomas are examples of cancers 
where TERTpMut are widespread through different stages and grades of the disease, 
suggesting their role as an early tumorigenic event (Kinde et al., 2013; Na Wang et 
al., 2014). Additionally, not all TERTpMut tumors display telomerase activation and 
some premalignant lesions also displayed these genetic alterations at the hTERT 
promoter region (Shain et al., 2015), supporting the hypothesis that TERTpMut may act 
as early events in the oncogenic process (Liu & Xing, 2016; Liu et al., 2013; Populo et 
al., 2014; Vinagre et al., 2013). By contrast, there are other cancers that do not 
commonly harbour TERTpMut, such as breast cancer, colorectal carcinoma and 
prostate cancer, but show telomerase activation  (Vinagre et al., 2014). Specifically, 
TERTpMut  have been shown to be absent, or rarely observed, in breast cancer (Gay-
Bellile et al., 2017; Killela et al., 2013; Shimoi et al., 2018), with the exception of  breast 
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phyllodes tumors, a rare BC subtype, in which these mutations were detected in 65% 
of the cases (Yoshida et al., 2015). Together, these observations suggest that this 
mutational mechanism is not likely to be involved in TERT upregulation in BC, and 
thus other mechanisms responsible for telomerase activation might be at play (Gay-
Bellile et al., 2017).  
Unanswered questions remain to be elucidated related to the diverse frequency of 
mutations amongst different cancers and histological types. Also, the coexistence of 
hTERT regulation mechanisms in the same tumor and the eventual collaborative 
effects between TERTpMut and other hTERT regulatory mechanisms resulting in 
differential telomerase activation is object for future studies. 
 
 
 
 
 
Figure 1.6 Mechanisms of hTERT regulation in cancer. Transcription factors and their 
binding sites, as well the positions of both hTERT promoter mutations, C228T and C250T, the 
hypermethylated region upstream to TSS (THOR) and TERT-miRNAs are shown. The cancer-
specific mutations within the core promoter, at -124 and -146 bp positions generate ETS 
binding motifs, leading to GABP transcription factor recruitment and consequently hTERT 
transcription. Binding of transcriptional activators (c-Myc) and repressors (WT1 and CTCF) to 
the hTERT promoter may be controlled by DNA methylation, in which methylated CpGs 
prevent their binding to the target sites, leading to hTERT activation (THOR region). MiRNAs 
targeting the 3’UTR promotes translation repression of hTERT mRNA. Black dots represent 
methylated CpG sites. ETS - E-twenty-six; TSS - transcription start site; ATG - start codon. 
Adapted from (Leão, Apolónio et al. 2018). 
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1.2.2.2 Epigenetic mechanisms of hTERT regulation in cancer 
 
Epigenetics consist in the study of heritable and reversible modifications, involved in 
gene regulation, that do not alter the DNA sequence (Ct & Morris, 2001; Tollefsbol, 
2009). These epigenetic modifications regulate gene expression patterns by hindering 
the binding of transcription factors to DNA and chromatin structure modulation (Biswas 
& Rao, 2017; Portela & Esteller, 2010). Among the most studied epigenetic alterations 
are DNA methylation, histone modifications and miRNAs, which interplay and are 
critical for normal development, differentiation and human disease  (Byler et al., 2014; 
Tollefsbol, 2012). Furthermore, it is known that epidemiological factors, such as diet, 
environmental agents, drugs and infections have a great impact on the epigenetic 
profile and therefore on the phenotype (Tollefsbol, 2011). Together, these epigenetic 
gene regulators play a key role in hTERT gene expression and thus, on telomerase 
reactivation (Lewis & Tollefsbol, 2016).  
 
1.2.2.2.1 Histone modifications 
 
A key epigenetic mechanism of hTERT regulation is histone modification, including 
histone acetylation, methylation, phosphorylation, and ubiquitinization (Sui et al., 
2013). Histones are responsible for chromatin organization carrying basic charges on 
their tails that are associated with DNA. By affecting the charge status of the histone 
tails, their affinity for DNA changes and this alters chromatin structure as a 
consequence (Lewis & Tollefsbol, 2016; Portela & Esteller, 2010). Most commonly, 
histone acetylation of H3 and H4, and methylation of H3K4, H3K36 and H3K79 are 
associated with an open chromatin state (euchromatin) and active gene transcription. 
Conversely, deacetylation of histones and high levels of H3K9, H3K27 and H4K20 
methylation reduces the DNA accessibility to transcription factors, and thus, is 
associated   with inactive gene transcription (heterochromatin) (Portela & Esteller, 
2010; Sui et al., 2013).  
Histone deacetylase (HDAC) inhibitors, such as tricostatin A (TSA) have been shown 
to induce hTERT mRNA expression and telomerase activity in normal human cells and 
upregulation of hTERT expression in telomerase-positive tumor cells (Hou et al., 2002; 
Takakura et al., 2001). Further studies have shown that lack of hTERT expression in 
ALT tumor cells (telomerase negative) is associated with histone H3 and H4 
deacetylation and H3K9 methylation, while hTERT transcription in telomerase-positive 
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cells is associated with H3 and H4 hyperacetylation and H3K4 methylation (Atkinson 
et al., 2005). These findings suggest that histone deacetylation is a critical factor for 
hTERT repression in human normal cells and that telomerase reactivation in 
telomerase-negative cells can be achieved by chromatin remodelling. Meeran et al. 
reported that sulforaphane (SFN), a common dietary component of vegetables, acts 
as a HDAC inhibitor, increasing the histone acetylation marks and decreasing inactive 
chromatin marks along the hTERT promoter. Interestingly, the SFN-induced 
hyperacetylation was associated with hTERT repression in breast cancer cells, since 
it promotes the binding of hTERT repressors such as MAD1 and CTCF to the hTERT 
regulatory region (Meeran, Patel, & Tollefsbol, 2010). Therefore, this study further 
evidences the impact of histone modifications in hTERT regulation and opens new 
opportunities for approaches to breast cancer prevention. 
 
1.2.2.2.2 MicroRNAs 
 
Non-coding RNA molecules, such as miRNAs have been closely involved in hTERT 
regulation in multiple types of cancer (Lewis & Tollefsbol, 2016). MiRNAs are short (20 
to 23 nucleotides) endogenous RNA molecules that have a crucial role in gene 
expression regulation (Esteller, 2008; Winter et al., 2009). Specifically, miRNAs have 
been reported to play critical roles in fundamental pathophysiological processes, such 
as cell proliferation, apoptosis, differentiation and metabolism, and also in several 
human diseases, including cancer (Di Leva, Calin, & Croce, 2006; Esteller, 2008; 
Huppi et al., 2007). In cancer, alterations in miRNA patterns are often associated with 
genomic events such as mutations, deletions, amplifications and transcriptional 
changes or may be due to defects in enzymes involved in miRNA biogenesis. 
Functionally, miRNAs mediate the post-transcriptional gene silencing of their target 
genes, inducing translation repression or mRNA degradation (Suzuki, Maruyama, & 
Kai, 2013). Downregulation of miRNAs in tumor tissues suggests a tumor suppressor 
function (suppressor-miRNAs), since a decrease in their expression levels normally 
contributes to oncogenesis. On the other hand, overexpression of miRNAs that target 
tumor suppressor genes have been associated with oncogenic activity (oncomiRNAs) 
(Cho, 2007; Pérez-Rivas et al., 2014). Therefore, depending on their target genes, 
miRNAs can act as tumor suppressors or oncogenes. 
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hTERT-targeting miRNAs negatively regulate its expression, inhibiting tumorigenesis 
and have been shown to be frequently downregulated in cancer, including breast 
(Figure 1.6) (Hrdlickova et al., 2014). MiRNAs can regulate hTERT in either direct or 
indirect manners. MiRNAs may directly bind to hTERT 3 prime untranslated region 
(3’UTR), and interfere with hTERT protein production as found in cancer cell lines 
(Hrdlickova et al., 2014; Lewis & Tollefsbol, 2016). For example, downregulation of 
mir-138 was shown to be associated with hTERT overexpression in anaplastic thyroid 
carcinoma cells, and the enforced overexpression of mir-138 induced a significant 
reduction in hTERT expression through interaction with hTERT 3’UTR (Mitomo et al., 
2008). Additionally, let-7g, miR-133a, miR-342-5p and miR-491-5p downregulated 
telomerase activity and inhibited cell proliferation in breast cancer cells (Hrdlickova et 
al., 2014). These miRNAs co-regulate hTERT, Wnt pathway-genes and importantly, 
might regulate other genes involved in oncogenesis, suggesting the presence of an 
oncogenic miRNA regulatory network involving telomerase activation (Cittelly et al., 
2010; Hrdlickova et al., 2014; Östling et al., 2011). As an example, miR-342-5p 
downregulation was previously associated with tamoxifen-resistant breast tumors 
(estrogen receptor pathway) (Cittelly et al., 2010). Additionally, Dinami et al 
demonstrated that ectopic expression of miR-296-5p and miR-512-5p reduced 
telomerase activity, drove telomere shortening and promote senescence and 
apoptosis by targeting hTERT in breast cancer cells (Dinami et al., 2017). MicroRNAs 
can also regulate hTERT indirectly by targeting transcription factors involved in hTERT 
regulation (Lewis & Tollefsbol, 2016). For example, mir-494 and mir-1294 were 
reported to downregulate c-Myc, which is a known transcriptional activator of hTERT 
(Lewis & Tollefsbol, 2016; Liu et al., 2015). Further, miR-34a, a known tumor 
suppressor in multiple types of cancer, was reported to induce cellular senescence by 
targeting c-Myc and FoxM1 in the telomere pathway (Xu et al., 2015). Specifically, one 
ongoing clinical trial (Phase I, NCT01829971) is testing MRX34, a liposomal miR-34a 
mimic in multiple malignancies (Rupaimoole & Slack, 2017). Hence, miRNAs that 
target hTERT appear to be a promising approach to prevent and treat cancers that are 
telomerase-dependent, like breast cancer. 
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1.2.2.2.3 hTERT promoter methylation 
 
DNA methylation, which was the first identified and the most well studied epigenetic 
process, is crucial in gene expression regulation (Tollefsbol, 2011). DNA methylation 
occurs genome-widely at CpG sites usually located in non-coding regions. This 
process, mediated by DNA methyltransferases (DNMTs), occurs mostly in the context 
of dinucleotide sequences 5’-CG-3, often referred to as CpG methylation and consists 
in the addition of a methyl group (-CH3) on the 5-carbon of a cytosine (C) base 
followed by a guanine (G) base (Esteller, 2008; Tollefsbol, 2011). CpG dinucleotide 
sequences are spread throughout the genome, but there are specific regions known 
as CpG islands where high frequency of CpG dinucleotides is observed. 80% of CpG 
sites are methylated in intergenic regions while most sites in the promoter and exon 1 
regions are typically unmethylated (Deaton & Bird, 2011). CpG islands are usually 
clustered near the gene promoters where transcription initiation occurs. About 70% of 
the human gene promoters contain CpG islands, and therefore DNA methylation is 
thought to play an important role in gene expression (Saxonov, Berg, & Brutlag, 2006; 
Deaton & Bird, 2011) . Promoter DNA methylation has been recognized as one of the 
most frequent and stable ways of gene expression control. Hitherto, promoter DNA 
methylation is thought to promote gene silencing. In actively transcribed genes, the 
promoter tends to be unmethylated, since DNA methylation has been associated with 
gene silencing by hindering transcription factor binding or affecting chromatin 
architecture (Baylin & Jones, 2011). In fact, in most cases, genes with methylated 
promoters are usually silenced while genes with unmethylated promoters are actively 
transcribed, the pattern observed in tumor suppressors and oncogenes in cancer, 
respectively (Hatada et al., 2006). During cancer progression, there is a progressive 
genome-wide hypomethylation of CpG sites along gene bodies and hypermethylation 
of CpG islands in gene promoter regions (Herman & Baylin, 2003). Thus, abnormal 
DNA methylation is a hallmark of cancer cells and is crucial in cancer development 
(Bartlett et al., 2013). 
Despite the powerful role of recurrent hTERT promoter mutations in hTERT activation, 
there are several tumor types that exhibit low or absence of these mutations, including 
breast and prostate cancer (Killela et al., 2013). Thus, the role of epigenetic 
mechanisms in cancer-specific hTERT regulation has been a topic of study for the 
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past decade, and several studies have shown contradicting effects of hTERT promoter 
methylation on hTERT expression. 
Although some authors have reported hypomethylation in the CpG islands covering 
hTERT promoter, others identified increased DNA methylation in hTERT-expressing 
cancers, including breast cancer cells (Dessain, Yu, & Reddel, 2000; Devereux et al., 
1999; Guilleret & Benhattar, 2004; Guilleret et al., 2002; Shin et al., 2003). In fact, 
hTERT was one of the first genes in which methylation of its promoter was positively 
correlated with gene expression (Guilleret et al., 2002). This correlation between 
hTERT promoter methylation, hTERT mRNA and telomerase activity suggests that 
methylation of hTERT promoter may be implicated in hTERT regulation, but in a 
different manner from other genes also regulated by promoter methylation (Guilleret 
et al., 2002). 
As mentioned above, promoter methylation is often associated with gene silencing. 
However, several studies have shown that methylation of specific regions within 
hTERT promoter, particularly, upstream of the hTERT core promoter, is associated 
with gene activation (Castelo-Branco et al., 2013; Zinn et al., 2007). The precise 
mechanisms by which the methylation pattern of hTERT promoter results in hTERT 
activation is still under investigation (Figure 1.6).  
There are several explanations as to how hTERT promoter methylation can result in 
hTERT activation. The first possibility is based on the prevention of repressive 
elements binding caused by DNA methylation at the repressive region: if part of the 
hTERT promoter is hypomethylated (unmethylated), the transcriptional repressors can 
bind the promoter and block the transcriptional machinery (Figure 1.6). Conversely, if 
partially methylated, hTERT promoter binding is prevented and therefore will allow the 
promoter to be activated by appropriate transcriptional factors. An interesting 
observation from these results is that proximal hTERT core promoter – allowing 
essential drivers of gene expression to access the promoter is almost always 
hypomethylated and associated with active chromatin marks, and the region upstream 
of core promoter is often hypermethylated (Azouz, Wu, & Hillion, 2010; Zinn et al., 
2007). Whether coincidental or reasonable, recurrent hTERT mutations seem to occur 
in the unmethylated region, which supports the hypothesis that ETS family factors 
binding to these sites activate hTERT expression (Huang et al., 2013). Evidence has 
been also given by experiments showing that demethylation of repressor binding sites 
by 5-aza-2-deoxycytidine, which globally reduces DNA methylation, results in reduced 
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levels of hTERT transcription (Tsujioka et al., 2015).  Also, factors such as CTCF, 
which interact with hTERT promoter, are known for organizing global chromosomal 
architecture, and methylation-sensitive binding of CTCF may be changing not only the 
accessibility but also chromosomal conformation and possible interactions with 
enhancers or silencers far away in distance. CTCF binds downstream to 
transcriptional start site (TSS) and represses hTERT transcription, but DNA 
methylation prevents CTCF binding and consequently allows the activation of 
telomerase in cancer cells (Renaud et al., 2007; Renaud et al., 2005). Wilms tumor 
protein (WT1) is another repressor of hTERT expression (Lopatina et al., 2003). WT1 
exhibits methylation-sensitive binding to DNA sequence, with reduced binding when 
one or more methylated bases are present (Avin, Umbricht, & Zeiger, 2016). WT1 
binding sites exhibit increased CpG methylation in cancer, including breast, which 
results in the blocking of repressive effects and consequently hTERT expression 
(Guilleret et al., 2002; Shin et al., 2003). MYC proto-oncogene encodes a ubiquitous 
transcription factor (c-Myc) which is overexpressed in several human cancers, being 
involved in the control of cell proliferation, differentiation and apoptosis (Mannava et 
al., 2008). c-Myc has a direct role in the induction of telomerase activity through hTERT 
transcription  (Wu et al., 1999). As CTCF and WT1, c-Myc binding is also methylation-
sensitive and its binding is absent or reduced when the binding site is methylated, 
resulting in reduced hTERT expression (Prendergast & Ziff, 1991).  
Another possible explanation is a more complex mechanism involving DNA 
methylation and chromosome structural changes (Ng & Bird, 1999). DNA methylation 
can contribute to changes in chromatin conformation influencing gene expression by 
affecting DNA exposure to transcription factor binding (Bert et al., 2013). DNA 
methylation is often linked to histone modifications and might control the accessibility 
of transcription factors to the promoter. Specific conformational changes caused by 
methylation of hTERT promoter may be causing differential recruitment and binding of 
factors that can drive hTERT expression in cancer (Lewis & Tollefsbol, 2016). As 
mentioned before, several histone post-translational modifications can affect the 
compaction state of chromatin, which influences the folding, position and organization 
of DNA, thereby affecting gene expression (Bannister & Kouzarides, 2011). For 
example, in hTERT promoter mutant cancers, monoallelic expression of hTERT is 
controlled by CpG methylation and chromatin modifications, in which TERTpMut gene 
show allele-specific DNA hypomethylation in the expressed allele, while the inactive 
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hTERT allele exhibits high levels of CpG methylation linked with enhanced Polycomb 
repressive complex 2 (PRC2) binding and H3K27me3 inactive chromatin marks (Stern 
et al., 2017). Also, Berletch et al., demonstrated that a decrease in hTERT promoter 
methylation and ablation of histone H3K9 acetylation contributed for the 
downregulation of hTERT gene expression in breast cancer cells (Berletch et al., 
2008). Therefore, both epigenetic mechanisms, DNA methylation and histone 
modification, seem to cooperate in hTERT regulation in multiple cancers, including 
breast. 
 
The absence of ALT mechanism and activating hTERT promoter mutations in breast 
cancer, suggest a major role for hTERT promoter methylation and consequent 
telomerase reactivation in this type of cancer. Therefore, this thesis focuses on hTERT 
epigenetic regulation through hTERT promoter methylation, and its clinical relevance 
is elucidated in the next section. 
 
1.2.3 Clinical relevance of hTERT promoter methylation 
 
Several cancer types including brain, breast, prostate, urothelium, colon, and blood 
showed high frequency of a hypermethylation signature in a specific region upstream 
of hTERT core promoter (Castelo-Branco et al., 2013; Zinn et al., 2007). More 
interestingly, even in melanomas where hTERT promoter mutations were first 
identified, hTERT promoter methylation was associated with hTERT upregulation 
(Seynnaeve et al., 2017). Despite high prevalence of this tumor-specific signature 
across various tumor types, there has been little effort put into translating these 
findings to apply in clinical settings. Methylation of a specific region in the hTERT 
promoter was identified as a potential biomarker of tumor progression and survival in 
pediatric gliomas (Castelo-Branco et al., 2013). This region termed THOR (TERT 
Hypermethylated Oncological Region) is hypermethylated in malignant tumours and 
hypomethylated in normal tissues and stem cells (Castelo-Branco et al., 2013). THOR 
is 100% specific and 96% sensitive for the detection of hTERT expressing malignant 
neoplasms. Additionally, THOR hypermethylation showed prognostic value, as it 
identified which low-grade tumours would progress to high-grade ones and predicted 
survival in a subset of pediatric cancers (Castelo-Branco et al., 2013). Moreover, 
THOR was further explored in prostate, pancreatic and bladder cancer, in which it was 
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shown to have a role as a potential diagnostic and prognostic marker (Castelo-Branco 
et al., 2016; Faleiro, Apolónio, et al., 2017; Leao et al., 2019). These findings have 
been expanded upon by multiple groups implicating hTERT promoter methylation in 
hTERT upregulation, and further demonstrating not only its diagnostic but, importantly, 
its clinical significance in cancer prognostic including thyroid cancer, acute myeloid 
leukemia/myelodysplastic syndrome, gastric cancer, medulloblastoma, meningioma, 
colorectal cancer and hepatocellular carcinoma (Choi et al., 2007; Fürtjes et al., 2016; 
Lindsey et al., 2014; Wang et al., 2016; Wun et al., 2016; Zhang et al., 2015; Zhao et 
al., 2016). In these studies, hTERT promoter hypermethylation was positively 
correlated with high hTERT expression, telomerase reactivation and in the vast 
majority of the cases correlated with worse clinical outcomes. 
As mentioned before, breast cancer is a telomerase-dependent disease, where 
telomerase reactivation occurs in 95% of the cases (Hiyama et al., 1996; Kulić et al., 
2016; Poremba et al., 1998). Furthermore, increased hTERT expression, telomerase 
activity and telomere shortening have been proposed as early events in breast 
tumorigenesis with clinical implications in this disease, since those have been 
associated with disease progression and reduced BC survival (Poremba et al., 1998; 
Rivenbark et al., 2013; Umbricht et al., 1999). However, the mechanisms responsible 
for telomerase activation in breast cancer are still not completely known. Regarding 
genetic mechanisms involved in hTERT regulation, hTERT amplifications were 
observed and associated with poor clinical outcome in breast carcinoma (Gay-Bellile 
et al., 2017; Zhang et al., 2000). hTERT polymorphisms were identified, however 
generated conflicting data in BC, whereas genomic rearrangements and the highly 
frequent hTERT promoter mutations were not yet or are rarely observed, respectively 
(Gay-Bellile et al., 2017). Epigenetically, several miRNAs and histone modifications 
have been identified as key post-transcriptional and post-translational regulators of 
hTERT, respectively (Hrdlickova et al., 2014). Finally, several studies have detected 
hTERT promoter methylation in breast cancer cells, but little is known about its 
contribution for hTERT upregulation and consequent telomerase activation, as well as 
its clinical significance. Therefore, based on the previous work on THOR performed 
by our group, there is a strong reason to investigate the diagnostic and prognostic role 
of THOR in breast cancer patients. Furthermore, THOR is a 36 base-pair region easy 
to amplify and the assay can be done on most tissues, including formalin-fixed, 
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paraffin-embedded (FFPE) tissues samples, which facilitates their translation into 
clinical practice (Castelo-Branco et al., 2013; Ludyga et al., 2012).  
 
In addition to hTERT DNA methylation profile, several studies have reported DNA 
methylation alterations in other genes relevant for BC development (Brooks et al., 
2010; Fleischer et al., 2014; Zhu et al., 2012;  Zhu et al., 2015). Therefore, in the next 
section of this thesis the importance of the epigenome in BC development, and in 
particular, DNA methylation aberrations in BC is highlighted. 
 
 
1.3 DNA Methylation Portrait in Breast Cancer 
 
1.3.1 DNA methylation alterations in breast cancer 
 
DNA methylation is the most well studied epigenetic mechanism and alterations in this 
epigenetic process commonly contribute to human disease (Tollefsbol, 2011). For 
example, imprinting disorders such as the Angelman and Silver Russell syndromes, 
autoimmune diseases, diabetes, autism and cancer are often associated with DNA 
methylation aberrations (Robertson, 2005; Tollefsbol, 2012). 
The process of DNA methylation is catalysed by DNA methyltransferases (DNMTs), 
which transfer a methyl group from S-adenosyl-methionine (SAM) to the fifth carbon 
of a cytosine (5mC) in the context of CpG dinucleotides. There are three main DNMTs: 
DNMT1, which is responsible for the maintenance of methylation patterns following 
DNA replication, and DNMT3A and DNMT3B, both de novo methyltransferases that 
target previously unmethylated CpGs (Jin & Liu, 2018; Tollefsbol, 2011). The reverse 
process, DNA demethylation, also occurs, and can be achieved passively or actively. 
Passive DNA demethylation occurs by the failure of DNA methylation maintenance 
machinery to methylate DNA after replication. By contrast, active demethylation is 
performed by Ten-eleven translocation (TET) enzymes, which catalyse the oxidation 
of 5mC to form 5-hydroxymethylcytosine (5hmC) and promote locus-specific removal 
of DNA methylation marks (Biswas & Rao, 2017; Kohli & Zhang, 2013). Therefore, 
dysregulation of DNMTs and TETs, which are usually upregulated and downregulated 
in cancer, respectively, strongly contributes to the  link between DNA methylation and 
cancer (Kohli & Zhang, 2013; Subramaniam et al., 2014). 
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Canonically, promoter methylation is thought to induce gene downregulation through 
the recruitment of methyl-binding domain proteins (MBDs), which change chromatin 
conformation and prevents the binding of transcription factors (Bert et al., 2013; 
Stefansson & Esteller, 2013). However, there are some exceptions to this dogma, and 
currently it is known that promoter CpG methylation can lead either to gene 
upregulation or downregulation (Bert et al., 2013; Castelo-Branco et al., 2013; Zinn et 
al., 2007). Both CpG hypermethylation and hypomethylation contribute to 
tumorigenesis. Specifically, hypermethylation is often associated to the silencing of 
tumor suppressor genes, thereby contributing to several hallmarks of cancer, while 
hypomethylation can contribute to genomic instability, oncogene activation and loss of 
imprinting (Tollefsbol., 2009). 
Nowadays, it is clear that DNA methylation patterns differ between tissue types, 
tumors and normal surrounding tissue (Szyf, 2012). Indeed, several studies have 
shown that differences in DNA methylation profiles between normal and malignant 
breast tissue have the potential to serve as a diagnostic and/or prognostic tools in 
breast cancer (Lewis et al., 2005; Mirza et al., 2007; Stefansson et al., 2015). DNMTs 
are overexpressed in breast cancer where about 30% of the patients revealed 
DNMT3B overexpression in the tumor tissue when compared to normal breast tissue, 
being this overexpression associated with poor relapse-free survival (Girault et al., 
2003). DNMT1 and DNMT3A were shown to be overexpressed in only 5 and 3% of 
breast carcinomas, thus, DNMT3B seems to play a predominant role in the observed 
DNA methylation aberrations in BC (Girault et al., 2003; Subramaniam et al., 2014). 
For instance, early DNA methylation changes associated with BC development were 
identified in invasive BC tissue at several genomic locations, including promoters, far-
upstream regions, introns, LINE-1 and satellite 2 DNA repeats (Rauscher et al., 2015). 
Zhu et al. reported that promoter hypermethylation of BRCA1 gene is a frequent event 
in triple-negative BC (TNBC), being associated with decreased overall survival and 
can be used as a biomarker for TNBC, in particular for the basal-like subtype (Zhu et 
al., 2015). Further studies investigated whether aberrant DNA methylation could be 
found in the serum of BC patients and their diagnostic and prognostic value (Mirza et 
al., 2007; Müller et al., 2003). In particular, the methylation pattern of RASSF1A and 
APC genes in serum DNA was associated with a poor clinical outcome and was 
considered more powerful than standard prognostic parameters (Müller et al., 2003). 
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Thus, these findings highlight the potential of DNA methylation based screening of 
serum to be used as a tool for BC diagnosis and prognosis. 
Although several studies have addressed the impact of DNA methylation alterations 
in BC and their clinical utility, to date, most studies have focused on a small number 
of genes (Mirza et al., 2007; Stefansson & Esteller, 2013; Zhu et al., 2015) and only a 
few studies have performed genome-wide analyses across multiple BC subtypes 
(Fleischer et al., 2014; Holm et al., 2016; Network, 2012; Stefansson et al., 2015). 
Specifically, Stefansson et al. identified two DNA methylation signatures associated 
with the Luminal-B and Basal-like molecular BC subtypes. These DNA methylation-
based subtypes, termed Epi-LumB and Epi-Basal, were characterized by CpG island 
promoter methylation and by hypomethylation events within the gene body, 
respectively, being both associated with a worst outcome (Stefansson et al., 2015). 
These results suggest that distinct mechanisms contribute to changes in the DNA 
methylation status between the different breast cancer subtypes, and more 
importantly, provide useful information beyond that of other clinical parameters for 
making better therapeutic decisions (Stefansson et al., 2015). Nevertheless, there is 
still a lot to explore about the epigenomic landscape of breast cancer, and in particular, 
the DNA methylation patterns behind BC heterogeneity. Furthermore, the advent of 
new technologies for genome-wide DNA methylation assessment, such as whole 
genome bisulfite sequencing (WGBS) and DNA Illumina Infinium 
HumanMethylation450 Array  (Illumina, San Diego, CA, USA) have provided 
opportunities to better address this question (Holm et al., 2016; Szyf, 2012). 
It is important to say that one of the biggest challenges in breast cancer clinical practice 
is the development of non-invasive molecular markers for early screening, diagnosis 
and treatment follow-up. In this context, several studies have demonstrated that the 
identification of DNA methylation signatures of BC through circulating tumor cells or in 
circulating DNA in blood reflect the methylation status of the tumor tissue, and thus, 
constitute a powerful clinical tool with a growing interest from the research community 
(Bettegowda et al., 2014; Müller et al., 2003; Silva et al., 1999; Szyf, 2012; 
Widschwendter et al., 2017). 
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1.3.2 Edition of DNA methylation marks in the mammalian genome  
 
DNA methylation is a dynamic epigenetic mark in mammals, which plays essential 
roles in many biological processes. This epigenetic mechanism cooperates with the 
other components of the epigenome and with the genome itself, thereby affecting gene 
expression, cell phenotype and promoting oncogenic transformation (Esteller, 2008; 
Shen & Laird, 2013). 
The establishment, maintenance and modification of DNA methylation marks are 
intricately regulated, and depends on the accurate work of the epigenetic machinery 
(Jones et al., 2016; Portela & Esteller, 2010). DNA methylation marks are stable yet 
reversible covalent modifications that are established by DNMTs, called writers, 
identified by proteins that recognize those modifications such as the methyl-CpG 
binding domain (MBD) proteins, termed readers. These epigenetic marks can be 
removed by TET enzymes, known as erasers of the epigenome (Jones et al., 2016). 
Therefore, the plasticity of DNA methylation patterns is highly dependent on the 
existence and interplay among all of these epigenetic players. Through the application 
of next generation sequencing it was possible to identify that mutations in writers, 
readers and erasers are common events in cancer, which contribute to the 
dysregulation of the epigenetic machinery, and consequently, to an altered epigenome 
(Jones et al., 2016; Kohli & Zhang, 2013; Yamazaki et al., 2015). Specifically, 
mutations in DNMT3A and TET2 have been frequently identified in acute myeloid 
leukaemia (AML) (Abdel-Wahab et al., 2009; Kim et al., 2013; Yamazaki et al., 2015).  
All the epigenetic players may be potentially targetable, and currently the targeting of 
DNA methylation marks for drug development constitute a growing area of interest, 
where some drugs were already approved by the FDA, such as the DNMTs inhibitors 
5-azacytidine (Vidaza) and 5-aza-2ʹ-deoxycytidine (decitabine) for AML and 
myelodysplastic syndromes treatment (Biswas & Rao, 2017; Jones et al., 2016). To 
date, these drugs have been tested in several clinical trials for the treatment of multiple 
malignancies, including breast (e.g. NCT01349959 and NCT01194908) (Zhu & Qian, 
2015). However, despite these drugs being considered promising anticancer agents, 
they act genome-wide, causing large-scale changes in gene expression instead of 
targeting specific loci (Hilton et al., 2015). 
Recent advances in genome editing technologies has enabled site-specific 
manipulation of the genome and epigenome of eukaryotic cells (Cox, Platt, & Zhang, 
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2015). This core technology for epigenome editing is useful not only to investigate the 
relationship between specific epigenetic marks and gene regulation, but also hold a 
great potential to benefit human heath since they bring new perspectives in the 
therapeutic setting (Cox et al., 2015; Gaj, Gersbach, & Barbas, 2014). There are 
different approaches based on programmable nucleases for epigenome editing, 
including zinc finger nucleases (ZFNs), transcription activator–like effector nucleases 
(TALENs), and clustered regularly interspaced short palindromic repeat (CRISPR)-
associated nuclease Cas9 (Hilton et al., 2015; Maeder et al., 2013). To date, several 
studies have reported to successfully targeted DNA modifications, methylation and 
demethylation using the above technologies. Furthermore, multiple authors 
demonstrated their utility for functional studies of epigenetic regulation (Liu et al., 2016; 
Maeder et al., 2013; Vojta et al., 2016). 
 
In this thesis, the focus is the CRISPR-Cas9 system where the next section describes 
the fundamentals of this technology. 
  
1.3.2.1 CRISPR-dCas9 system technology 
 
The clustered regularly interspaced short palindromic repeats (CRISPR)-Cas system 
consists in a natural “immune system” that was discovered in 1987 in Escherichia coli 
(Garneau et al., 2010; Ishino et al., 1987). In bacteria, this naturally occurring CRISPR-
Cas system provides acquired immunity against invading foreign DNA via RNA-guided 
DNA cleavage, and was recently adapted to be used in genome and epigenome 
editing (Figure 1.7) (Garneau et al., 2010; Ishino, Krupovic, & Forterre, 2018; Sander 
& Joung, 2014). Briefly, in the engineered CRISPR-Cas system, two components must 
be introduced into and expressed in the cells in order to perform genome editing: the 
Cas9 nuclease and a guide RNA (gRNA). Through DNA-gRNA base complementarity, 
the Cas9 binds to the targeted DNA and mediates DNA cleavage. The gRNA 
comprises a short synthetic RNA composed of a “scaffold” sequence necessary for 
Cas9-binding and a ∼20 nucleotide “targeting” sequence, which must be unique 
compared to the rest of the genome and complementary to the target DNA sequence. 
Furthermore, the target sequence should be immediately upstream of a protospacer 
adjacent motif (PAM), which is specifically recognized and required for Cas9 binding 
to DNA (Gaj et al., 2014; Komor, Badran, & Liu, 2017; Sander & Joung, 2014). 
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Currently, with the advances on CRISPR-Cas technology, several modifications to the 
original CRISPR-Cas system are available, which allow its application beyond genome 
editing through DNA cleavage. These novel approaches allow the epigenome editing 
at specific loci, thereby enabling the direct study of precise epigenetic modifications in 
gene regulation (Komor et al., 2017; Vojta et al., 2016).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Bacterial immune system and engineered CRISPR-Cas systems. A. In 
bacteria, the CRISPR systems incorporate foreign DNA sequences into CRISPR repeated 
arrays, which are processed into CRISPR RNAs (crRNAs) each harboring a “protospacer” 
region complementary to the foreign DNA. crRNAs anneal to transactivating crRNAs 
(tracrRNAs) and then this pair of RNAs by association with the nuclease Cas9 induce 
sequence-specific cleavage and silencing of pathogenic DNA. B. The engineered CRISPR-
Cas system is based on a fusion between a crRNA and a fixed tracrRNA sequence. This single 
gRNA by association with Cas9 mediates target DNA cleavage of sites that are 
complementary to the nucleotide sequence of the gRNA and that are located near to a PAM 
sequence. Adapted from (Sander & Joung, 2014). 
 
 
The modified CRISPR-Cas approaches for epigenome editing are based on the use 
of a catalytically inactive or “dead” nuclease Cas9 (dCas9) fused to a variety of 
epigenetic modifiers, in which the dCas9-sgRNA complex is targeted to specific 
loci without inducing double strand breaks (Komor et al., 2017; Liu et al., 2016; Vojta 
et al., 2016). For example, the fusion of dCas with the effector domain of transcriptional 
A B 
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activators such as, herpes simplex viral protein 16 (VP16 or VP64) or repressors like 
Krüppel-associated box (KRAB) has been shown to regulate endogenous gene 
expression in human and mouse cells (Gilbert et al., 2013; Hilton et al., 2015; Perez-
Pinera et al., 2013). Nevertheless, this indirect method of epigenome editing does not 
allow the direct modulation of the chromatin state, and consequently, evaluate the role 
of specific epigenetic marks in gene regulation. Therefore, the fusion of dCas9 with 
enzymatic epigenetic modifiers, such as the histone acetyltransferase p300, histone 
demethylase LSD1, DNA demethylase TET1 and DNA methyltransferase DNMT3A 
allows a direct modification of epigenetic marks and the control of downstream gene 
expression (Hilton et al., 2015; Komor et al., 2017; Liu et al., 2016; Morita et al., 2016). 
Hence, these diverse applications of CRISPR-Cas9 systems have transformed the 
genome-editing field and have contributed to great advances in basic research, 
biotechnology and clinical research (Ishino et al., 2018). 
 
1.3.2.2 Targeted DNA modifications by CRISPR-dCas9 system 
 
As explained above, in the modified CRISPR-dCas9 system, the dCas9 maintain their 
properties of binding to the dsDNA based on the complementarity between the 
engineered gRNA and the target DNA site, while the function is given by fusion of 
dCas9 to a novel effector domain (Hilton et al., 2015; Vojta et al., 2016).  
To date, several researchers have demonstrated that CRISPR-dCas technology 
enables precise DNA methylation edition in a targeted and reliable manner 
(Choudhury et al., 2016; Morita et al., 2016; Vojta et al., 2016). Specifically, targeted 
DNA methylation or demethylation can be achieved through the fusion of dCas9 with 
the functional domain of DNMT3A or TET1 enzymatic domain, respectively (Figure 
1.8) (Liu et al., 2016; Vojta et al., 2016). For example, using dCas9-DNMT3A 
constructs, Vojta and colleagues demonstrated that targeted CpG methylation within 
specific regions of IL6ST and BACH2 promoters led to a decrease of their cognate 
expression, and more importantly, the DNA methylation marks were mantained across 
mitotic divisions (Vojta et al., 2016). On the contrary, Choudhury et al reported that the 
removal of DNA methylation marks within the promoter of BRCA1 gene by dCas9-
TET1, induced gene transcriptional activation in different tumor cell lines, and 
consequently, contributed to a reduction in cell proliferation (Choudhury et al., 2016). 
Further studies demonstrated that targeting of the dCas9-TET1 or -DNMT3A fusion 
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protein to methylated or unmethylated promoter sites caused the activation or 
silencing of the corresponding gene, respectively. Additionaly, using transgenic mice, 
the authors have shown that these tools can modify the DNA methylation patterns in 
vivo (Liu et al., 2016). These results further evidence the role of DNA methylation 
marks on gene regulation and highlight the efficacy of the CRISPR-Cas9 tool for 
manipulating gene expression. Moreover, this tool has clinical potential, since DNA 
methylation marks are reversible, and thus, constitute a promising therapeutic target 
for several diseases, including cancer. 
 
 
 
 
 
 
 
 
 
Figure 1.8 CRISPR-dCas9 system for targeted DNA modifications. Schematic 
representation of a catalytically inactive Cas9 (dCas9) fused with TET1 for targeted DNA 
demethylation, and with DNMT3A for de novo methylation of specific sequences. C – cytosine; 
mC – 5-methylcytosine. Adapted from (Liu et al., 2016). 
 
 
1.4 Objectives and Specific Aims 
 
Breast cancer remains a leading cause of death amongst women worldwide. One of 
the factors contributing for this scenario is the lack of robust clinical biomarkers for 
early screening and disease prognosis. Therefore, given the molecular heterogeneity 
and clinical variability of this disease, the identification of biomarkers that can predict 
tumor behaviour is an important yet unmet need.  
The ability of self-renewal is a known hallmark of cancer, which in around 95% of 
breast cancer cases is attained through telomerase (hTERT) reactivation. Although 
for the past 20 years researchers have focus on understanding the mechanisms 
behind telomerase reactivation in cancer, these are yet to be fully understood. The 
   Chapter 1. 
48 
 
hypermethylation of a specific region of hTERT promoter is one of the recently 
discovered mechanisms associated with hTERT upregulation in cancer. However, the 
role and clinical potential of the TERT Hypermethylated Oncological Region (THOR) 
in breast cancer has never been addressed. Thus, the main goal of the study reported 
in this thesis was to explore the potential of THOR as a clinical biomarker and an 
eventual therapeutic target for breast cancer disease.  
In order to achieve this main goal several studies were performed according to the 
following three specific aims: 
 
I. To evaluate the role of THOR methylation status in invasive breast cancer and 
its relationship with disease progression in patients with BC: 
 
The exciting findings on THOR methylation reported in other cancer types, led us to 
hypothesize that THOR is a signature of telomerase-dependent cancers, and may 
represent a diagnostic and/or prognostic tool. Therefore, through application of current 
next generation technologies and the powerful sensitivity (96%) and specificity (100%) 
of THOR, the main ambition of this study is to investigate whether THOR can be useful 
as a diagnostic and prognostic tool for breast cancer disease. Furthermore, since 
breast cancer is a highly heterogeneous disease, presenting different responses to 
therapeutics, THOR can be a promising tool to help in the management of therapeutic 
response and thus contribute for a better clinical outcome. Hence, we aim to 
investigate in our series of breast cancer tissue samples, if there is a relationship 
between THOR methylation status and breast cancer progression and also correlate 
THOR with hTERT expression and evaluate whether THOR could improve or add 
diagnostic/prognostic value to the current available biomarkers, such as CA-15.3, CEA 
and Ki-67. 
 
II. To evaluate if targeted THOR demethylation can induce hTERT 
downregulation, and thus, breast cancer suppression, through application of a 
modified CRISPR-dCas9 system for epigenome editing: 
 
One of the most important features of DNA methylation marks is its reversibility, which 
is a major aspect for the development of epigenetic therapy. Based on this and taking 
into account the recent engineered technologies for epigenome editing, through the 
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use of enzymatic epigenetic modifiers it is possible to induce epigenetic remodeling 
and modify specific DNA methylation marks, thereby affecting gene regulation and cell 
phenotype. Furthermore, although THOR has revealed to be a specific cancer 
signature associated with hTERT expression in several cancer types, such as prostate 
and bladder, causality remains to be tested. Also, the mechanistic role of THOR 
methylation in hTERT upregulation in breast cancer is unknown. Therefore, in this 
second aim we propose to clarify those points using a Luciferase-based assay and 
through the use of CRISPR-dCas9 system fused with a TET1 demethylase enzyme. 
The CRISPR-dCas9/TET1 system will allow us to evaluate whether targeted THOR 
demethylation can lead to hTERT downregulation and affect cell phenotype of breast 
cancer cell lines. DNA demethylation of THOR, may eventually be the basis for 
developing a specific therapeutic target for breast cancer. 
 
III. To determine DNA methylation patterns with biomarker potential within 
molecular and clinical subtypes of breast cancer: 
 
DNA methylation has been a focus of cancer research in the last years and in fact 
several studies reported DNA methylation alterations in different genes relevant for 
breast cancer development. Nevertheless, there is lack of knowledge regarding the 
DNA methylation portrait in breast cancer since the existent studies have been 
focused on a small number of genes and only a few studies have performed genome-
wide analyses across multiple BC subtypes. Therefore, genome-wide methylation 
studies in breast cancer should not only evidence the importance of epigenetic 
changes in breast carcinogenesis but also highlight new players in BC and identify 
candidates for future clinical applications. Based on this, the third aim of this work, is 
to perform a genome-wide DNA methylation analysis through access to public data 
from The Cancer Genome Atlas (TCGA) and METABRIC Consortium, and identify 
eventual DNA methylation signatures that could be useful for breast cancer 
classification and prognosis. 
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2.1 Introduction 
 
Breast cancer (BC) is the most common type of cancer and a leading cause of cancer-
related mortality among women worldwide (Bray et al., 2018). It is considered a 
heterogeneous disease, differing greatly between and within tumors as well as among 
different individuals, which is reflected by distinct clinical outcomes and therapeutic 
responses (Ng et al., 2015; Turashvili & Brogi, 2017; Zardavas et al., 2015). This reality 
contributed to the diverse BC classification systems, including clinical stage, 
histopathological features and molecular profile, and constitutes a major challenge to 
improve treatment and maximize patients’ survival (Bedard et al., 2013; Senkus et al., 
2015).  
Several biomarkers and gene expression profiling tests have enabled a more 
comprehensive view of the molecular identity of BC and have been proposed as useful 
tools in BC clinical practice (Cardoso et al., 2016; Senkus et al., 2015). However, the 
majority of these biomarkers are RNA-based tissue markers, and consequently cannot 
be used as a standard procedure in clinical routine (Khatcheressian et al., 2013; 
Ludwig & Weinstein, 2005; Sauter, 2017). Furthermore, genomic tests such as 
Mammaprint (Agendia, Huntington Beach, CA) and Oncotype DX (Genomic Health, 
Redwood City, CA), although providing valuable prognostic and/or predictive 
information in early-stage breast cancer, due to tumor heterogeneity, are not 
representative of the current tumor burden nor useful for long term monitoring, being 
also very expensive (Duffy et al., 2017; Sauter, 2017). Therefore, there is lack of 
validated biomarkers to anticipate BC diagnosis and to help predict tumor behaviour 
and aid in therapeutic decisions (Khatcheressian et al., 2013; Sauter, 2017; Tanos & 
Thierry, 2018). 
Limitless self-renewal is a critical feature for cancer development, being achieved 
through telomerase reactivation in around 95% of breast cancer cases (Hanahan & 
Weinberg, 2011; Kulić et al., 2016; Poremba et al., 1998). Telomerase activity, as well 
as the expression of the catalytic subunit of the telomerase complex, Telomerase 
Reverse Transcriptase (TERT), have been observed in most malignant BC, being 
considered attractive biomarkers for BC diagnosis and prognosis (Kulić et al., 2016; 
Poremba et al., 2002; Rivenbark et al., 2013). However, despite intense research in 
this field, the implementation of a telomerase-based biomarker or therapeutic target 
has not yet been possible. Indeed, the analysis of telomerase activity and hTERT 
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expression is highly dependent on the quality of tissue samples, requiring high quality 
RNA and cell extracts, which are challenging to obtain in clinical practice (Castelo-
Branco et al., 2016; Ludyga et al., 2012). Therefore, a DNA-based assay associated 
with telomerase activity and/or hTERT expression may constitute a useful diagnostic 
and prognostic tool in BC. 
Recently, genetic and epigenetic events were shown to regulate hTERT and to have 
clinical implications in hTERT activation-dependent cancers, such as BC (Leão et al., 
2018; Vinagre et al., 2013). One of the mechanisms associated with hTERT 
expression in cancer is the hypermethylation of a specific region of hTERT promoter 
defined by our group as TERT Hypermethylated Oncological Region (THOR) (Castelo-
Branco et al., 2013, 2016). This region was defined as a 433 base pairs (bp) genomic 
region within the hTERT promoter (Chr5:1,295,321–1,295,753, GRCh37/hg19) 
comprising 52 CpG sites and located upstream of the common C228T and C250T 
TERTpMut sites (Castelo-Branco et al., 2013; Lee et al., 2019). THOR is 
hypermethylated in hTERT-expressing tumors and hypomethylated in normal tissues 
and stem cells, being associated with tumor progression and survival in pediatric 
gliomas, prostate, pancreatic and bladder cancer (Castelo-Branco et al., 2013, 2016; 
Faleiro, Apolónio, et al., 2017; Leao et al., 2019).  
Based on these exciting findings, the first aim of the present study was to investigate 
the potential of THOR as a clinical biomarker for breast cancer. For this purpose, 
THOR methylation status was analysed in the breast invasive carcinoma cohort from 
The Cancer Genome Atlas (open access), and in two validation cohorts composed by 
benign tissue from healthy women and invasive breast carcinoma tissue samples from 
Centro Hospitalar Universitário do Algarve (CHUAlgarve, Portugal). In this chapter, 
the association between THOR and the clinicopathological features of breast cancer 
is also elucidated.  
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2.2 Materials and Methods 
 
2.2.1 Open access data 
 
The Cancer Genome Atlas (TCGA) data for Breast Invasive Carcinoma cohort (BRCA) 
was extracted from the TCGA data portal via the UCSC Cancer Genome Browser 
(https://xena.ucsc.edu/welcome-to-ucsc-xena/). 
In order to evaluate the methylation status of the hTERT hypermethylated oncologic 
region (THOR), level 3 methylation data derived from the Illumina Infinium 
HumanMethylation450K array was assessed in BRCA cohort (normal tissue (n = 98) 
and primary tumor (n = 743)). The methylation status of the probe cg11625005 
(chr5:1295737, GRCh37/hg19 genome assembly), which targets a CpG site within 
THOR region was analysed. DNA methylation status is presented as beta-values (-
values) ranging from 0 to 1, which corresponds to unmethylated and completely 
methylated DNA, respectively. 
The specificity and sensitivity of methylation levels for breast cancer diagnosis were 
evaluated by receiver-operator curve (ROC) analysis (Zweig & Campbell, 1993) with 
diagnostic validity suggested by an area under the ROC curve (AUC) ≥ 0.8.  
hTERT gene expression data was derived from Illumina HiSeq 2000 RNA Sequencing 
(normal tissue (n = 85) and primary tumor (n = 742)). This dataset includes gene-level 
transcription estimates, as in log2 [x + 1] transformed RNASeq by Expectation 
Maximization (RSEM) normalized count. 
Patients submitted to neoadjuvant therapy were not included in the present study. The 
normal tissue corresponds to normal tissue adjacent to the tumor. 
 
2.2.2 Patients’ and tissue sample selection 
 
In order to validate and complement the data from the TCGA database, we have 
further evaluated the role of THOR methylation status by analyzing 5 representative 
CpG sites within THOR in several BC samples. Two independent cohorts, a discovery 
cohort composed of 17 paired samples (normal-matched and tumor tissue) and a 
validation cohort including 240 BC tissue samples were used. All the patients were 
female and diagnosed with BC at the Centro Hospitalar Universitário do Algarve 
(CHUAlgarve, Hospital de Faro, Portugal). 
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Formalin-fixed, paraffin-embedded (FFPE) tissue samples and patients’ clinical data 
were retrospectively collected upon consent according to the Ethics Boards of the 
Hospital de Faro (Supplementary Files 2.1 and 2.2). Patients were selected based on 
the availability of FFPE tissue, follow-up time and available clinical information. All 
patients underwent surgery (either conservative surgery or modified radical 
mastectomy) and those included in the validation cohort were followed for a mean 
period of 72.3 months. All patients submitted to any neoadjuvant treatment that could 
alter the normal evolution of the disease were excluded.  
Demographic and clinical information, such as age at diagnosis, menopausal status, 
disease grade and TNM stage, were obtained from patients’ medical/pathology 
records and are presented in Table 2.1. The normal-matched tumor tissue isolated 
from a different surgical quadrant from where tumors were isolated was possible to 
analyse in the patients’ samples included in the discovery cohort (n=17). Further, 
considering the validation cohort (n=240), for some of the cases in which the patients 
had experienced metastasis, the metastatic tissue was also analysed (n=6).  
Healthy breast tissue derived from women submitted to reduction mammoplasty for 
reasons not related to cancer, were included as normal controls (n=26) (Maia et al., 
2009). Samples were collected with the approval from the Addenbrooke’s Hospital 
(Cambridge, United Kingdom) Local Research Ethics Committee (REC reference 
06/Q0108/221). 
For clinical purposes we used the cut-off of 30.86% methylation with an AUC of 0.9574 
(p< 0.0001, 100% specificity and 78.84% sensitivity).  
 
2.2.3 DNA isolation and THOR methylation analysis 
 
For THOR methylation analysis in both patients’ cohorts (discovery and validation), 
genomic DNA was extracted from FFPE tissue sections using the Maxwell16 FFPE 
Tissue LEV DNA purification Kit (Promega, Cat. AS1130). The tumor area of each 
FFPE tissue block was carefully selected to ensure that the DNA sample was not 
contaminated with DNA from the tumor-adjacent normal tissue. After DNA extraction, 
DNA concentration was measured using the Nanodrop 2000 system (Thermo 
Scientific). 
The analysis of THOR methylation was performed through bisulfite pyrosequencing 
as previously described (Castelo-Branco et al., 2013) at the Genomic Core Facility of 
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IBIMA (Biomedical Institute of Malaga, Spain). In order to distinguish methylated 
cytosines from unmethylated ones, the DNA samples were first submitted to bisulfite 
treatment, which remains as the gold-standard method for DNA methylation analysis 
(Kurdyukov & Bullock, 2016). The bisulfite treatment converts unmethylated cytosines 
into uracil, which is then replaced by thymine during PCR amplification, while 
methylated cytosines remain unchanged during the treatment, and therefore, can be 
used as a readout of the DNA methylation state (Krueger et al., 2012). Once 
converted, the DNA is PCR amplified and sequenced, in this case by pyrosequencing. 
Bisulfite pyrosequencing is a sequencing-by-synthesis method that quantitatively 
determines the level of methylation at individual CpG sites from PCR amplicons 
correspondent to regions up to 100 bp in length (Bassil, Huang, & Murphy, 2013). 
Comparing the signal intensities of C or T incorporation at a CpG site within the 
amplicon provides an accurate measure of the amount of methylation at that position 
within the sample (Bassil et al., 2013; Kurdyukov & Bullock, 2016). 
Briefly, for quantitative sodium bisulfite pyrosequencing analysis, 500 ng of genomic 
DNA was treated with sodium bisulfite using EZ DNA MethylationTM Kit (Zymo 
research, D5001). The region of interest was then amplified by PCR and followed by 
pyrosequencing, which was carried out using the PyroMark Q24 (Qiagen), according 
to the manufacturer’s protocol (Pyro-Gold reagents). Targeted assays were designed 
using the PyroMark Assay Design Software 1.0 (Qiagen). Forward 
ATGATGTGGAGGTTTTGGGAATAG, reverse CCCAACCTAAAAACAACCCTAAAT 
and sequencing GGAGGTTTTGGGAATAG primers were used for PCR and 
pyrosequencing. The assay target region within THOR was 36 bp in length comprising 
5 CpG sites (chr5:1295586, chr5:1295590, chr5:1295593, chr5:1295605 and 
chr5:1295618, GRCh37/hg19 genome assembly). This region was named by us as 
Upstream-of-the Transcription-Start-Site (UTSS region). Calculation of the percentage 
of THOR methylation was done as the average value of these 5 CpG sites. 
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Table 2.1 Demographic and clinical features of discovery and validation cohorts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable 
Discovery Cohort  (n=17) 
 Number              %    m            
Validation Cohort (n=240) 
 Number                 % 
Age 
Mean (range) 
 
60.3 (41-86) 
 
- 
 
59 (29-87) 
 
- 
Menopausal status 
Pre-menopausal 
Post-menopausal 
 
7 
10 
 
41.2 
58.8 
 
68 
172 
 
28.3 
71.7 
Histological type 
Ductal 
Lobular 
Other 
 
16 
1 
- 
 
94.1 
5.9 
- 
 
195 
36 
9 
 
81.3 
15 
3.7 
Tumor size 
pT1 
pT2 
pT3 
pT4 
 
11 
4 
1 
1 
 
64.7 
23.5 
5.9 
5.9 
 
134 
101 
1 
4 
 
56 
42.1 
0.42 
1.67 
Lymph Nodes 
N0 
N1 
N2 
N3 
 
8 
8 
- 
1 
 
47.1 
47.1 
- 
5.9 
 
121 
75 
33 
11 
 
50.4 
31.3 
13.8 
4.6 
Stage (TNM) 
I 
II 
III 
IV 
 
6 
8 
3 
- 
 
35.3 
47.1 
17.6 
- 
 
87 
102 
44 
7 
 
36.3 
42.5 
18.3 
2.9 
Grade 
1 
2 
3 
 
3 
12 
2 
 
17.6 
70.6 
11.8 
 
23 
169 
48 
 
9.6 
70.4 
20 
ER status 
Negative 
Positive 
 
2 
15 
 
11.8 
88.2 
 
59 
181 
 
24.6 
75.4 
PR status 
Negative 
Positive 
 
7 
10 
 
41.2 
58.9 
 
92 
148 
 
38.3 
61.7 
HER2 status 
Negative 
Positive 
 
13 
4 
 
76.5 
23.5 
 
193 
47 
 
80.4 
19.6 
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2.2.4 RNA extraction and hTERT expression analysis 
  
RNA extraction was performed for those patients’ samples in which tumor tissue from 
the same FFPE block was available. Total RNA was isolated using the RNeasy FFPE 
Kit (Qiagen, 73504) following the manufacturer’s recommendations. RNA was reverse 
transcribed using SuperScript IV Reverse Transcriptase following manufacturer’s 
instructions (Invitrogen, 8090010). The resulting complementary DNA (cDNA) was 
diluted to a final concentration of 50 ng/ µL with RNase/DNase free water. 
In this study, the gene expression estimation of hTERT was performed using the 
Droplet Digital PCR (ddPCR) technology, which has proven to provide more precise 
and reproducible results in FFPE tissue samples, where RNA normally has poor 
quality and sample availability is more limited (Taylor, Laperriere, & Germain, 2017). 
When compared to qPCR, ddPCR technology involves a first step where the PCR 
reaction sample is partitioned into several individual PCR reactions (droplets), and 
thus, after PCR amplification, it allows the absolute quantification of positive 
reactions, containing the target molecule, by comparison to the fraction of negative 
ones (Arvia et al., 2017). Therefore, it provides a more sensitive quantification of 
gene expression, being useful particularly when low amounts of nucleic acids are 
used. 
The QX200 Droplet Digital PCR (ddPCR) system (Bio-Rad Laboratories, CA, USA) 
and the following Taqman probes (Life Technologies, USA), TERT probe 
Hs00972650_m1 and TBP probe Hs00427621_m1, as an endogenous control, were 
used in a duplex reaction mode. The 20 µL gene expression reaction mix consisted of 
10 µL of 2x ddPCR SuperMix for Probes (Bio-Rad Laboratories, 1863023), 1 µL of the 
target assay (labeled with FAM), 1 µL of the endogenous control assay (labeled with 
VIC), 4 µL nuclease-free water and 4 µL of cDNA (200 ng). The gene expression 
assays were previously validated by temperature gradient to ensure optimal 
separation of target and control droplets. Data was analyzed using Quanta-Soft v1.4 
(Bio-Rad Laboratories). Different controls (no template, no reverse transcriptase (RT) 
and Human Universal RNA) were run in parallel with the study samples. TERT/TBP 
ratio of clinical breast FFPE samples was determined for each sample (Heredia et al., 
2013; Zhu et al., 2016). Then, the obtained ratios were calibrated for HeLa cell line 
transcript ratios. The results obtained represent relative expression of breast tumour 
samples relative to HeLa cell line (Castelo-Branco et al., 2013). As previously used in 
Chapter 2. 
60 
 
our laboratory, samples with less than 500 mRNA TBP transcripts (copies/20 µL) were 
excluded from our analysis. 
 
2.2.5 Immunohistochemistry of Ki-67 cell proliferation marker 
 
Ki-67 is expressed in proliferating cells and absent in quiescent cells, being a well-
known cell proliferation marker (Sobecki et al., 2017). Since Ki-67 was not determined 
at the time of diagnosis for the major part of the patients’ samples, we assessed the 
Ki-67 status in those samples.  
The immunohistochemical staining of Ki-67 was performed using the Ultravision 
Quanto detection technology HRP DAB (Peroxidase - Diaminobenzidine) in the DAKO 
Autostainer Plus system. Briefly, the tissue blocks were sectioned into thin slices (4 
μm) and then mounted onto glass slides positively charged. Sections were 
deparaffinized in xylene and rehydrated using decreasing concentrations of ethanol 
followed by 3x washes in water. After antigen retrieval and endogenous peroxidase 
blocking, samples were first incubated with the primary antibody anti-Ki67 (rabbit 
monoclonal antibody, clone SP6, Master Diagnóstica) and then with the HRP polymer 
Quanto (universal secondary antibody conjugated to a peroxidase, Master 
Diagnóstica), according to manufacturer's recommended protocol. The polymer 
complex was visualized by addition of DAB substrate/chromogen. In the presence of 
peroxidase, DAB produces a brown precipitate, which is an indicator of Ki-67 positive 
cells. Counterstain was done by haematoxylin staining. Then, slides were dehydrated 
using increasing concentrations of ethanol, followed by incubation in xylene and 
mounting with coverquick medium (Coverquick 2000, VWR).  As a positive control, 
amygdala tissue was used. The pathologist interpreted the Ki-67 immunostaining 
results according to the Service of Anatomical Pathology and Oncology (University of 
Malaga, Spain) standard practice. 
For the present study, we considered a “high Ki-67 index” when 20% of cancer cell 
nuclei stained positively. Slides were examined by light microscopy using the Axio 
Imager 2 Microscope and images were obtained at 100x magnification (100 micron 
scale bar). 
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2.2.6 Statistical analysis  
 
To assess the difference in cg11625005/THOR methylation between normal and 
malignant tissue, a two-tailed Mann-Whitney U test was used. To test the association 
of THOR with disease stage, molecular subtypes, lymph node invasion and other 
pathological features, the One-way analysis of variance (ANOVA), the Kruskall-Wallis 
test and the Mann-Whitney U test were used. Overall survival (OS) and progression-
free survival (PFS) were determined by Kaplan-Meier Survival curves and compared 
using the log-rank test. Hazard ratios (HR) were obtained using Cox regression model. 
Both univariate and multivariate analysis were done for overall survival (time-to-death) 
using SPSS (version 24). All the remaining statistical analyses were performed using 
GraphPad Prism 5.0 software. A p-value below 0.05 was considered statistically 
significant. 
 
 
2.3 Results and Discussion 
 
2.3.1 THOR (cg11625005) is hypermethylated in invasive breast carcinoma 
  
In order to assess if THOR signature is observed in breast cancer, the CpG site within 
THOR, targeted by the probe cg11625005 (Figure 2.1) was analysed in the breast 
invasive carcinoma cohort from TCGA (n=841, Figure 2.2) using the Illumina Infinium 
450k array. Breast invasive carcinoma revealed higher THOR methylation, with a 
mean β-value of 0.73, when compared to normal tissue with a mean β-value of 0.46 
(p<0.0001; Figure 2.2A). Furthermore, taking into account the 92 pairs of primary 
tumors and normal matched tissue samples, a 1.6-fold increase in cg11625005 
methylation was evident in tumor tissue relative to the normal breast tissue 
(Supplementary Figure 2.1). Through analysis of the area under the ROC curve (AUC) 
(Zweig & Campbell, 1993) this CpG site within THOR (cg11625005) was able to 
distinguish breast tumor tissue from normal tissue (AUC > 0.9567 and p<0.0001), thus 
evidencing its diagnostic potential. Therefore, THOR hypermethylation in breast 
cancer is in agreement with previous results observed for other cancer types, such as 
prostate, pancreatic and bladder cancer (Castelo-Branco et al., 2016; Faleiro, 
Apolónio, et al., 2017; Leao et al., 2019). 
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Figure 2.1 Schematic representation of the hTERT promoter region (GRCh37/hg19). The 
Illumina Infinium HumanMethylation450 array covers the area of interest with the probe 
cg11625005. THOR localizes between -159 and -591 base pairs from the TSS, between the 
proximal and distal regions of the TERT promoter. The position of the probe cg11625005 used 
to evaluate THOR methylation status is shown (chr5:1295737). C250T (chr5:1295250) and 
C228T (chr5:1295228) represent TERT promoter mutations commonly found in cancer tissue. 
The scheme is not scaled. THOR - TERT hypermethylated oncologic region; TSS - 
transcription start site. Adapted from (Faleiro, Apolónio, et al., 2017). 
 
 
Additionally, to evaluate whether THOR methylation is associated with hTERT 
expression in BC, hTERT gene-level transcription estimates (expressed as RSEM 
counts) derived from the Illumina RNA-seq dataset from TCGA were analysed. As 
expected, significant differences were observed between normal and breast 
carcinoma tissue (p<0.0001, Figure 2.2B; Supplementary Figure 2.2). Moreover, as 
previously reported in other cancer types (Castelo-Branco et al., 2013; Faleiro, 
Apolónio, et al., 2017), correlation analysis revealed that THOR methylation 
(cg11625005) status is positively correlated with hTERT expression (p<0.0001, 
r=0.1626; Figure 2.2C) in malignant breast tissue, which further supports a role for 
hTERT promoter methylation in hTERT transcriptional activation in BC. The CpG site 
within THOR (cg11625005) was also analysed in the other cancers belonging to the 
top 5 most common cancers worldwide (Bray et al., 2018) available at TCGA 
(Supplementary Table 2.1). In all cancers, both cg11625005 methylation and hTERT 
expression were higher in tumor tissue in comparison to normal tissue (p<0.0001, 
Supplementary Table 2.1), with the exception of stomach cancer, in which it was not 
possible to perform statistical analysis regarding THOR methylation due to the lack of 
normal tissue samples (n=2). The fact that all analyzed cancer types have THOR 
hypermethylated and rely on telomerase activation for their telomere maintenance 
(Gay-Bellile et al., 2017; Hanahan & Weinberg, 2011; Zinn et al., 2007), further 
suggests THOR as a mechanism involved in hTERT upregulation in cancer 
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(Supplementary Table 2.1). More importantly, hypermethylated THOR is a potential 
biomarker to be used in the clinical setting. 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 THOR (cg11625005) is specifically hypermethylated in malignant breast 
tissue and is positively correlated with hTERT expression in breast carcinoma. A. Breast 
invasive carcinoma shows higher THOR methylation (cg11625005) when compared to benign 
breast tissue (p<0.0001). B. hTERT is differentially expressed in benign and malignant breast 
tissue (p<0.0001) C. and it is positively correlated with THOR methylation status (cg11625005) 
in breast cancer (r=0.1626, p<0.0001, Spearman correlation). In A. and B. statistical 
differences were assessed using the two-tailed Mann-Whitney U test. 
 
 
To assess if THOR (cg11625005) could be a useful tool for predicting disease 
progression, methylation levels were analysed according to disease stage (I–IV), 
metastatic tissue and molecular subtypes. In breast cancer, THOR was able to 
differentiate normal tissue from all disease stages, including stage I (normal vs. stage 
I-IV, p<0.0001, Figure 2.3A). Additionally, THOR also distinguishes normal from 
metastatic tissue in BC (p=0.0005, Figure 2.3A). Significant differences between the 
disease stages were not observed (Figure 2.3A), however, there is a tendency to 
higher methylation values in stage IV, as well as in metastatic tissue when compared 
A 
C
A 
 A 
B
A 
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to primary tumor tissue. It is important to mention that only a small number of 
metastatic tissue samples were available at TCGA (n=5), and thus, probably with a 
larger number of metastatic samples this analysis could be more consistent.  
THOR revealed to be differently methylated across the different molecular BC 
subtypes (Figure 2.3B). Specifically, within the luminal group, patients with luminal B 
subtype have higher levels of THOR methylation when compared to luminal A (p<0.01, 
Figure 2.3B; Supplementary Figure 2.2). Since luminal B tumors are usually 
associated with lower levels of hormone receptors and tend to be higher histological 
grade than luminal A (Schnitt, 2010), the observed higher levels of THOR methylation 
amongst the luminal B patients suggests that THOR has prognostic potential and 
could be useful to help differentiate luminal B from luminal A patients. Interestingly, 
the HER2 subtype shows the lowest levels of THOR methylation (cg11625005). 
However, it has been documented that this specific subtype of breast cancer is also 
associated with ALT mechanism to maintain telomere integrity (Subhawong et al., 
2009; Xu et al., 2014). Therefore, since both telomere maintenance mechanisms, 
hTERT-dependent and ALT mechanism coexist and may cooperate in HER2-enriched 
tumors (Xu et al., 2014), THOR hypermethylation may be more heterogeneous in this 
particular subtype (Figure 2.3B). Regarding the basal-like subtype, which comprises 
mainly the triple-negative (ER, PR and HER2) tumors, it is considered to be related 
with a poor prognosis, however, some studies reported that these tumors are very 
heterogeneous, differing in terms of histological features, biomarker expression profile 
and clinical outcome (Schnitt, 2010; Stevens, Vachon, & Couch, 2013). This facts may 
justify the heterogeneity observed in THOR methylation status in these tumors (Figure 
2.3B).  
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Figure 2.3 THOR (cg11625005) discriminates between normal and malignant breast 
tissue. A. THOR methylation (cg11625005) levels are higher across the different disease 
stages and metastatic tissue than in benign breast tissue (p<0.0001). B. THOR methylation 
(cg11625005) levels are significantly different among the molecular breast cancer subtypes. 
Statistical differences were assessed using the Kruskall-Wallis test (A) and One-way ANOVA 
with Tukey's post-hoc test (B). Statistical significance was considered as follows, *p<0.05, 
**p<0.01 and ***p<0.001. 
 
 
2.3.2 THOR as a novel disease biomarker for breast cancer 
 
To further explore THOR as a candidate breast cancer biomarker, 5 CpG sites within 
THOR were analyzed through pyrosequencing in multiple normal and malignant BC 
samples from the cohorts aforementioned (Table 1). In all breast cancer cases, from 
discovery and validation cohorts, THOR was specifically hypermethylated in malignant 
breast tissues when compared to healthy tissue (p<0.0001, Figures 2.4A and 2.4B). 
Paired samples (n=17, discovery cohort), where matched benign and malignant 
tissues were available, revealed that THOR methylation was significantly higher in the 
tumor specimen than in the corresponding normal tissue (p=0.0119, Figure 2.4A). A 
higher degree of THOR methylation was also observed in normal-adjacent tissue 
when compared to the healthy breast tissue (p<0.0001, Figure 2.4A). This finding 
suggests that normal-adjacent tissue although being clinically considered as normal 
tissue by the pathologists, biologically, could be already malignant, or eventually, the 
area of normal-adjacent tissue could be contaminated with some malignant cells 
derived from the primary tumor.  
A B 
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Regarding the validation cohort, we found that THOR is hypermethylated in malignant 
breast tissue, with a mean methylation of 40.23%, when compared to benign tissue 
with a mean methylation of 12.81% (p<0.0001, Figure 2.4B). As mentioned before, 
follow-up time and information related with the clinical outcome were collected for 
patients included in the validation cohort. A 5-year overall survival of 81.1% and a 10-
year overall survival of around 73.4% were observed for those patients 
(Supplementary Figure 2.3A). As expected, the most advanced disease stages (stage 
III and IV) were associated with a lower overall and progression-free survival 
(p=0.0006 and p<0.0001, Supplementary Figure 2.3B and C, respectively), which is in 
concordance with the survival rates normally observed for BC disease stages (André 
et al., 2014; Howlader et al., 2014; Torre et al., 2015). 
Since invasive BC is stratified according to clinical stages and the presence of 
hormone receptors as predictors of clinical outcome (American cancer society, 2013; 
Rakha & Green, 2017), we initially tested THOR ability to distinguish stages and 
molecular groups. THOR methylation was significantly higher in any disease stage 
than in benign tissue (p<0.0001, Figure 2.4C). Importantly, THOR status allows the 
differentiation of malignant tumor from normal tissue from the earliest stage of disease 
(p<0.0001, Figure 2.4C), suggesting that THOR methylation is an early event in BC 
carcinogenesis.  Moreover, as previously observed for the CpG site within THOR 
(cg11625005) analyzed from TCGA data, THOR region has diagnostic potential in BC, 
distinguishing tumor tissue from normal tissue with an AUC of 0.9574 (p<0.0001, 
100% specificity and 78.84% sensitivity).  Notably, these results highlight the potential 
of THOR to be used in clinical practice as a cancer screening tool or early diagnostic 
biomarker for breast cancer, much needed in the clinical setting (Ludwig & Weinstein, 
2005; Sauter, 2017; Tanos & Thierry, 2018). 
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Figure 2.4 THOR methylation status in breast carcinoma. Pyrosequencing analysis 
reveals that THOR methylation levels are significantly higher in normal adjacent tissue and 
malignant breast tissue when compared to healthy benign tissue (p<0.0001) in both the A. 
discovery and B. validation cohorts, being also increased in the malignant tissue when 
compared to its corresponding normal (p=0.0119, discovery cohort (A)). C. THOR methylation 
is significantly higher between any disease stage and benign tissue (p<0.0001). D. THOR 
methylation levels according to hormone receptor and HER2 status in comparison to benign 
tissue (p<0.0001). Statistical differences were assessed using the two-tailed Mann-Whitney U 
test (A and B) and the Kruskall-Wallis test (C and D). Statistical significance was considered 
as follows, *p<0.05, **p<0.01 and ***p<0.001. 
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Similarly, THOR demonstrated to be higher in malignant tissue independently of the 
hormone receptor status (p<0.0001, Figure 2.4D) when compared to benign tissue. 
Interestingly, an identical degree of THOR methylation was observed for hormone 
receptor-positive tumors (ER/PR+) and both hormone receptor- and HER2-negative 
tumors (TNBC), while the HER2- positive ones exhibited the lowest THOR methylation 
levels (Figure 2.4D). The lower THOR methylation levels observed in HER2-positive 
tumors (Figure 2.4D and Table 2.3) may be related with the fact that other mechanisms 
of hTERT regulation and/or telomere maintenance, as ALT mechanisms, may be at 
play (Subhawong et al., 2009; Xu et al., 2014). Furthermore, there are evidences that 
HER2 gene overexpression or amplification can be heterogeneously distributed within 
a given cancer, and thus, in a clinically considered HER2-positive tumor there are 
some cancer cells that lack HER2 amplification, and that may compensate their 
absence through other molecular alterations (Ng et al., 2015). Interestingly, as 
observed for TNBC, which are HER2-negative, THOR methylation was increased 
when compared with the other molecular groups (TNBC: 42.02% vs. ER/PR+: 40.17% 
vs. HER2+: 36.8%, Figure 2.4D), being these results significant when compared to 
HER2-positive tumors (p=0.0396, Figure 2.4D). These findings suggest that THOR 
methylation may contribute to select cells capable of growing in the absence of 
epidermal growth factor. 
To further evaluate the role of THOR in disease progression, THOR status was also 
determined in the metastatic tissue derived from patients who had metastasis and 
whose metastatic tissue was available (validation cohort). A fold increase of 1.37 was 
observed in the metastatic tissue samples in comparison to the correspondent primary 
tumor (Figure 2.5). Considering that breast cancers commonly display intra-tumor 
heterogeneity, this slight increase in THOR methylation in the metastatic tissue may 
suggest that the cell clones with higher THOR methylation levels within the primary 
tumor, were those that had higher invasive and metastatic potential and, consequently, 
contributed for the development of distant metastasis (Bedard et al., 2013).  
Furthermore, taking into account the patients’ clinical outcome, by stratification of the 
patients, in THOR low and THOR high, according with the threshold of 30.86% 
methylation as previously mentioned (AUC of 0.9574, p<0.0001), it is possible to 
observe a higher percentage of patients with THOR high amongst patients who had 
local recurrence (66.7% vs. 33.3%) and/or metastasis (80% vs. 20%) (Figure 2.6). 
Therefore, although in both univariate and multivariate analysis THOR did not reveal 
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the ability to predict patient survival (Table 2.2), their value as a prognostic biomarker 
should be further evaluated. For instance, a larger cohort including a higher number 
of samples for which follow-up data is available, and a longer period of time, as well 
as more samples belonging to the more aggressive subtypes, such as HER2-enriched 
and TNBC should be used to clarify this point. 
 
 
 
Figure 2.5. THOR methylation status in matched malignant breast tissues. A. THOR 
methylation was increased in the metastatic tissue (p=0.0646) when compared to its 
corresponding primary tumor, however the data did not reach statistical significance. B. A fold 
increase of 1.37 in THOR methylation from the primary to the metastatic sites was observed. 
Data was normalized in order to show fold increase.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 THOR according to clinical outcome. A higher percentage of patients with 
THORHigh is observed amongst patients that had A. local recurrence (66.7% vs. 33.3%) and 
B. metastasis (80% vs. 20%). The cut-off value of 30.86% methylation was used as a 
threshold.  
Local recurrence 
 
 
Metastasis 
66.7% 
33.3% 
80% 
20% 
A B 
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Table 2.2 Univariate and multivariate analysis according to overall survival among 
patients included in the validation cohort. 
HR- Hazard ratio. 
 
 
2.3.3 Relationship between THOR and clinical features of breast cancer 
 
THOR methylation status was also analysed according to the demographic and 
clinicopathological features of the patients included in the validation cohort (Table 2.1), 
and a summary of these results is shown in Table 2.3. The levels of THOR methylation 
were significantly different between HER2-negative and –positive tumors (p= 0.0371, 
Table 2.3), in which the HER2-negative ones are more likely to have a higher THOR 
methylation status than HER2-positive tumors. Indeed, as previously stated, the 
TNBC, being HER2-negative tumors, tend to exhibit a higher degree of THOR 
methylation when compared to HER2-positive ones (p=0.0396, Figure 2.4D). Patients 
with higher THOR methylation also seemed more likely to have pN3 nodal involvement 
(pN3: 44.83% vs. pN0: 39.79%) and lobular tumors (lobular: 43.09% vs. ductal: 
39.96%), however these differences do not reach statistical significance. No significant 
differences were found between THOR methylation status and the other main 
pathological parameters, namely, histological type, grade, stage, tumor size, lymph 
node involvement, hormone receptor status and Ki-67 proliferation marker. Also, there 
was no association between THOR methylation levels and the age of patients, 
residence area or menopausal status (Table 2.3).  
Regarding Ki-67 proliferation marker, this parameter was assessed by 
immunohistochemistry in patients’ samples for two reasons (Figure 2.7). First, 
because for the majority of the cases the Ki-67 index was not determined at the time 
of diagnosis, and it could be relevant to differentiate the low proliferative tumors (low 
 Univariate Analysis Multivariate Analysis 
Variable HR 95% CI p-value HR 95% CI p-value 
Age (<50 vs.≥50) 1.066 
1.044 to 1.088 0.001 
1.061 
1.036 to 1.085 0.001 
Stage 1.891 
1.405 to 2.545 0.001 
1.581 
1.118 to 2.238 0.01 
THOR 1.006 0.983 to 1.034 0.638 1.006 0.980 to 1.033 0.659 
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Ki-67) from highly proliferative ones (higher Ki-67 index), representing respectively the 
molecular subtypes, luminal A and luminal B (Bustreo et al., 2016; Feeley et al., 2014).  
 
 
Table 2.3 THOR methylation status in association with clinical features of breast cancer. 
Variable THOR Methylation (%) (mean) p-value 
Age (n=240) 
 <50 
 ≥50 
  
41.20 
39.93 
0.5458 
Residence area (n=233) 
Sotavento 
Barlavento 
  
40.36 
39.58 
0.7490 
Menopausal Status (n=240) 
Pre-menopause 
Pos-menopause 
  
40.03 
40.31 
0.8861 
Stage (n=240) 
I  
II 
III  
IV 
  
40.20 
39.82 
41.44 
38.96 
0.9111 
Tumor size (n=240) 
pT1 
pT2 
pT3 and pT4 
  
40.17 
40.33 
39.79 
0.8905 
Nodal status (n=240) 
pN0 
pN1  
pN2 
pN3 
  
39.79 
40.33 
39.94 
44.83 
0.780 
Grade (n=240) 
I 
II 
III 
  
38.47 
40.64 
39.63 
0.7488 
Histological Type (n=240) 
Ductal 
Lobular 
Mix 
Other 
  
39.96 
43.09 
29.67 
36.99 
0.1872 
ER status (n=240) 
Positive 
Negative 
  
40.31 
39.98 
0.8760 
PR status (n=240) 
Positive 
Negative 
  
40.35 
40.04 
0.8685 
HER2 (n=240) 
Positive 
Negative 
  
36.80 
41.06 
0.0371 
Ki67 (n=129)* 
<20 
≥20 
  
39.26 
41.70 
0.3211 
*For 111 patients it was not possible to determine Ki-67 status. 
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In the present study, as suggested in the last St. Gallen conference (Gnant et al., 
2015), the cut-off value of 20% was used to classify the tumors in “low Ki-67” (Ki-67 
lower than 20%) and “high Ki-67” (higher or equal to 20%). Secondly, as previous 
studies have reported a positive correlation between Ki-67 and telomerase activity 
(Kulić et al., 2016), we aimed at further exploring whether Ki-67 could be positively 
correlated with hTERT expression, and subsequently with THOR methylation status. 
However, as mentioned above, THOR methylation was higher in tumors with an 
increased Ki-67 index (41.70% vs. 39.26%), but statistical significance was not 
reached (p=0.3211, Table 2.3).  
Several studies have shown that both hTERT expression and telomerase activity are 
increased in carcinoma in situ and invasive BC disease (Poremba et al., 1998; 
Rivenbark et al., 2013). Nevertheless, their role as prognostic predictors has 
generated conflicting data. On one hand, some studies reported a positive correlation 
between those markers and clinicopathological features and/or disease outcome, but 
others have not found any association (Elkak et al., 2006; Kulić et al., 2016; Lu et al., 
2011; Poremba et al., 1998). Therefore, alterations on hTERT and telomerase 
expression in breast cancer have been difficult to validate, since so far the results have 
varied according to the cohort under study. Thus, although THOR methylation in the 
present study is not associated with most clinicopathological features of BC or disease 
prognosis in the future, a larger cohort should be used to validate these results. 
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Figure 2.7 Immunohistochemical staining of breast tissue using the Ki-67 antibody. A. 
Low Ki-67 index (10%) in stage I and grade I carcinoma; B. high Ki-67 (80%) in stage II and 
grade II carcinoma and C. positive control, amygdala tissue. Ki-67 positive cells exhibited 
DAB-positive (brown) staining; negative cells were stained with hematoxylin counterstain. 
Magnification 100X, scale bar 100 μm. 
 
 
It is known that one of the biggest challenges in BC consists in the improvement of 
disease management, particularly to find a sensitive and specific biomarker capable 
to detect early breast tumors (Sauter, 2017; Tanos & Thierry, 2018). Regarding the 
serum-based markers currently available for breast cancer surveillance 
(Khatcheressian et al., 2013; Ludwig & Weinstein, 2005), CEA and CA 15-3, these are 
both included in the internal guidelines of the CHUAlgarve, being usually determined 
before BC surgery. Hence, the CEA and CA 15-3 preoperative values were collected 
from patients’ medical records in order to compare them according to the different 
stages of disease. A high percentage of patients with invasive breast cancer had 
normal values, below the reference value, of both biomarkers (Figures 2.8A and 2.8B). 
A 
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For instance, at stage III of disease, 70% of the patients had normal values of CEA 
and 60% of them had normal values of CA 15-3 (Figures 2.8 A and 2.8B), which 
evidences lack of specificity and sensitivity as previously reported (Lumachi et al., 
2004). This results are in agreement with the current concerns regarding the beneficial 
use of these biomarkers. By contrast, regarding THOR methylation status, a high 
percentage of patients with invasive disease, including those with stage I, had high 
levels of THOR methylation (Figure 2.8C). The cut-off value of 30.86% methylation 
was used (AUC: 0.9574, p<0.0001). These findings further evidence that THOR is 
more representative of the current tumor status than CA 15-3 and CEA and thus, could 
be used as a valuable and more robust tool for BC management. 
In particular, for CA 15-3, although it is considered the most widely used serum marker 
in patients with BC, its clinical value is dubious (Duffy, Evoy, & McDermott, 2010). On 
the one hand, although elevated levels of CA 15-3 are found in the majority of patients 
with advanced BC, this glycoprotein is not breast cancer-specific, and increased levels 
can be present in other types of cancers, such as the ovarian and pancreatic and in 
non-cancer diseases, including hypothyroidism and chronic hepatitis (Duffy et al., 
2010; Hashimoto & Matsubara, 1989). On the other hand, due to lack of sensitivity for 
patients with early disease, its main use is limited for monitoring therapy in patients 
with metastatic BC (Lumachi et al., 2004). Furthermore, according with the 
recommendations available in different guidelines, the use of tumor markers, such as 
CA 15-3 and CEA, is not recommended for routine follow-up in asymptomatic patients 
with no specific findings on clinical examination (Duffy et al., 2010; Khatcheressian et 
al., 2013; Senkus et al., 2015). These facts evidence that further research is required 
to evaluate the contribution of biomarkers such as THOR hypermethylation to BC 
management and promote its translation into clinical practice. THOR hypermethylation 
could be useful for BC diagnosis in tissue biopsies and eventually in blood samples 
for disease screening and monitoring. The latter, through THOR methylation analysis 
in circulating tumor DNA or by detection of circulating tumor cells and later 
characterization of their malignant potential by THOR methylation analysis. 
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Figure 2.8 THOR is more representative of invasive breast disease than CA 15.3 and 
CEA biomarkers. A. CEA B. CA 15-3 and C. THOR levels according to disease stages. 
Reference values: CA 15-3 ≤ 31.3 U/mL, CEA ≤ 3ng/mL and THOR ≤30.86% (AUC: 0.9574, 
p<0.0001 with 100% specificity and 78.84% sensitivity). 
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2.3.4 THOR hypermethylation associates with hTERT expression 
 
During the past years several studies have shown a positive correlation between 
hTERT expression and telomerase activity in breast and other cancers (Kirkpatrick et 
al., 2003; Kulić et al., 2016; Vinagre et al., 2013). As a result, research efforts have 
been focused on the hTERT promoter region to determine the underlying mechanisms 
involved in hTERT upregulation in cancer (Kyo & Inoue, 2002; Tollefsbol, 2009). As 
mentioned previously, hTERT promoter mutations and DNA methylation are major 
regulators of hTERT in cancer (Vinagre et al., 2013; Zinn et al., 2007), however, since 
hTERT promoter mutations are absent or rarely observed in breast cancer (Shimoi et 
al., 2018), the present study suggests that hTERT promoter methylation may have a 
crucial role in hTERT expression and consequent telomerase reactivation in this type 
of cancer. This evidence supports our results and points to THOR methylation as a 
regulatory mechanism of hTERT transcriptional activation (Figure 2.9). The patients 
were stratified in two groups based on the methylation cut-off value previously 
specified (30.86%), and as observed, patients with higher THOR methylation levels 
were associated with higher hTERT mRNA expression levels in malignant tissue 
(p=0.0227, Figure 2.9), further supporting the role of hTERT promoter methylation in 
hTERT transcriptional activation. Interestingly, the two patients with the highest 
hTERT expression levels included in THOR high group, had both grade II tumors, 
stage IIb and Ki-67 ≥ 20%, suggesting that the highly proliferative and more invasive 
tumors tend to have THOR hypermethylated and higher hTERT expression. By 
contrast, also within THOR low group there were patients with higher hTERT 
expression, in which one of them had grade II and stage IIb disease and low Ki-67 (≤ 
20%), and the other had grade III, stage IIb, Ki-67 ≥ 20% and was considered as triple-
negative breast cancer (TNBC). These results demonstrate the intrinsic heterogeneity 
that characterize breast tumors (Ng et al., 2015), since some of the most aggressive 
tumors, like TNBC, had concomitantly higher hTERT mRNA levels and low THOR 
methylation, indicating that perhaps other genetic or epigenetic mechanisms (Leão et 
al., 2018) are contributing to the increase of hTERT expression.  
Unfortunately, due to the lack availability of tissue or poor RNA quality of some 
samples, only for a small portion of tissue samples (n=26) it was possible to perform 
both RNA extraction and hTERT expression analysis. Therefore, correlation studies 
between hTERT expression and disease stage or according to other clinico-
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pathological features could not be performed. Furthermore, in order to properly 
investigate the impact of THOR methylation in hTERT expression and telomerase 
reactivation, hTERT protein status and telomerase activity should be evaluated.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9 hTERT expression is higher in patients with higher THOR methylation. 
Comparative quantitative ddPCR analysis of hTERT expression shows a higher level of 
expression in patients with higher THOR methylation status. THOR low and THOR high were 
categorized using the cut-off value of 30.86% (AUC > 0.9574, p<0.0001 with 100% specificity 
and 78.84% sensitivity). TERT/TBP ratios were calibrated for HeLa cells. Statistical 
differences was assessed using two-tailed, unpaired Student’s t- test with Welch’s correction. 
 
 
2.4 Conclusion 
 
As previously stated, the major goal of the present study was to investigate the role of 
THOR methylation status in invasive breast cancer and its potential as a clinical 
biomarker. To evaluate this hypothesis, open access data from TCGA and two 
independent patient cohorts from CHUAlgarve (Faro, Portugal) were used. 
In this work, all cohorts analyzed, TCGA and CHUAlgarve cohorts, revealed that 
THOR was significantly hypermethylated in malignant breast tissue when compared 
to benign tissue. Furthermore, THOR status was able to differentiate cancer from 
normal tissue from the earliest stage of disease (AUC >0.9574 and p<0.0001), 
evidencing its potential as a candidate biomarker for BC screening or early BC 
diagnosis, which constitutes a major clinical challenge (Ludwig & Weinstein, 2005; 
Sauter, 2017; Tanos & Thierry, 2018). 
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Considering the main clinicopathological features of breast cancer, significant 
differences were observed between THOR methylation and HER2 status, being 
HER2-negative tumors more likely to have THOR hypermethylated than HER2-
positive tumors. Interestingly, the triple-negative breast cancer (ER/PR-negative and 
HER2-negative), revealed the highest levels of THOR methylation when compared to 
the other molecular groups, being statistically different in relation to HER2-positive 
tumors. Therefore, THOR may be a promising tool to monitor triple-negative breast 
cancer and, more importantly, since THOR may be potentially drug-targetable, it may 
represents a new therapeutic approach for this BC subtype, for which the currently 
available therapies are not truly effective. 
Notably, regarding CEA and CA 15-3 serum-biomarkers, THOR methylation status 
proved to be more representative of the tumor status than those biomarkers and thus, 
could be used as a valuable and more robust tool for BC management. Moreover, as 
proven in this and other studies, THOR is a DNA based marker, and consequently, 
when compared to RNA-based markers, provides robust results when analysed from 
paraffin embedded tissue samples, which constitute the main source of tumor DNA 
worldwide. Furthermore, although being considered a candidate biomarker for BC 
diagnostic in biopsies, THOR hypermethylation could also be used as a liquid biopsy, 
through detection of circulating tumor cells in blood and later characterization of THOR 
status. 
Additionally, our results points to THOR methylation as a regulatory mechanism of 
hTERT transcriptional activation, since patients with higher THOR methylation levels 
exhibited the highest levels of hTERT expression. Nevertheless, further studies are 
required to better understand the role of hTERT promoter methylation (THOR) in 
hTERT transcriptional activation in breast cancer.  
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2.5 Supplementary Material 
 
Supplementary Figure 2.1 THOR methylation (cg11625005) between normal-matched 
and primary breast tumor. Each bar represents methylation beta-values of a case with tumor 
(n=92, red portion) and correspondent normal breast tissue control (n=92, blue portion). A 1.6-
fold increase in cg11625005 methylation levels was observed in tumor tissue when compared 
to the matching normal breast tissue. 
 
 
Supplementary Figure 2.2 Heatmap of THOR methylation (cg11625005) and hTERT 
expression according to BC molecular subtypes. Low methylation - blue; High methylation 
- red. Low hTERT expression - green; High hTERT expression - red. Data derived from 
invasive breast carcinoma cohort at The Cancer Genome Atlas. ER - Estrogen receptor; PR - 
Progesterone receptor; HER2 - Human epidermal growth factor receptor 2.  
 
 
Positive 
            
Negative 
PAM50       ER                PR             HER2     cg11625005     hTERT expression 
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Supplementary Table 2.1 THOR methylation (cg11625005) and hTERT expression in the 
5 most common cancers worldwide in 2018. 
 
Cancer Type 
cg11625005 methylation 
(β-values) 
hTERT  expression 
(RNA-seq) 
Normal Tumor 
p-value* 
(N vs. T) 
Normal Tumor 
p-value* 
(N vs. T) 
Lung cancer 0.38 (n=75) 
0.67 
(n=830) 
p<0.0001 
0.17 
(n=29) 
3.03 
(n=825) 
p<0.0001 
Breast invasive 
carcinoma 
0.46 (n=98) 
0.73 
(n=743) 
p<0.0001 
0.64 
(n=85) 
1.94 
(n=742) 
p<0.0001 
Colon & Rectum 
adenocarcinoma 
0.64 (n=45) 
0.74 
(n=370) 
p<0.0001 
3.17 
(n=21) 
4.03 
(n=370) 
p<0.0001 
Prostate 
adenocarcinoma 
0.53 (n=50) 
0.72 
(n=497) 
p<0.0001 
0.44 
(n=35) 
1.68 
(n=497) 
p<0.0001 
Stomach 
adenocarcinoma 
0.64 (n=2) 
0.67 
(n=396) 
- 
1.67 
(n=35) 
3.95 
(n=415) 
p<0.0001 
* Statistical analysis using Mann-Whitney test. Data derived from The Cancer Genome Atlas. 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2.3 Patients’ survival included in the validation cohort. A. 5-year 
overall survival of the whole cohort. Patients at early disease stages are significantly 
associated with a B. better overall and C. progression-free survival. Vertical lines indicate 
censoring.  
A 
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The following Supplementary Files referent to this chapter are available in digital 
support: 
 
Supplementary File 2.1 Proposal for collaboration in a research project UAlg-CHUAlgarve. 
 
Supplementary File 2.2 Approval letter from the Hospital de Faro (CHUAlgarve) Local 
Research Ethics Committee. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Chapter 3. Uncovering the impact of THOR 
methylation on hTERT transcriptional regulation 
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3.1 Introduction 
 
One of the cancer pathways mainly altered in breast cancer is the telomere 
maintenance pathway (Shi et al., 2017), which is responsible for the replicative 
immortality of cancer cells (Hanahan & Weinberg, 2011). Telomeres are nucleoprotein 
structures located at the chromosomal ends that protect them from nucleolytic 
degradation and end-to-end fusions during cell division, thus, playing a central role in 
genome stability and cancer prevention (de Lange, 2005; Martinez & Blasco, 2015). 
Telomere maintenance is achieved through telomerase reactivation, which elongates 
telomeres in the majority of breast cancer cases (95%) (Kulić et al., 2016; Morin, 1989; 
Poremba et al., 1998). Telomerase consists in a ribonucleoprotein complex, 
composed of a catalytic subunit, the human telomerase reverse transcriptase (hTERT) 
and a RNA subunit, termed human telomerase RNA component (hTERC), and it has 
been proposed that its activity is mainly determined through re-expression of the 
catalytic subunit, hTERT (Akincilar et al., 2016; Morales et al., 1999). 
hTERT is tightly regulated by both genetic and epigenetic mechanisms, however, the 
complexity behind its regulation in cancer remains to be fully understood (Leão et al., 
2018; Vinagre et al., 2013). So far, several hTERT regulatory mechanisms were 
identified, such as, hTERT amplifications, hTERT promoter mutations, hTERT 
promoter methylation and hTERT-targeting miRNAs (Castelo-Branco et al., 2013; 
Horn et al., 2013; Hrdlickova et al., 2014). Specifically, a hypermethylated region within 
the hTERT promoter has been associated with hTERT upregulation in hTERT 
expressing cancers (Castelo-Branco et al., 2013; Guilleret & Benhattar, 2004). This 
region was further studied by our group, which named it TERT Hypermethylated 
Oncological Region (THOR) and demonstrated its association with tumor progression 
and survival in hTERT-dependent cancers, such as prostate, bladder and pancreatic 
cancer (Castelo-Branco et al., 2013, 2016; Faleiro, Apolónio, et al., 2017; Leao et al., 
2019). Nevertheless, the exact functional impact of THOR on hTERT promoter activity 
is still under investigation. 
One possible explanation for the mechanism by which hTERT promoter methylation 
leads to hTERT upregulation is that transcriptional factors binding may be prevented 
either by a direct interference or via chromatin conformational changes (Bert et al., 
2013; Stefansson & Esteller, 2013). Indeed, some transcriptional repressors, including 
Mad1, CTCF, myeloid-specific zinc finger protein 2 (MZF-2) and Wilms’ Tumor 1 
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(WT1) were reported to have binding sites within hTERT promoter, and consequently, 
their binding may be hampered by CpG methylation (Fujimoto et al., 2000; Kyo et al., 
2008; Zinn et al., 2007).  
DNA methylation marks are established by DNA methyltransferases (DNMTs), and 
can be actively reversed by Ten-eleven translocation (TET) enzymes (Biswas & Rao, 
2017; Jones et al., 2016). Therefore, DNA methylation patterns are highly dependent 
on the accurate work of these epigenetic modifiers, which are usually dysregulated in 
cancer (Jones et al., 2016; Portela & Esteller, 2010). These epigenetic marks are 
reversible modifications, and recently, through the use of epigenome editing tools can 
be manipulated in a targeted manner (Cox et al., 2015). Clustered regularly 
interspaced short palindromic repeat (CRISPR)-associated nuclease Cas9 is one of 
the most recently applied technologies for epigenome edition, in particular for targeted 
DNA modifications (Hilton et al., 2015; Komor et al., 2017; Vojta et al., 2016). 
Currently, CRISPR-Cas approaches to induce targeted DNA methylation modifications 
are based on the use of a catalytically inactive or “dead” nuclease Cas9 (dCas9) fused 
to the functional domain of DNMT3A or TET1 enzymes (Liu et al., 2016; Vojta et al., 
2016). For example, Liu et al. reported that targeting DNA methylation or 
demethylation constructs, including dCas9-DNMT3A or -TET1 fusion protein, to 
unmethylated or methylated specific promoter regions caused the silencing or 
activation of the corresponding gene, respectively (Liu et al., 2016). Therefore, these 
results highlight the efficacy of the CRISPR-dCas9 tool for manipulating gene 
expression, and its utility to evaluate the functional significance of DNA methylation 
patterns regarding gene expression and other biological processes. 
Hence, the main objective of the study reported in this chapter was to investigate the 
functional role of THOR hypermethylation in hTERT gene regulation using the 
modified CRISPR-dCas9 system. Therefore, first, THOR region was analyzed using 
open access data and a luciferase-based assay. Then, the CRISPR-dCas9 system 
fused to TET1 demethylase enzyme was used to evaluate whether targeted THOR 
demethylation could lead to hTERT downregulation in breast cancer cell lines.  
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3.2 Materials and Methods 
 
3.2.1 Roadmap Epigenomics database analysis 
 
Epigenomic data from different normal breast cells, including breast stem cells, 
myoepithelial, luminal and fibroblasts, were analyzed using the Roadmap 
Epigenomics database (Roadmap Epigenomics Consortium et al., 2015) from the NIH 
Roadmap Epigenomics Mapping Consortium 
(http://www.roadmapepigenomics.org/data/). Data including DNA methylation levels 
(Methylated DNA immunoprecipitation, MeDIP), histone modification marks 
(Chromatin immunoprecipitation, ChIP), and chromatin accessibility (Chromatin state 
based on the Hidden Markov Model, ChromHMM)(Ernst & Kellis, 2012) datasets were 
analysed. DNA methylation patterns, active histone marks, H3K4me1, H3K4me3 and 
H3K9ac, repressive histone marks, H3K27me3 and H3K9me3, and chromatin status 
(ChromHMM) were mapped for THOR region (chr5:1295321-1295753) based on the 
GRCh37/hg19 genome assembly. 
 
3.2.2 Cell lines 
 
MCF-7 and MDA-MB-231 human breast cancer cell lines, HeLa cervical cancer cell 
and WI-38 fibroblasts were acquired from the American Type Culture Collection 
(ATCC). BT-20 human breast cancer cell line was kindly provided by Dr. Joana 
Paredes (IPATIMUP, Porto, Portugal) and the human medulloblastoma cell line 
ONS76 was kindly provided by Dr. Michael Taylor (Brain Tumor Research Centre, The 
Hospital for Sick Children, Toronto, Canada). 
All cells mentioned above were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM), high glucose, pyruvate (Gibco®, 11995065) supplemented with 10% fetal 
bovine serum (FBS) (Gibco®, 10270106) and 1% penicillin/streptomycin (P/S) 
(Gibco®, 15140). Cells were maintained on cell culture plates or T-flasks and kept at 
37ºC in a humidified incubator with 5% CO2. The medium was changed every two 
days and cells were split between 1:3 and 1:5 as they reached around 70% 
confluence. Cells were dissociated using Trypsin EDTA (0.25%) (Gibco®, 25200) after 
being washed with phosphate buffered saline (PBS) (Gibco®, 70011036), followed by 
Trypsin inactivation with medium and centrifugation at 250 xg for 5 min. 
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3.2.3 DNA isolation and pyrosequencing analysis 
 
Genomic DNA was isolated from the different breast cancer cell lines (MCF-7, MDA-
MB-231 and BT-20) and controls (HeLa and W1-38 fibroblasts) using the DNeasy 
Blood & Tissue Kit (Qiagen, 69504), following the manufacturer’s protocol. After DNA 
extraction, DNA concentration was measured using the Nanodrop 2000 system 
(Thermo Scientific). 
The analysis of THOR methylation in the different BC cell lines and controls was 
performed by quantitative sodium bisulfite pyrosequencing as previously described in 
the materials and methods section from chapter 2. HeLa and WI-38 fibroblast cells 
were used as positive and negative controls, respectively.  
 
3.2.4 hTERT expression analysis 
 
hTERT expression was determined in all breast cancer cell lines (MCF-7, MDA-MB-
231 and BT-20) and controls (HeLa and W1-38 fibroblasts) by quantitative real-time 
polymerase chain reaction (qPCR).  
Total RNA was extracted using RNeasy Mini Kit (Qiagen, 74104) according to 
manufacturer’s protocol. Then 1 µg of total RNA was reverse transcribed to 
complementary DNA (cDNA) using the SuperScript™ IV Reverse Transcriptase 
(Invitrogen, 18090050) following manufacturer’s instructions. The resulting cDNA was 
diluted to a final concentration of 20 ng/µl with RNase, DNase free water. The qPCR 
mixture and cycle conditions were defined as previously reported (Castelo-Branco et 
al., 2013). Briefly, 12 µl of qPCR mixture was composed of 60 ng of cDNA, 6 µl of 
SYBR Select Master mix (Life Technologies, 4472908), 300 nM of forward and reverse 
primers. QPCR cycles and analysis was performed on CFX96 Real-Time PCR System 
(Bio-Rad) using the CFX ManagerTM Software (BioRad). Cycling conditions for the 
reaction were an initial step for heat-labile uracil-DNA glycosylase (UDG) activation at 
50°C for 2 min, DNA polymerase activation at 95°C for 5 min, followed by 45 cycles of 
denaturation at 95°C for 15 sec and annealing/extension at 60°C for 1 min. To validate 
the reaction specificity, a melting curve was generated for each sample by submitting 
it to temperatures from 60ºC to 95ºC with 0.5ºC increments. 
The endogenous housekeeping gene Hypoxanthine Guanine Phosphoribosyl 
Transferase (HPRT1) and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
were used as normalization controls (Castelo-Branco et al., 2013). Primers were 
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obtained from Nzytech and are described in Table 3.1. The hTERT expression levels 
from different cell lines were normalized to hTERT levels observed in HeLa. The 
relative quantification of gene expression was determined using the ΔΔCT method, 
using the following formula: fold change in gene expression, 2- ΔΔCt = 2- {ΔCt (tested samples) 
- ΔCt (reference sample)}, where ΔCt = Ct (gene of interest) – Ct (housekeeping gene). No 
template (without cDNA sample) and no RT (without SYBR master mix) controls were 
run in parallel. All the reactions were performed in triplicates. 
 
 
Table 3.1 Primer sequences used for quantitative PCR analysis. 
Gene 
Forward primer 
(5’- 3’) 
Reverse primer 
(5’-3’) 
 
hTERT 
 
 
GCC TTC AAG AGC CAC GTC 
 
CCA CGA ACT GTC GCA TGT 
 
HPRT1 
 
 
GAPDH 
 
GAC CAG TCA ACA GGG GAC AT 
 
 
CTG GGC TAC ACT GAG CAC C 
 
GTG TCA ATT ATA TCT TCC ACA ATC 
AAG 
 
AAG TGG TCG TTG AGG GCA ATG 
 
 
 
3.2.5 hTERT promoter mutation detection 
 
Sanger sequencing of PCR products was used to identify specific hTERT promoter 
mutations (1,295,250 G>A and 1,295,228 G>A, C>T on opposite strand) in all breast 
cancer cell lines and controls (ONS76 and WI-38). ONS76 cell line and WI-38 
fibroblasts were used as positive (harbours C228T mutation) and negative controls, 
respectively. 
DNA extraction from all cell lines was performed using the DNeasy Blood & Tissue Kit 
(Qiagen, 69504) following the manufacturer’s protocol. Then a 100-base pair (bp) PCR 
amplicon encompassing the proximal hTERT promoter was amplified using primers 
complementary to genomic DNA with added sequencing tag overhangs: 5’-
ACACTGACGACATGGTTCTACA-GGCCGCGGAAAGGAAGGGG (forward); 5’-
TACGGTAGCAGAGACTTGGTCT-CGCCTCCTCCGCGCGGAC (reverse).  
The PCR was run in 20 µL reactions composed of 10 µL of HotStarTaq Plus Master 
Mix DNA polymerase (Qiagen, 203643), 0.5 µL of each primer (10 µM), 1 µL of 
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glycerol, 7 µL of H2O and 1 µL of genomic DNA (50 ng). PCR conditions were the 
following: 95°C for 5 min, followed by 40 cycles of denaturation at 95°C for 30 sec, 
annealing at 64°C for 1 min and extension at 72ºC for 45 sec and one cycle for finally 
extension at 72°C for 7 min. After PCR amplification, 4 µL of each product was run on 
a gel to confirm if the product was successfully amplified. The resulting PCR product 
was purified using the QIAquick PCR Purification Kit  (Qiagen, 28106) and 50 ng of 
DNA was sequenced both in the forward and reverse directions using 5’-
ACACTGACGACATGGTTCTACA and 5’-TACGGTAGCAGAGACTTGGTCT 
sequencing primers, respectively. Mutations were recognized on sequencing 
electropherograms. 
 
3.2.6 Functional analysis of the impact of THOR on hTERT promoter activity 
 
The effect of THOR on regulation of gene expression was assessed using a luciferase-
based assay. The pGL4 vector (Promega, E6651) is a promoter-less firefly luciferase 
reporter, into which promoter elements can be cloned to investigate their effect on 
gene transcription control. After transfection in mammalian cells, the expression of 
luciferase and its subsequent activity is proportional to the promoter transcriptional 
activity.  
In the present study, four different hTERT promoter-Luc vectors harboring luciferase 
under the promoter of hTERT were used. Specifically, hTERT core promoter 
(chr5:1,295,151-1,295,395, named Core) and the region containing hTERT core 
promoter and THOR (chr5:1,295,151-1,295,743, named Core + THOR) and two 
additional constructs containing the same regions but the recurrent C228T mutation in 
addition, CoreM and CoreM + THOR, were used. These plasmid vectors were 
previously generated in our lab (Lee et al., 2019) and for the present work their DNA 
sequences were confirmed by sanger sequencing and are available in digital support 
(Supplementary File 3.1). DH5α competent cells (Invitrogen, 18265017) were 
transformed with all plasmid constructs in order to obtain high copy number, and after 
24 hours of bacterial incubation, plasmid vectors were obtained using Plasmid Midi Kit 
(Qiagen, 12143). All 4 constructs plus pGL4-empty vector were then transiently 
transfected into breast cancer cell lines (MCF-7, MDA-MB-231, BT-20), using 
Lipofectamine 3000 transfection reagent (Invitrogen, L3000015) according to 
manufacturer’s instructions. Control plasmid pRL Renilla luciferase vector (Promega, 
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E2231) was co-transfected to normalize the readings. Then, 24 hours post-
transfection the cells were lysed, and firefly and Renilla luciferase activity was 
measured using Dual-Luciferase® Reporter Assay System (Promega, E1910) and the 
luminescence signal was measured using the 96-Well microplate reader Tecan 
infinite® 200. All reporter gene expression experiments were performed in triplicate. 
The reporter gene expression analyses represent the normalization with the internal 
control Renilla and against the pGL4 empty vector. 
 
3.2.7 Targeted demethylation of THOR – first approach 
 
Targeted demethylation of THOR was approached by using the modified CRISPR-
dCas9 (Clustered, Regularly Interspaced, Short Palindromic Repeat–CRISPR-
associated protein) system (Hilton et al., 2015; Sander & Joung, 2014).  
In order to induce targeted demethylation of THOR in breast cancer cell lines, plasmids 
expressing both a catalytically inactive endonuclease Cas9 (dCas9) fused with TET1 
demethylase enzyme, dCas9-TET1, and a specific single guide RNA (gRNA) targeting 
THOR in the hTERT promoter were used (Figure 3.1).  
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Schematic representation of the CRISPR-dCas9 system to specifically 
demethylate THOR. A catalytically inactive mutant Cas9 (dCas9) is fused with TET1 
demethylase enzyme for erasing DNA methylation marks in the specific region of THOR and 
inactivate hTERT expression. 
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3.2.7.1 gRNAs design 
 
To demethylate THOR, eight gRNAs targeting THOR region were designed (Figure 
3.2 and Table 3.2) using the Benchling CRISPR design software 
(https://www.benchling.com/crispr/) (Hsu, Lander, & Zhang, 2014; Kemaladewi et al., 
2017). This tool allows the optimal design of gRNAs according to the target location, 
specificity and binding efficiency. Primer information for gRNA design and construction 
is listed in Supplementary Table 3.1. 
 
 
Figure 3.2 Scheme of hTERT promoter region for targeted THOR demethylation. Eight 
sgRNAs were selected targeting THOR region of human TERT gene. The sgRNAs 
recognizing their respective target sites are shown in blue, with the arrows pointing towards 
the protospacer adjacent motif (PAM) sequence. The sequenced region is 351 bp long and 
located upstream to the transcription start site (TSS). CpG sites are represented as dot blots 
and were sequenced with a specific panel of primers. Nine CpG sites proximal to the TSS are 
highlighted in light green (Fragment A2); fifteen CpGs located in mid THOR are highlighted in 
light blue (Fragment A3) and six CpGs correspondent to UTSS region are highlighted in light 
orange (Fragment A4). The fragment A1 corresponds to the core promoter, where hTERT 
promoter mutations (C228T and C250T) occur. In the scheme is represented the negative 
strand (5’ to 3’) and gRNAs targeting the positive strand are represented from 3’ to 5’. 
 
 
 
 
 
 
 
 
 
gRNA 1 
gRNA 2 gRNA 3 gRNA 4 gRNA 5 
gRNA 6 
gRNA 7 
gRNA 8 
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Table 3.2 List of gRNA sequences targeting THOR region. 
guide # Position Strand 
Sequence 
(5’-3’) 
PAM 
(NGG) 
guide 1 1295346 -1 CCAGGACCGCGCTTCCCACG TGG 
guide 2 1295383 1 TCTGTGCCCGCGAATCCACT GGG 
guide 3 1295431 1 GCTGCTCCGGGCGGACCCGG GGG 
guide 4 1295483 1 GCTCGCGCTCCCAGGGTGCA GGG 
guide 5 1295535 1 TCGAATCGGCCTAGGCTGTG GGG 
guide 6 1295565 1 AGGGAGGGGCCATGATGTGG AGG 
guide 7 1295587 1 GCCCTGGGAACAGGTGCGTG CGG 
guide 8 1295610 -1 GGGTCTCCGGATCAGGCCAG CGG 
 
 
3.2.7.2 Cloning strategy 
 
In order to induce targeted demethylation of THOR, plasmids expressing dCas9-TET1 
and pgRNA-modified plasmids expressing a gRNA targeting THOR region were used 
for co-transfection in breast cancer cell lines. Also, a catalytically inactive 
endonuclease Cas9 (dCas9) fused with a catalytically dead form of TET1, dCas9-TET-
IN, was used as a negative control (Table 3.3). The dCas9-TET1 (Addgene plasmid, 
#84475), dCas9-TET-IN (Addgene plasmid, #84479) and pgRNA-modified (Addgene 
plasmid, #84477)  plasmids were a gift from Dr. Rudolf Jaenisch (Liu et al., 2016). 
The gRNA expression plasmids were cloned by inserting annealed oligos into modified 
pgRNA plasmid with AarI site. Briefly, in order to clone the target sequence into the 
pgRNA plasmid, the vector was digested with AarI (Thermo Scientific: ER1581) and 
dephosphorylated using Shrimp Alkaline Phosphatase (rSAP) (NEB, M0371S), 
followed by gel DNA extraction with QIAquick Gel Extraction Kit (Qiagen, 28704). 
Then, each pair of oligos were phosphorylated with T4 Polynucleotide Kinase (NEB, 
M0201S) and annealed following the Zhang’s protocol (Cong et al., 2013). The 
digested pgRNA plasmid and annealed oligos were ligated using T4 DNA Ligase 
(NEB, M0202S) overnight at 16ºC. Transformation was performed in NEB stable 
competent E. coli (NEB, C3040H) followed by mini-prep using QIAprep® Spin 
Miniprep Kit (Qiagen, 27104) and Sanger screening of positive colonies by 5’-
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GAAACTCACCCTAACTG-3’ (SL-51_forward primer). Positive clones were then 
grown in Luria-Bertani (LB) broth medium (Fisher BioReagents™, BP1426-500) 
supplemented with ampicillin (100 µg/mL). After overnight incubation at 37C with 
shaking (225 rpm), plasmid DNA was extracted using Plasmid Midi Kit (Qiagen, 
12143). 
Regarding dCas9-TET1 and dCas9-TET-IN plasmids, transformation was performed 
in NEB stable competent E. coli according to manufacturer’s instructions, followed by 
overnight growth in LB broth medium supplemented with ampicillin (100 µg/mL), and 
plasmid DNA extraction using Plasmid Midi Kit. All constructs were sequenced before 
transfection and their DNA sequences are listed in Supplementary File 3.2. 
 
 
Table 3.3 List of plasmid vectors used in the first approach of targeted THOR 
demethylation experiments. 
 
Plasmid vectors Description 
Addgene 
Reference 
dCas9-TET1_CD 
dCas9 fused with the catalytic domain of 
TET1. 
Vector size: 15 573 bp 
Selection marker: ZeocineR 
#84475 
dCas9-TET1_IN 
dCas9 fused with an inactive catalytic domain 
of TET1 (H1672Y and D1674A mutations). 
Vector size: 15 573 bp 
Selection marker: ZeocineR 
#84479 
pgRNA-modified 
guide RNA expression vector. 
Vector size: 8 317 bp 
Selection marker: Puromycin 
#84477 
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3.2.7.3 Cell transfection and antibiotic selection 
 
In order to evaluate co-transfection efficiency and since dCas9-TET1 plasmid does 
not encode a fluorescent marker, a green fluorescent protein (GFP)- encoding 
plasmid, the pGIPZ, which has a similar size to dCas9-TET1 plasmid (around 12 kb) 
was co-transfected with the sgRNA vector encoding a mCHerry fluorescent protein 
(red). The pGIPZ vector was gently given by Dr. Ronald Cohn (Peter Gilgan Centre 
for Research and Learning, The Hospital for Sick Children, Toronto, Canada).  
In initial experiments, cell harvest at different time-points were tested and the day 4 
after transfection was selected to harvest the cells for further analyses. This time-point 
was also selected taking into consideration the previous studies in targeted DNA 
(de)methylation, in which the authors reported that the highest peak in CpG 
demethylation or methylation was observed within 3 to 6 days post-transfection 
(Maeder et al., 2013; Vojta et al., 2016; Xu et al., 2016). 
In brief, for THOR demethylation experiments, cells were seeded into 10 cm dishes 
and transiently co-transfected the next day with both dCas9-TET1 and pgRNA-guide 
plasmids using Lipofectamine 3000 transfection reagent (Invitrogen, L3000015) 
according to manufacturer’s protocols. Transfection efficiency was evaluated 24 and 
48 hours post-transfection. Then, cells were selected 48h post-transfection using 1.5 
µg/ml of puromycin, and were harvested 2 days later (4 days post-transfection) for 
DNA methylation and hTERT expression quantification. Double antibiotic selection 
using puromycin and zeocin was not feasible because, while puromycin has a fast 
mode of action, killing the majority of mammalian cell lines within 2 to 4 days at low 
doses, zeocin takes about 2 to 3 weeks to cause cell death, therefore, it is not 
appropriate to be used in transiently transfected cells. 
In all experiments, dCas9-TET1_IN co-transfected with the sgRNA plasmid were used 
as a negative control, as well as, dCas9-TET1 alone, mock-transfected (transfection 
reagents without plasmid DNA) and non-transfected cells. 
 
 
3.2.7.4 THOR methylation analysis  
 
To evaluate the effect of targeted DNA demethylation in THOR region and assess 
gRNAs efficacy, DNA methylation was initially analysed by Sanger sequencing and 
then quantified using next generation sequencing (NGS), MiSeq system technology. 
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Four days post-transfection, genomic DNA was isolated using the DNeasy Blood & 
Tissue Kit (Qiagen, 69504) according to the manufacturer’s protocol. After DNA 
extraction, DNA concentration was measured using the Nanodrop 2000 system 
(Thermo Scientific). Then, 100 ng of genomic DNA was bisulfite converted using EZ 
DNA MethylationTM Kit (Zymo research, D5001) in accordance to the manufacturer's 
protocol. The bisulfite converted DNA was PCR amplified using a panel of primers, 
targeting three individual amplicons, A2-proximal THOR, A3-mid THOR and A4-UTSS 
THOR, comprising CpG sites within the entire target THOR region (Table 3.4). Briefly, 
HotStarTaq Plus Master Mix kit (Qiagen, 203643) was used to PCR amplify target 
amplicons (size around 120 bp), according to the following PCR cycle conditions: an 
initial step at 95ºC for 15 min, 40 cycles of denaturation at 94ºC for 30 sec, annealing 
at 46ºC for 45 sec and extension at 72ºC for 30 sec, and a final extension step at 72ºC 
for 10 min. The obtained PCR products were run on a gel to confirm if the product was 
successfully amplified and then PCR purified (Qiagen, 28106). After that, DNA was 
sequenced by Sanger using the forward primer 5’-CAGCGTCAGATGTGTATAAGAG-
3’ and reverse primer 5’-GGCTCGGAGATGTGTATAAGAG-3’. 
As mentioned before, after screening DNA methylation using Sanger sequencing, the 
same PCR products were submitted to MiSeq in order to validate and quantify DNA 
methylation status. The MiSeq system is based on Illumina sequencing by synthesis 
(SBS) technology and enables high-throughput DNA sequencing at single-base 
resolution in specific targeted regions (Illumina, 2011; Kurdyukov & Bullock, 2016). 
For NGS using MiSeq platform, the resulting PCR products (size around 120 bp), were 
prepared in accordance to the 16S Metagenomic Sequencing Library Preparation 
guide (15044223 B, Illumina) and were sequenced following the manufacturer’s 
instructions for the MiSeq Reagent Kit v3 (Illumina) to obtain single-end 125-nucleotide 
read lengths. Sequence reads were identified using standard Illumina base-calling 
software. Adapter sequences were trimmed and sequencing reads containing at least 
one base with a Phred quality score below 20 were discarded prior to analysis. FastQ 
files were aligned against the reference genome (GRCh37/hg19) using BS-Seeker 2 
(default parameters) with a mapping efficiency of above 96.6%. After PCR, converted 
bases (unmethylated cytosines) are identified as thymine in the sequencing data, and 
the methylation level of each sampled cytosine was calculated as the number of reads 
reporting a C, divided by the total number of reads reporting either a C or T. 
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Table 3.4 List of primers for PCR amplification of amplicons within THOR. 
 
Target 
Amplicons 
Primer Sequence 
(5’-3’) 
Amplicon 2 
103 bp 
9 CpG sites 
Forward: AGTTGGAAGGTGAAGGGGTAGG 
 
Reverse: AACTCCCAATAAATTC 
Amplicon 3 
113 bp 
15 CpG sites 
Forward: GAATTTATTGGGAGTT 
 
Reverse: TCCCTACACCCTAAAAA 
Amplicon 4 
115 bp 
 6 CpG sites 
Forward: GTTTAGGTTGTGGGGTAATT 
 
Reverse: CTAAAAACAACCCTAAATC 
 
Primer overhangs 
 
Forward: TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG 
 
Reverse: GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG 
 
 
3.2.7.5 hTERT expression analysis 
 
For all experiments hTERT expression was determined by qPCR as described above 
in this section (page 88). 
 
3.2.8 Targeted demethylation of THOR – second approach 
 
Since the extent of THOR demethylation was not so obvious by using the traditional 
CRISPR-dCas9 system, a second approach was tested in order to improve the 
demethylation efficiency. In this second approach, a dCas9 fused to a SunTag was 
used to recruit multiple copies of an antibody fused to the TET1 demethylase enzyme 
was used (Figure 3.3) (Morita et al., 2016). 
A SunTag consists in a tandem repeat of ten copies of the 19 amino-acid GCN4 
peptide separated by 5-amino-acid linkers that is able to recruit multiple copies of an 
antibody-fused protein, thus enabling signal amplification in gene expression studies 
(Tanenbaum et al., 2014). Based on this, in order to enhance targeted demethylation 
by TET1 enzyme, Morita and colleagues, modified the 5-amino-acid linker length of 
the original SunTag to 22 amino acids, and demonstrated that this new system allows 
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efficient recruitment of an anti-GCN4 scFv fused to TET1 to the target site, improving 
significantly the demethylation efficiency (Morita et al., 2016). 
 
 
 
 
 
 
 
 
Figure 3.3 Targeted demethylation using CRISPR–dCas9 and a peptide-repeat-based 
amplification system. To achieve efficient targeted demethylation of specific DNA loci, 
dCas9 is fused to a peptide repeat sequence, the GCN4 peptide, in order to recruit multiple 
copies of an antibody-ScFv fused to the TET1 demethylase enzyme. Thus, multiple copies of 
TET1 can demethylate the target more efficiently. scFv - single-chain variable fragment 
antibody; CH3 - Methyl group. Adapted from (Morita et al., 2016). 
 
 
3.2.8.1 gRNAs design 
 
In this second approach, gRNA 5 and gRNA 7 previously designed and mentioned 
above were used. These two gRNAs were selected taking into account the results 
obtained using the first THOR demethylation approach and the specificity and 
efficiency scores among the designed gRNAs (Supplementary Table 3.1). 
Primer information for gRNA design and construction with the proper overhangs for 
the cloning strategy in the new plasmid vector is included in Supplementary Table 3.2. 
 
3.2.8.2 Cloning strategy 
 
A single vector, named pPlatTET-gRNA2 (Addgene plasmid #82559), including the 
gRNA-encoding gene under the control of the U6 promoter, and the sequences 
encoding  dCas9 fused with the GCN4 array system, and the antibody-sfGFP-TET1 
fusion was used for targeting THOR demethylation (Morita et al., 2016). In the present 
study we refer to the pPlatTET-gRNA2 vector as TET_MO. Also, a dCas9 with the 
GCN4 array system and the antibody-sfGFP fused with a catalytically dead form of 
TET1, termed IN_MO, was used as a negative control. The pPlatTET-gRNA2 
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(TET_MO)  (Addgene plasmid #82559) and the inactive mutant plasmid, IN_MO, were 
a gift from Izuho Hatada (Morita et al., 2016). 
Cloning was performed by restriction in an AflII site in the single vector (Table 3.5) and 
Gibson assembly-mediated incorporation of the gRNA insert fragment. In a first step, 
each pair of oligos were prepared using Phusion High-Fidelity PCR Master Mix (NEB, 
M0531S), in which 5 µL of Phusion master mix was added to 1 µL of each 
oligonucleotide (5 pmol/ µL) and 3 µl of water, followed by one PCR cycle as follows: 
denaturation at 98°C for 30 sec, annealing at 50°C for 30 sec and an extension step 
at 72°C for 3 min. Then, 20 µl of H2O was added to the previous PCR product. After 
oligos preparation, in order to clone the gRNA target sequence into the pPlatTET-
gRNA2, the plasmid was digested with AflII (NEB, R0520S) through incubation at 37°C 
for 3 hours, followed by heat inactivation at 65 °C for 20 min. The cloning was 
performed using Gibson Assembly, in which 100 ng of the digested plasmid was mixed 
with 0.5 µL of the oligonucleotide mixture prepared previously, 5 µL of Gibson 
Assembly Master Mix (NEB, E2611S), and H2O to perform a final volume of 10 µL, 
followed by incubation at 50 °C for 60 min. The resulting reaction was transformed into 
NEB stable competent E. coli (NEB, C3040H) which were spread over agar LB 
medium containing the antibiotic kanamycin (50 µg/ml). Plasmid extraction was 
performed by mini-prep, using QIAprep® Spin Miniprep Kit (Qiagen, 27104), followed 
by Sanger screening of positive colonies using the primer 5’-
CATAAAATGAATGCAATTGTTGTTG-3’ (pTET-gRNA-S5684 forward primer). All 
constructs were sequenced before transfection and their DNA sequences are listed in 
Supplementary File 3.3. 
 
 
Table 3.5 Plasmid vector used in the second approach of targeted THOR demethylation 
experiments. 
Plasmid vector Description 
Addgene 
Reference 
pPlatTET-gRNA2  
All in one vector containing dCas9 peptide 
array with a 22aa linker, antibody-sfGFP-
TET1CD and gRNA expression system. 
Vector size: 14 283 bp 
Selection marker: Neomycin 
#82559 
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3.2.8.3 Cell transfection and fluorescence-activated cell sorting  
 
Cells were seeded into 10 cm dishes and cultured in DMEM medium supplemented 
with 10% FBS and 1% P/S. Transfection was performed using Lipofectamine 3000 
transfection reagent (Invitrogen, L3000015) according to manufacturer’s protocols. 
The medium was changed 12h post-transfection and cells were incubated until 48h 
post-transfection. Then, single-cell suspensions were prepared and the proportion of 
viable GFP positive cells, pPlatTET-gRNA2 transfected, was selected by fluorescence 
activated cell sorting (FACS) using FACSAria II (BD Biosciences). 
Briefly, cells were washed with PBS solution and dissociated using trypsin. Then, a 
centrifugation at 220xg for 6 min was performed, the cells were washed once again 
with PBS and again centrifuged at 220xg for 6 min. A single-cell suspension was 
prepared by resupending the cells with the necessary volume of a mixed solution of 
PBS and propidium iodide (PI) (1 µg/ml of PI) to provide a cell concentration of 5×106 
cells per ml. The PI dye was added in order to allow the selection of viable cells during 
sorting. Right before running on the sorter, the cell suspensions were filtered through 
a 70 µm nylon mesh and kept on ice until sorting. Lastly, after sorting, cell pellets of 
PI-/GFP+ were prepared for both DNA and RNA extraction for downstream analysis of 
DNA methylation and qPCR, respectively. Cell sorting data were analysed using the 
FlowJo software. 
In all experiments, non-transfected cells (NT), mock-transfected (transfection reagents 
without plasmid DNA) cells, pPlatTET-gRNA2 empty vector (TET_MO), the inactive 
mutant empty vector (IN_MO) and cloned with the gRNAs (IN_guide), were used as 
negative controls. 
 
3.2.8.4 THOR methylation analysis  
 
THOR methylation analysis was assessed as described previously, in the first 
approach section of targeted THOR demethylation (page 95). 
 
3.2.8.5 hTERT expression analysis 
 
For all experiments hTERT expression was determined by qPCR as previously 
described (page 88). 
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3.2.9 In vivo pilot study 
 
To evaluate whether cell growth in vivo is affected by THOR demethylation, a pilot 
study using a small group of mice was performed.  
Briefly, cells were transfected and sorted as described previously in this chapter. Then, 
35 µL of a cell suspension containing 1.6 X 105 cells was mixed with 35 µL of Matrigel 
basement membrane matrix (BD Biosciences, 354234), and the cell suspension was 
immediately injected subcutaneously into the posterior right flank of 6-week-old non-
obese diabetic/severe combined immunodeficient (NOD/ SCID) mice (2 mice per 
group; The Jackson Laboratory). In this pilot study, non-transfected cells, mock-
transfected (without plasmid DNA) cells and cells transfected with pPlatTET-gRNA2 
empty vector (TET_MO), were used as negative controls.  
Each mouse was anesthetized with isoflurane anesthetic before the xenotransplant. 
Tumor sizes were monitored over time using a caliper, and tumor volume was 
calculated according to the formula, V = L x W x H /2 (V- volume, L- length, W- width, 
H- height) (Monga et al., 2000; Tomayko & Reynolds, 1989). Once tumors in control 
groups of mice reached 1.5 cm3, animals were euthanized using CO2. Tumor tissue 
was isolated, formalin-fixed and paraffin-embedded for histological analysis by 
hematoxylin and eosin staining. Animals were housed in a laboratory animal facility 
certified by the Canadian Council of Animal Care, and all in vivo procedures were 
approved by the Hospital for Sick Children’s Animal Care Committee.  
 
3.2.10 Statistical analysis  
 
To assess the difference in THOR methylation and hTERT expression experiments, 
as well as the significance of reporter gene expression assays, the two-tailed Student’s 
t-test was used. All statistical analyses were performed using the GraphPad Prism 5.0 
software. A p-value below 0.05 was considered statistically significant. 
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3.3 Results and Discussion 
 
3.3.1 THOR is located in a repressive chromatin region 
 
As demonstrated in Chapter 2, the cg11625005 site localized within THOR was 
hypermethylated and positively correlated with hTERT transcription in breast tumor 
tissue (Figure 2.2). Likewise, in the validation studies, THOR hypermethylation was 
revealed as a breast cancer signature and a potential regulatory mechanism of hTERT 
transcriptional activation. These findings contradict one of the central models of DNA 
methylation regulation, specifying that promoter methylation leads to gene silencing 
(Bert et al., 2013; Portela & Esteller, 2010). Therefore, to further investigate the 
mechanistic role of THOR in hTERT regulation, THOR, localized within the hTERT 
promoter, was analysed using the Roadmap Epigenomics database (Roadmap 
Epigenomics Consortium et al., 2015). 
Epigenomic data derived from different normal breast cells was used to plot DNA 
methylation status (MeDIP), histone modification marks (ChIP) and chromatin 
accessibility (ChromHMM) for THOR (chr5:1295321-1295753, GRCh37/hg19 genome 
assembly). Roadmap analysis revealed that THOR was located in a polycomb 
repressive chromatin region in the different normal breast cells analyzed (Figure 3.4). 
This region is associated with enrichment of repressive chromatin marks, such as the 
H3K27me3 mark (facultative heterochromatin) and lack of active histone marks, 
namely, H3K9ac, H3K4me1 and H3K4me3 (Figure 3.4). Furthermore, according to 
MeDIP-Seq data, THOR is hypomethylated in normal breast cells, therefore, the gain 
of methylation in THOR in breast tumor tissue may contribute to hTERT transcriptional 
activation by blocking the binding of transcriptional repressors or modifying the 
repressive chromatin conformation (Portela & Esteller, 2010). 
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Figure 3.4 THOR is localized in a repressive chromatin region in normal breast cells. 
According to MeDIP-Seq data, THOR is hypomethylated in the different normal breast cells 
analyzed. ChIP-Seq data evidence enrichment of histone repressive marks (H3K27me3 
(green peaks)) and low recruitment of active histone marks (H3K9ac, H3K4me1 and 
H3K4me3) in normal cells. ChromHMM classified THOR as a repressed polycomb region 
(grey color). In this scheme, THOR is highlighted in a red frame, chr5:1295321-1295753, 
according to GRCh37/hg19 genome assembly. 
 
 
3.3.2 hTERT expression, THOR status and TERTpMut profile in BC cells 
 
In order to characterize the breast cancer cell lines used in this study we evaluated 
the basal patterns of hTERT expression, THOR methylation status and hTERT 
promoter mutations. 
THOR was hypermethylated in all BC cells (i.e., MCF-7, MDA-MB-231 and BT-20 cell 
lines) and in HeLa cells when compared to normal fibroblasts (WI-38 cell line), in which 
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the mean methylation value of the 5 CpG sites was around 6.5% (Figure 3.5A). Among 
BC cell lines, higher THOR methylation (90-95%) and hTERT mRNA levels were 
observed in MCF-7 and MDA-MB-231 cells (Figures 3.5A and 3.5B). These data are 
in agreement with other studies on CpG methylation covering hTERT promoter, where 
the authors identified increased DNA methylation in hTERT-expressing BC cells 
(Guilleret et al., 2002; Zinn et al., 2007). In contrast, THOR methylation in BT-20 cells 
was around 46% and hTERT mRNA expression was almost absent (Figures 3.5A and 
3.5B). These results are concordant with previously reported studies, in which due to 
a low or absent telomerase activity, a telomerase-independent telomere maintenance 
mechanism has been proposed to operate in this cell line (Bièche et al., 2000; 
Raymond et al., 1999). 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 THOR hypermethylation and hTERT expression in breast cancer cell lines.  
A. THOR is hypermethylated in cancer cells when compared to normal cells (human lung 
fibroblasts). THOR methylation is represented as the mean percentage value of the 5 CpG 
sites analysed. B. hTERT expression by qPCR shows higher hTERT mRNA levels in MCF-7 
and MDA-MB-231 cell lines when compared to BT-20 cells and controls. Fibroblasts and HeLa 
cells, were used as negative and positive control, respectively. Normalization was performed 
by using HPRT1 and GAPDH expression and calculated relative to HeLa cells. For both 
analyses, column bars represent the mean of 3 independent experiments ± SD. P-values were 
determined using two-tailed, unpaired Student’s t- test with Welch’s correction and statistical 
significance was considered as follows, *p<0.05, **p<0.01 and ***p<0.001. 
 
 
The presence of the two recurrent hTERT promoter non-coding mutations (Huang et 
al., 2013), C228T and C250T, located at -124 and -146 bp upstream from ATG, 
respectively, was assessed by Sanger sequencing in BC cells (Supplementary Figure 
3.1). As expected, both TERTpMut were not detected in BC cells, with the exception of 
B A 
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MDA-MB-231 cell line, in which C228T was identified (Table 3.6 and Supplementary 
Figure 3.1), as previously demonstrated by other authors (Huang et al., 2015). As 
shown in Figure 3.5B, hTERT mRNA levels are significantly higher in MDA-MB-231 
cell line when compared to MCF-7 cell line (p<0.01), which does not harbour any of 
these TERTpMut. However, since TERTpMut  are rarely observed in BC, it is unlikely that 
this mutational mechanism is relevant for hTERT upregulation in BC (Gay-Bellile et 
al., 2017; Shimoi et al., 2018).  
Based on this data, amongst the cell lines analysed, the MCF-7 cell line is the most 
suitable cell line to investigate the effect of targeted THOR demethylation in BC, since 
it shows high THOR methylation and hTERT expression. Moreover, the presence of 
C228T mutation in MDA-MB-231 cell line could be a confounding factor for those 
experiments. 
 
 
Table 3.6 hTERT promoter mutation status in human breast cancer cell lines. 
BC Cell lines 
hTERT promoter mutations 
C228T (-124 C/T) C250T (-146 C/T) 
MCF-7 wt wt 
MDA-MB-231 mut wt 
BT-20 wt wt 
         wt – wild-type; mut- mutant. 
 
 
3.3.3 Unmethylated THOR is a repressive element of hTERT promoter  
 
To functionally investigate the role of THOR as a transcriptional regulatory element of 
hTERT in breast cancer, different reporter gene constructs harboring luciferase under 
the control of hTERT promoter were used. 
Specifically, reporter gene expression was compared between the following four 
constructs, Core and Core + Thor, containing the hTERT core promoter alone and with 
THOR region, respectively, and with or without the C228T TERTpMut (Figure 3.6A and 
Supplementary File 3.1). As expected, the addition of THOR to the hTERT core 
promoter significantly decreased luciferase activity by an average 1.8-fold when 
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compared to the hTERT Core promoter alone in all BC cell lines tested (Figure 3.6B). 
Importantly, unmethylated THOR repressed hTERT promoter activity regardless of 
TERTpMut status, since the addition of THOR to the C228T mutated TERT core 
promoter counteracted the activating effect caused by this mutation (Figure 3.6B). 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 3.6 Unmethylated THOR decreases reporter gene expression. A. Schematic 
representation of the TERT promoter and the luciferase constructs with and without the 
presence of THOR and/or C228T TERTpmut are shown. THOR (grey) is a transcriptional 
regulatory element located upstream of the hTERT core promoter (yellow). B. Normalized fold 
changes in hTERT promoter activity are shown for the specified luciferase constructs 
transfected into BC cell lines, MCF-7, MDA-MB-231 and BT-20. The addition of THOR to the 
hTERT core promoter significantly decreases reporter gene expression when compared to the 
hTERT core promoter alone, in the absence or presence of C228T mutation. Column bars 
represent the mean of 3 independent experiments ± SD. Statistical significance was 
considered as follows, *p<0.05, **p<0.01 and ***p<0.001. PGL4 - empty vector, Core - hTERT 
core promoter, Core + Thor - hTERT core promoter plus THOR region, CoreM - hTERT core 
promoter with C228T mutation, CoreM + Thor - hTERT core promoter with C228T mutation 
plus THOR region. 
A 
B 
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These findings are in concordance with the previous results obtained in other cancer 
cell lines (Lee et al., 2019), further demonstrating that unmethylated THOR acts as a 
repressive element on hTERT promoter activity. Furthermore, as evidenced by the 
roadmap analysis of THOR region, these data support the hypothesis that THOR 
hypermethylation prevents the binding of repressive elements and allows for 
constitutive hTERT expression in cancer. Additionally, although TERTpMut is 
considered a major cancer-associated genetic mechanism of hTERT upregulation, 
many cancers such as breast and prostate cancer, exhibit hTERT upregulation without 
TERTpMut (Castelo-Branco et al., 2016; Gaspar et al., 2018; Killela et al., 2013; Lee et 
al., 2019),  which further highlights that other mechanisms such as THOR 
hypermethylation may contribute to hTERT transcription and telomerase activation. 
Importantly, as observed in the MDA-MB-231 cell line, which exhibited THOR 
hypermethylation and C228T TERTpMut (Figure 3.5 and Table 3.6), and in other cell 
lines and multiple tumors (Lee et al., 2019), both hTERT regulatory mechanisms can 
co-exist in order to upregulate hTERT expression and activate telomerase in cancer. 
Therefore, THOR hypermethylation should be further investigated in order to have a 
better understanding of its biological mechanism and impact in breast carcinogenesis. 
Moreover, since DNA methylation is a reversible epigenetic mark, THOR 
hypermethylation is a potential therapeutic target for breast cancer treatment, in 
particular for those breast cancer subtypes in which the currently available therapies 
are not truly effective, such as TNBC and metastatic BC (Stevens et al., 2013). 
 
3.3.4 Targeting THOR demethylation - First approach 
 
To further evaluate the biological role of THOR hypermethylation in hTERT 
transcriptional activation in breast cancer, we used a modified CRISPR-dCas9 system 
to manipulate DNA methylation (Hilton et al., 2015; Sander & Joung, 2014). Based on 
previous studies, the catalytic domain of TET1 demethylase is considered the 
functional domain of choice for removing DNA methylation marks in specific CpGs 
sites (Liu et al., 2016; Maeder et al., 2013). Targeted editing of DNA methylation was 
achieved using plasmids expressing both a catalytically inactive endonuclease Cas9 
(dCas9) fused with the catalytic domain of TET1, dCas9-TET1, and a specific guide 
RNA (gRNA) targeting THOR (Supplementary File 3.2). Also, a dCas9 fused with a 
catalytically dead form of TET1 (dCas9-TET-IN) was used in the absence and in the 
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presence of gRNAs (Supplementary File 3.2) in order to investigate if the sole binding 
of dCas9-TET-IN plus gRNAs affects CpG methylation level (Liu et al., 2016). 
The MCF-7 cell line was selected to evaluate the effect of targeted THOR 
demethylation in breast cancer, since this cell line has THOR hypermethylated (around 
95%), does not harbour hTERT promoter mutations, and is an hTERT-expressing cell 
line (Figure 3.5 and Table 3.6). To determine whether dCas9-TET1 can supress 
hTERT expression by inducing demethylation of THOR, eight gRNAs targeting THOR 
region within hTERT promoter were tested (Figure 3.2). Since dCas9-TET1 plasmid 
does not encode a fluorescent marker, in order to evaluate the co-transfection 
efficiency, a GFP-expressing plasmid, pGIPZ, with a similar size to dCas9-TET1 
plasmid (around 12 kb) was co-transfected with the sgRNA vector, which encodes a 
mCHerry fluorescent protein (red). Based on this, as MCF-7-transfected cells 
displayed high co-transfection efficiency (Supplementary Figure 3.2C and D), we 
extrapolate that the co-transfection efficiency would be identical for dCas9-TET1 and 
sgRNA co-transfection. Then, dCas9-TET1- and each individual gRNA-expressing 
vectors were transiently co-transfected into MCF-7 cells. At day 4 post-transfection, 
cells were harvested for DNA methylation and hTERT mRNA expression 
quantification. As aforementioned, this time-point was selected taking into account the 
results obtained by previous studies on targeted DNA (de)methylation, in which the 
authors demonstrated by time course experiments that the highest CpGs 
demethylation or methylation efficiency was observed within 3 to 6 days post 
transfection (Maeder et al., 2013; Vojta et al., 2016; Xu et al., 2016). 
In each assay, THOR methylation status was analyzed by Sanger sequencing and 
then these results were quantitatively confirmed using MiSeq. As shown in Figures 3.7 
and 3.8, dCas9-TET1 and each one of the eight gRNAs targeting THOR alone were 
not able to significantly reduce CpG methylation across the three amplicons (A2, A3 
and A4) assessed in this region, having a behaviour similar to the negative controls 
(NT, Mock, TET, TET-IN and TET-IN/gRNAs). However, when cells were co-
transfected with dCas9-TET1 and gRNA7, a slight decrease between 15% to 20% in 
THOR methylation within the amplicon A4 was observed at CpGs with the genomic 
coordinates chr5:1295546, chr5:1295605 and chr5:1295618 (Figure 3.8A and 
Supplementary Figure 3.3). By contrast, the dCas9 with a catalytically dead TET1 co-
transfected with gRNA7 (IN_g7) did not show any decrease in methylation (Figure 
3.8B), as well as the remaining negative controls. Thus, these results demonstrate 
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that this system induces gRNA-dependent specific demethylation, although the extent 
of demethylation is only around 20% and in a small number of targeted CpGs sites of 
the hTERT promoter. Therefore, dCas9-TET1 co-transfected with each one of the 
eight gRNAs targeting THOR were not able to induce hTERT downregulation due to 
the low demethylation efficiency (Figures 3.7C and 3.8C). These results are in 
agreement with some previous studies where the highest targeted demethylation or 
methylation activities using a simple design of CRISPR-dCas9 system with a single 
gRNA were between 14% and 35%, reaching up to 55% when more than one gRNA 
were simultaneously targeted for specific regions of target genes (Morita et al., 2016; 
Vojta et al., 2016). As demonstrated by Vojta and colleagues, the co-transfection with 
a pool of gRNAs resulted in a large increase in methylation levels of target gene 
promoters accompanied by a significant decrease in their mRNA expression levels 
(Vojta et al., 2016). On the contrary, according to Morita et al., the demethylation 
activity in the target CpG sites was not improved, even when they tested 
simultaneously multiple gRNAs targeting the STAT3-binding site (Morita et al., 2016).  
Regarding the results obtained by the authors that generated the plasmids used in the 
present study, they reported that these constructs enable targeted demethylation 
(dCas9-TET1) or methylation (dCas9-DNMT3A) on CpGs of target genes’ promoter, 
affecting significantly their gene expression (Liu et al., 2016). Specifically, they 
reported that targeted demethylation of the BDNF promoter IV or the MyoD distal 
enhancer induced BDNF expression in neurons or activated MyoD-induced muscle 
cell reprogramming, respectively (Liu et al., 2016). Nevertheless, the experimental 
approach used by Liu and collaborators was different. While they used a lentiviral 
approach, in the present study, lentiviral constructs were not used and, instead, 
transient transfection was performed due to technical limitations. As lentiviruses can 
infect mammalian cells with a high efficiency, integrating the exogenous DNA 
constructs into the host cell genome, it is expected a superior efficacy using this 
approach when compared to transient transfection (Liu et al., 2016; Shearer & 
Saunders, 2015). Moreover, Liu et al. investigated the effect of CpG methylation 
edition in other target genes and in different host cells, which can also impact the final 
results. 
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Figure 3.7 Targeted THOR demethylation using dCas9-TET1 and gRNAs 1 to 4. 
Methylation levels of each individual CpGs in THOR, 4 days post-transfection A. with dCas9-
TET1 alone (TET) or TET with individual gRNAs from 1 to 4 (TETg1 to g4) targeting THOR or 
B. with an inactive form of TET1 (TET_IN) alone or with gRNAs (INg1 to g4). Genomic 
coordinates of each CpG and the distance of the first position of each amplicon (A2, A3 and 
A4) in relation to transcription start site is shown. C. RT-qPCR analysis shows no significant 
differences in hTERT mRNA levels in MCF-7 cells. Expression levels for cells transfected with 
the TET1- inactive plus gRNA1 (INg1) and TET1 plus gRNA1 (TETg1) is shown, and is 
representative of the expression levels obtained for the other gRNAs. Normalization was 
performed using GAPDH expression and calculated relative to non-transfected MCF-7 cells 
(NT). For both analyses, bars represent the mean of 2 independent experiments ± SD. 
A 
B 
C 
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Figure 3.8 Targeted THOR demethylation using dCas9-TET1 and gRNAs 5 to 8. 
Methylation levels of each individual CpGs in THOR, 4 days post-transfection A. with dCas9-
TET1 alone (TET) or TET with individual gRNAs from 5 to 8 (TETg5 to g8) targeting THOR or 
B. with an inactive form of TET1 (TET_IN) alone or with gRNAs (INg5 to g8). Genomic 
coordinates of each CpG and the distance of the first position of each amplicon (A2, A3 and 
A4) in relation to transcription start site is shown. C. qPCR analysis shows no significant 
differences in hTERT mRNA levels in MCF-7 cells. Expression levels for cells transfected with 
the TET1-inactive plus gRNA5 (INg5) and TET1 plus gRNA5 (TETg5) is shown, and is 
representative of the expression levels obtained for the other gRNAs. Normalization was 
performed using GAPDH expression and calculated relative to non-transfected MCF-7 cells 
(NT). For both analyses, bars represent the mean of 2 independent experiments ± SD. 
A 
B 
C 
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3.3.5 dCas9–peptide repeat and scFv–TET1 system enables targeted THOR 
demethylation 
 
In order to evaluate whether demethylation induced by the dCas9-TET1/gRNA 7 
system (Figure 3.8A) could be improved, a second experimental approach using a 
dCas9 fused to a SunTag and an antibody-fused to TET1 was performed (Figure 3.3) 
(Morita et al., 2016).  
This modified system intends to augment the number of TET1 copies operating to 
attain efficient targeted demethylation of specific DNA loci (Morita et al., 2016; 
Tanenbaum et al., 2014). Also, when associated with fluorescence-activated cell 
sorting (FACS) to select GFP-expressing cells, allows a remarkable improvement of 
demethylation efficiency as exemplified by the demethylation status from 14% to about 
95% within the STAT3-binding site in the GFAP promoter (Morita et al., 2016).  
Based on this, we followed the same approach for targeted demethylation of THOR 
on MCF-7 cells. Briefly, 48h post-transfection of the constructs into MCF-7 cells, the 
population of viable (PI-negative) GFP-positive cells was selected by cell sorting. As 
observed in the Supplementary Figure 3.4, the transfection efficiency was low, around 
3-5%, which is probably related to the size of the plasmid that has around 15kb, and 
therefore, is more challenging to deliver. Nonetheless, this range of transfection 
efficiency is in agreement with that obtained by Morita et al. 
As shown in Figure 3.9, we observed a significant improvement in THOR 
demethylation using this system when compared to the dCas9-TET1 and gRNA 
plasmids used in the first approach (Figures 3.7A and 3.8A). In this second approach, 
the gRNA 7 was used, as it demonstrated to slightly reduce THOR methylation within 
the A4 (Figure 3.8A), and also the gRNA 5, which has the highest specificity and 
efficiency scores among the designed gRNAs (Supplementary Table 3.1), and thus, it 
was expected to induce more efficiently targeted THOR demethylation. As observed 
in Figure 3.9 and Supplementary Figure 3.5, the TETg7_MO, significantly reduced 
methylation in several CpG sites across the three amplicons (A2, A3 and A4) within 
THOR, in contrast to negative controls. The DNA sequencing electropherograms 
revealed an increase of thymine in diverse CpG sites that are originally methylated in 
the negative controls (TET_MO), meaning that those CpGs were demethylated by 
TETg7_MO (Supplementary Figure 3.5), since they were converted into uracil during 
bisulfite treatment and replaced by thymine following PCR. These data were confirmed 
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by MiSeq and, as shown in Figure 3.9, TETg7_MO induced a significant reduction 
(p=0.0013, Figure 3.9C) in methylation levels from 15% to 70% in several CpGs 
located within THOR. For instance, within the amplicon A4, there was a decrease in 
methylation levels of 60% and 70% in CpGs located at positions chr5:1295605 and 
chr5:1295618, respectively, when compared to negative controls (NT, Mock and 
TET_MO). Similarly, transfection with TETg5_MO also led to a decrease in CpG 
methylation over the three amplicons assessed within THOR. However, the latter did 
not cause such a significant demethylation as that observed for TETg7_MO (Figure 
3.9). Interestingly, TETg5_MO was able to reduce the methylation status of three 
CpGs located at positions chr5:1295586, chr5:1295590 and chr5:1295593 within the 
amplicon A4 that were not affected by TETg7_MO (Figure 3.9A).  These CpG sites 
correspond to the target-binding sites of gRNA 7, and, as previously reported by other 
studies, the CpG methylation status may not be altered at the gRNA-targeted sites, 
but those in the nearby sequences or within 100 and 300 bp in distance can be 
significantly modified (Choudhury et al., 2016; Liu et al., 2016; Xu et al., 2016). Indeed, 
the highest levels of demethylation either for individually transfection of TETg7_MO or 
TETg5_MO, were observed at CpG sites proximal to the dCas9/gRNA binding sites 
(Figure 3.9). However, the CpG region within 200-250 bp in distance from the gRNA-
targeted sites was also affected. Additionally, co-transfection with both gRNAs, gRNA 
5 and gRNA 7, was performed to test whether demethylation activity within THOR 
could be further improved. As shown in Figure 3.9, the multiple targeting resulted in 
demethylation levels similar to those observed for individual TETg7_MO transfection 
(p=0.0020, Figure 3.9C). This finding resembles a previous study in which a pool of 
gRNAs targeting different sites in RANKL and MAGEB2 promoters did not show 
additive effects in transcriptional upregulation of target genes (Xu et al., 2016). The 
same was reported by Hilton et al., who found that a dCas9-fused to p300 histone 
acetyltransferase core domain used to activate gene expression, induced statistically 
equivalent gene expression levels with the best individual gRNA or by co-transfection 
(Hilton et al., 2015). On the other hand, these observations contradict some previous 
studies that reported synergic effects in demethylation and gene transcription levels 
using multiple gRNAs targeting their respective gene promoters (Liu et al., 2016; 
Morita et al., 2016). 
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Figure 3.9 Targeted THOR demethylation using CRISPR–dCas9 and a peptide-repeat-
based system. Demethylation activities quantified by MiSeq for both A. active (TET_MO) and 
B. a catalytically dead TET1 (IN_MO) are shown. 48h post-transfection cells were sorted by 
FACS to select GFP-expressing cells, and submitted to bisulfite treatment. Genomic 
coordinates of each CpG site and the distance of the first position of each amplicon in relation 
to transcription start site is shown. C. TETg7_MO and TETg5+g7 induced significant targeted 
demethylation of THOR within hTERT promoter. CpG methylation was calculated as the mean 
percentage of all CpG sites. Bars represent the mean of 3 independent experiments ± SD. P-
values were determined using two-tailed, unpaired Student’s t- test and statistical significance 
was considered as follows, *p<0.05, **p<0.01 and ***p<0.001. 
A 
B 
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Despite the demethylation efficiency within THOR being improved with this CRISPR–
dCas9 peptide-repeat-based system, it was not sufficient to induce hTERT 
downregulation (Figure 3.10). A slight decrease in hTERT mRNA levels caused either 
by individual transfection of gRNA 5 (TETg5_MO, p=0.0824), gRNA 7 (TETg7_MO, 
p=0.0780) or upon co-transfection (TETg5+g7_MO, p=0.0873) was observed when 
compared to the empty vector (TET_MO) (Figure 3.10A).  Nevertheless, these results 
do not establish a causal relationship between the demethylation of THOR within the 
hTERT promoter and its transcriptional inactivation. 
Several factors may explain the fact that the THOR demethylation, although 
significant, did not affect hTERT mRNA expression. For instance, as observed in 
Figure 3.9A, several CpGs sites over the amplicon A3 were only slightly demethylated, 
by about 10% to 20%, and therefore, the observed demethylation may not be sufficient 
to allow the binding of transcription factors. Indeed, transcription factors, such as 
Wilms’ tumor 1 (WT1) and myeloid-specific zinc finger protein-2 (MZF-2) are known to 
bind the genomic region within THOR and to induce hTERT transcriptional repression 
in cancer cells (Avin et al., 2016; Fujimoto et al., 2000; Kyo et al., 2008). Furthermore, 
WT1 binding to DNA is methylation-sensitive, and thus, is impaired when one or more 
CpGs sites are methylated (Avin et al., 2016; Guilleret et al., 2002), whereas the MZF-
2 binding requires further investigation to known if it is methylation-sensitive. 
Furthermore, as previously reported, effective modification of the DNA methylation 
status is highly dependent on the targeted region, since some regions might be harder 
to be accessed by the dCas9-guided system components (Choudhury et al., 2016). 
Moreover, the efficient transfection and expression of the dCas9-guided system, as 
well as the balance between the exogenous dCas9-based demethylation system and 
the endogenous epigenomic machinery may also affect the efficiency of TET1 activity, 
and thus, the methylation status of a given sequence (Sander & Joung, 2014; Xu et 
al., 2016). In addition, some of the limitations of the present study is that only the gRNA 
5 and gRNA 7 were tested using this CRISPR–dCas9 and a peptide-repeat-based 
system, and so, the demethylation efficiency of the other designed gRNAs 
(Supplementary Table 3.1) within hTERT promoter is unknown. Also, assessing the 
transcriptional repressors that bind within THOR by ChIP and then, design the gRNAs 
targeting the precise binding site of the most potent transcriptional repressor, would 
be useful to evaluate whether THOR demethylation mediate hTERT downregulation 
by hindering the binding of transcription repressors.  
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Importantly, as shown in Figures 3.9B and 3.10B, a catalytic dead form of TET1 
(IN_MO) alone or in the presence of gRNAs targeting THOR does not have any impact 
in THOR demethylation (Figure 3.9B) or in hTERT mRNA expression (Figure 3.10B). 
As well, no demethylation or alteration in hTERT mRNA levels was observed in the 
presence of only TET_MO (Figures 3.9 and 3.10), indicating that targeted 
demethylation only occurs in the presence of both components, the dCas9-GCN4 and 
antibody-TET1-gRNA complex. Hence, these findings further evidence the efficacy 
and specificity of the CRISPR-dCas9 system to manipulate DNA methylation in a 
targeted manner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Effect of targeted THOR demethylation using a CRISPR–dCas9 and a 
peptide-repeat-based system on hTERT expression. A. RT-qPCR analysis shows no 
differences in hTERT mRNA levels in cells transfected with TET_MO alone or with individual 
gRNA 5 (TETg5_MO, p=0.0824) and 7 (TETg7_MO, p=0.0780) targeting THOR and with both 
gRNAs (TETg5+g7_MO, p=0.0873). B. hTERT mRNA expression in MCF-7 cells transfected 
with an inactive form of TET1 (TET_IN) alone or with gRNAs targeting THOR (INg5_MO, 
INg7_MO and INg5+g7_MO). Normalization was performed using GAPDH expression and 
calculated relative to TET_MO transfected cells (A) or to IN_MO transfected cells (B). For both 
analyses, bars represent the mean of 3 independent experiments ± SD. P-values were 
determined using two-tailed, unpaired Student’s t- test. 
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3.3.6 TETg7_MO xenotransplants exhibited delayed tumor growth in mice  
 
To evaluate whether THOR demethylation using the CRISPR–dCas9 and a peptide-
repeat-based system affects cell growth in vivo, TETg7_MO-transfected MCF-7 cells 
were subcutaneously injected into NOD/SCID mice. 
As shown in Figure 3.11A, tumor growth was remarkably suppressed in TETg7_MO 
xenotransplanted mice when compared to the control mice groups (NT, Mock and 
TET_MO). Specifically, the TETg7_MO-transfected MCF-7 cells only started to 
develop palpable tumors 76 days after injection, while all the negative controls 
developed palpable tumors 28 days post-injection (Figure 3.11A). Nevertheless, 
statistical inference could not be assessed as only two mice were used per group.  
Interestingly, as evidenced by histological analysis, the xenotransplants from the 
negative controls (NT, Mock, and TET_MO) were characterized by evident cell 
polymorphism, accompanied by marked anisocytosis and anisokaryosis, and 
exhibited poorly defined cell borders and higher mitotic activity (Figure 3.11B). On the 
contrary, the MCF7-TETg7 xenotransplants were composed of cells well 
individualized, displaying regular nuclei and minimal cytologic atypia (Figure 3.11B). 
Therefore, these microscopic findings suggest TETg7_MO xenotransplants as being 
low grade tumors, which tend to grow slowly, in comparison with the high grade tumors 
corresponding to NT, Mock and TET_MO xenotransplants. Taken together, these data 
suggest that THOR demethylation might prevent tumor cell proliferation and growth. 
In this context, although the impact on hTERT mRNA expression was not significant 
(Figure 3.10), it is not known whether this slight reduction observed in hTERT mRNA 
levels was biologically relevant, as neither hTERT protein levels or telomerase activity 
were assessed. Furthermore, apart from hTERT being crucial for limitless self-renewal 
through telomere maintenance in breast cancer, it also regulates other biological 
processes and gene pathways (Cong & Shay, 2008; Hanahan & Weinberg, 2011). 
Accordingly, THOR demethylation observed within hTERT promoter, and the 
consequent slight reduction on hTERT expression, may have impacted on other 
genes, such as those involved in Wnt-β-catenin signaling pathway and in resistance 
to apoptosis, both being crucial for breast tumorigenesis (Cong & Shay, 2008; Park et 
al., 2009). Nevertheless, it is important to state that this in vivo study requires further 
validation, since only two mice per condition were used. Also, functional assays should 
be performed to evaluate whether cell proliferation and invasion capabilities were 
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affected by TETg7_MO-mediated demethylation. In this context, colony formation and 
cell viability assays, such as the Alamar Blue assay could be performed in vitro  
(Rampersad, 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 In vivo study of TETg7_MO demethylation effect in MCF-7 xenotransplants. 
A. Time course of tumor growth in NOD/SCID mice after subcutaneous injection of 1.6x105 
MCF-7 cells. Cells were harvested 48h post-transfection and sorted by FACS to select GFP-
expressing cells. Tumors corresponding to NT, Mock and TET_MO conditions (black lines) 
grew rapidly when compared to TETg7_MO condition (red line), where tumor growth was 
markedly suppressed. Two mice per condition were used and time represent the days post 
MCF-7 cell injection. B. Hematoxylin and Eosin staining of MCF-7 xenotransplants, original 
magnification 20x. NT, MOCK and TET_MO xenotransplants correspond to densely 
cellular tumors, composed of polygonal cells with solid pattern in scant fibrous stroma. Cells 
have variably indistinct cell borders, scant amounts of eosinophilic cytoplasm, round to oval 
nuclei vesicular or with finely stippled chromatin; there is also marked anisocytosis and 
anisokaryosis, and mitotic figures (white arrowhead), on average 1-2 per one 40x high-power 
field (HPF). In contrast, TETg7_MO xenotransplants are composed of polygonal cells 
arranged in haphazard islands separated by variably thick bands of fibrous connective tissue, 
and with a prominent basal lamina (black arrowhead). Cells show only moderate anisocytosis 
and anisokaryosis, with smaller nuclei, more abundant and clear cytoplasm, and mitotic figures 
are less frequent, averaging 1-2 per five 40x HPF.  
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3.4 Conclusion 
 
The main purpose of the study reported in this chapter was to investigate the 
mechanistic role of THOR hypermethylation on hTERT upregulation in breast cancer. 
First, THOR hypermethylated region (433 bp) was studied using the Roadmap 
Epigenomics database, which demonstrated that it is located in a repressive chromatin 
region upstream of the hTERT core promoter. Indeed, this finding was further 
supported by luciferase reporter assays, in which unmethylated THOR repressed 
hTERT promoter activity regardless of TERTpMut status in BC cell lines. Therefore, 
these data suggest that THOR hypermethylation may be a mechanism that cancer 
cells acquire to maintain hTERT expression and a constitutively activated telomerase. 
Hence, to test this hypothesis, the CRISPR-dCas9 technology was used to evaluate 
whether targeted THOR demethylation could revert hTERT upregulation in BC. Two 
different targeted demethylation approaches were tested, a simple CRISPR-dCas9 
system fused with a TET1 demethylase enzyme and a CRISPR-dCas9 peptide-
repeat-based system. Our results revealed site specific demethylation at THOR within 
hTERT gene promoter. However, the demethylation efficiency was markedly improved 
using the second approach, in which the same gRNAs targeting THOR increased 
demethylation from 15% to up to 70% at some targeted CpG sites. Furthermore, 
although the highest degree of demethylation being observed at CpG sites near to the 
dCas9/gRNA binding sites, the CpG region within 200-250 bp in distance from the 
targeted site was also demethylated, thus demonstrating long-range demethylation 
effects, which was also observed in other previous studies. One explanation for this 
improvement on demethylation efficiency is related to the fact that this CRISPR 
peptide-repeat based system allows a higher recruitment of TET1 activity to the 
targeted site when compared to the CRISPR-dCas9 system used in the first approach. 
However, despite THOR demethylation efficiency has been improved, it was not 
sufficient to reduce hTERT expression levels, and thus, does not allow us to establish 
a causality effect between THOR demethylation and hTERT transcriptional 
inactivation. Additionally, the in vivo study suggests that MCF-7 cells transfected with 
TETg7_MO, tend to grow slower and form smaller tumors when compared to negative 
controls. Therefore, although a significant decrease was not observed in hTERT 
mRNA levels, it is not known whether telomerase activity was affected by THOR 
demethylation, and thus, this parameter should also be assessed in the future studies.  
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Altogether, the DNA methylation editing approach reported here, revealed that 
targeted THOR demethylation can be achieved. However, further functional studies 
are needed to demonstrate the precise mechanism of THOR hypermethylation as a 
positive regulator of hTERT transcription in BC. Moreover, since these epigenome 
editing tools have been successfully applied in vivo, demethylation of THOR and its 
biological effects should be further studied as it presents itself as a potential 
therapeutic target for breast cancer. 
 
 
3.5 Supplementary Material 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 3.1 hTERT promoter mutation screening in BC cell lines. In the 
upper portion of the figure are represented a wild-type sequence of hTERT promoter from WI-
38 fibroblasts, and a C228T hTERT promoter mutation sequence from ONS-76 
medulloblastoma cell line. MCF-7 and BT-20 cells are wild-type for both TERTpMut, while MDA-
MB-231 cells harbour the C228T TERTpMut, as evidenced by the nucleotide changes at C228T 
mutation.  
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Supplementary Figure 3.2 Co-transfection efficiency of pGIPZ and sgRNA plasmids in 
MCF-7 cells. MCF-7 cells were visualized by fluorescence microscopy 24h post-transfection 
with both pGIPZ and sgRNA plasmids. A. Untransfected cells in GFP and mCherry channel 
(negative control). MCF-7 cells co-transfected cells under B. transmitted light C. GFP filter and 
D. mCherry filter. MCF-7-transfected cells displayed high co-transfection efficiency. All images 
are shown at 10x magnification. 
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Supplementary Figure 3.3 Bisulfite Sanger sequencing of amplicon A4 within THOR. 
DNA sequencing electropherogram of amplicon A4, four days post-transfection and following 
bisulfite treatment. In the upper panels of the figure are represented the DNA sequencing 
results for negative controls, non-transfected MCF-7 cells (NT), Mock (without plasmid DNA) 
and TET (dCas9-TET1 alone), while in the bottom is represented the TETg7 (dCas9-TET1-
g7). The CpG positions within amplicon 4 are highlighted in blue. The methylated CpG 
cytosines remained intact in all negative controls, while in the CpG sites indicated with the red 
arrows in the TETg7 panel were partially demethylated since it was detected an increase in 
thymine peaks in those sites. 
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Supplementary Figure 3.4 Cell sorting analysis of cell viability and transfection 
efficiency in MCF-7 cells. MCF-7 cells were transfected with the dCas9-TET1_MO plasmid 
alone (TET_MO) and with gRNA 7 (TETg7_MO). Two days post-transfection, MCF-7 cells 
were stained with propidium iodide (PI) as described in the materials and methods section, 
and cell viability and transfection efficiency were quantified using a FACS flow cytometer (BD 
Biosciences) with a 488-nm blue laser. In the upper panel, the square shows the PI-negative 
cells (viable), while in the bottom panel are represented the selection of PI-negative/GFP-
positive cells. 
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Supplementary Figure 3.5 Demethylation of CpG sites across amplicons A2, A3 and A4 
within THOR using the TETg7_MO plasmid. DNA sequencing electropherogram of 
amplicons A. A2, B. A3 and C. A4, 48h post-transfection and after FACS sorting to select 
GFP-expressing cells, followed by bisulfite treatment. For each amplicon, are represented the 
DNA sequencing results for TET_MO (negative control) and TETg7_MO. The CpG positions 
within each amplicon are highlighted in blue. The methylated CpG cytosines remained intact 
in the negative controls (TET_MO), while the CpG sites indicated with the red arrows 
(TETg7_MO) were partially demethylated, converted into uracil and replaced by thymine 
following PCR, since it was detected an increase in thymine peaks in those sites. 
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All the following Supplementary Files and Tables referent to this chapter are available 
in digital support: 
 
Supplementary File 3.1 Plasmid constructs used in luciferase-based assays. 
 
Supplementary File 3.2 Plasmid DNA sequences of dCas9-TET1, dCas9-TET1-IN and 
pgRNA cloned with each gRNA. 
 
Supplementary File 3.3 Plasmid DNA sequences of vectors used in the second targeted 
THOR demethylation approach. 
 
Supplementary Table 3.1 List of primer sequences to construct guide RNAs targeting THOR. 
 
Supplementary Table 3.2 Primer sequences to construct guide RNAs used in the second 
approach of targeted THOR demethylation. 
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4.1 Introduction 
 
Breast cancer  is a highly heterogeneous disease, comprising multiple histological and 
molecular subtypes that are associated with distinct clinical behaviours and 
therapeutic responses (Malhotra et al., 2010; Zardavas et al., 2015). Early detection 
and improved treatment have led to better outcomes, however BC still ranks among 
the leading causes of cancer-related deaths (Torre et al., 2015). BC has traditionally 
been classified based on tumor size, regional lymph node infiltration, histology, grade, 
and immunohistochemical evaluation of estrogen receptor (ER), progesterone 
receptor (PR), human epidermal growth factor receptor 2 (HER2) and proliferation 
marker Ki-67 (Bustreo et al., 2016; Senkus et al., 2015). These factors are the most 
significant prognostic and therapeutic predictors in current BC clinical practice.  
Recently, with the advent of high-throughput technologies, gene expression profiling 
has enabled a more comprehensive view of the molecular identity of breast cancer. 
Five major molecular and outcome related BC subtypes, known as PAM50 subtypes, 
were identified based on genome-wide expression analyses: Luminal-A, Luminal-B, 
HER-2, Normal-like and Basal-like (Malhotra et al., 2010; Network, 2012; Schnitt, 
2010; Sørlie et al., 2001). Breast cancer classification based on PAM50 subtypes and 
risk of recurrence (ROR) score have shown to significantly contribute to prognostic 
assessment and to facilitate more precise therapeutic decisions (Ohnstad et al., 2017). 
Other genomic tests, such as Mammaprint (Agendia, Huntington Beach, CA) and 
Oncotype DX (Genomic Health, Redwood City, CA) may also be used to provide 
prognostic and/or predictive information in early-stage breast cancer beyond the 
standard clinicopathological assessment and to determine the likelihood of benefit 
from adjuvant chemotherapy (Cardoso et al., 2016; Senkus et al., 2015). Tailoring 
treatment to individual tumor subtypes has the potential to greatly improve breast 
cancer management and survival (Byler et al., 2014; Ludwig & Weinstein, 2005). 
Epigenetic marks, including DNA methylation, histone modifications and miRNAs, are 
important regulators of gene expression in normal development and disease (Deaton 
& Bird, 2011; Portela & Esteller, 2010). They also serve as prognostic biomarkers 
(Castelo-Branco P et al. 2013; Brock et al. 2008) in cancer and are increasingly being 
investigated as therapeutic targets (Faleiro, Leao, et al., 2017; Jones et al., 2016). 
DNA methylation involves addition of a methyl group to the cytosine pyrimidine ring in 
CpG dinucleotides by DNA methyltransferases (DNMTs) (Rodríguez-paredes & 
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Esteller, 2011). Canonically, promoter methylation is thought to decrease gene 
expression by recruitment of methyl-binding domain proteins (MBDs), that change 
chromatin conformation thereby preventing binding of transcription factors (Bert et al., 
2013; Castelo-Branco et al., 2013; Stefansson & Esteller, 2013). In BC, several studies 
have reported promoter hypermethylation leading to silencing of tumor suppressor 
genes, including BRCA1 (Zhu et al., 2015), E-cadherin (Shargh et al., 2014) and TMS1 
(Mirza et al., 2007). By contrast, the Wilms’ tumor suppressor 1 (WT1) gene is 
overexpressed in breast tumor tissue despite hypermethylation of its promoter (Loeb 
et al., 2001). Thus, methylation changes in the gene promoter may correlate with either 
upregulation or downregulation of the associated gene (Bert et al., 2013; Brooks et al., 
2010; Castelo-Branco et al., 2013, 2016).  
Differences in DNA methylation profiles between normal and malignant breast tissue 
have the potential to serve as a diagnostic and/or prognostic tool in breast cancer 
(Lewis et al., 2005; Mirza et al., 2007; Stefansson & Esteller, 2013). To date, most 
studies have examined a small number of genes (Mirza et al., 2007; Stefansson & 
Esteller, 2013; Zhu et al., 2015), and only a few studies have performed genome-wide 
analyses across multiple BC subtypes (Fleischer et al., 2014; Holm et al., 2016; 
Network, 2012). As a result, further studies regarding genome-wide DNA methylation 
profiles are needed to better understand the contribution of DNA methylation patterns 
to breast cancer heterogeneity. Here we investigate whole genome DNA methylation 
patterns in BC, highlighting the potential importance of epigenetic changes in breast 
carcinogenesis, and identifying novel DNA methylation markers that could be useful 
for breast cancer classification and prognosis. 
 
 
4.2 Materials and Methods 
 
4.2.1 Datasets 
 
Bioinformatic analyses were performed on publicly available databases including DNA 
methylation and gene expression data from breast tumor samples derived from The 
Cancer Genome Atlas Consortium (TCGA) (Network, 2012) and the Molecular 
Taxonomy of Breast Cancer International Consortium (METABRIC) (Curtis et al., 
2012). 
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4.2.2 DNA methylation and gene expression analysis 
 
All TCGA data were retrieved from the TCGA data portal 
(https://portal.gdc.cancer.gov/). The DNA methylation data was derived from the 
Illumina Infinium Human Methylation 450k array. The methylation score for each CpG 
site is represented as beta values and range from 0 to 1, corresponding to 
unmethylated and completely methylated DNA, respectively. CpG sites were 
considered as differentially-methylated when Δβ (between tumors and normal tissues) 
is equal or greater than 0.4. Gene expression data was derived from Illumina HiSeq 
2000 RNA Sequencing. This dataset includes gene-level transcription estimates, 
expressed in RSEM normalized count.  
METABRIC gene expression data was retrieved from the METABRIC dataset (Curtis 
et al., 2012) for 1992 primary breast cancer and 144 normal tissue samples. Gene 
transcriptional profiling derived from the Illumina HT-12 v3 platform and data were 
normalized as previously described (Curtis et al., 2012). 
DAVID (http://david-d.ncifcrf.gov/) was used for Gene Ontology enrichment analysis, 
to test whether the genes of interest are more associated with a specific biological 
function or process. 
 
4.2.3 Gene set enrichment analysis 
  
Genes ranked according to the coefficient of Spearman correlation were analysed for 
pathway enrichment using the Gene Set Enrichment Analysis software (Mootha et al., 
2003). This software consists in a computational method that determines if an a priori 
defined gene set display statistically significant enrichment at the top or bottom of an 
ordered gene list. Gene sets were retrieved from the KEGG database (Kanehisa & 
Goto, 2000; Kanehisa et al., 2016), which integrates genomic and chemical 
information of the biological system. Pathways with a False Discovery Rate (FDR) 
lower than 5% were considered significantly enriched. 
 
4.2.4 Principal component and hierarchical clustering analyses 
 
Principal component and hierarchical clustering analyses were performed using 
FactoMineR (Lê, Josse, & Husson, 2008) and gplots (Warnes et al., 2016) R 
packages, respectively.  
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4.2.5 OncoScore 
 
OncoScore is a bioinformatics tool that ranks genes according to their association with 
cancer, based on the available scientific literature. A score is attributed to each specific 
gene according to the total number of citations in scientific literature and its citations 
prevalence in cancer-related articles. 
OncoScore data was accessed on 22/06/2017 through the R package OncoScore 
(Rocco et al., 2017), version 1.4.2. https://github.com/danro9685/OncoScore. 
 
4.2.6 Diagnostic and prognostic value analyses 
 
Differentially-methylated CpG sites located in the OncoScore-selected genes were 
analysed in terms of their diagnostic potential. The specificity and sensitivity of 
methylation levels for breast cancer diagnosis were evaluated by receiver-operator 
curve (ROC) analysis (Zweig & Campbell, 1993) with diagnostic validity suggested by 
an area under the ROC curve (AUC) ≥ 0.8.  
To evaluate the prognostic ability of CpG sites, Kaplan-Meier survival curves were 
generated and log-rank p-value and Hazard Ratios with 95% confidence intervals were 
calculated (Kaplan & Meier, 1958). Based on the AUC, a cut-off value was established 
for each probe in order to distinguish patients with CpG sites hypomethylated (blue) 
from those with CpG sites hypermethylated (red). Optimal cut-off values were 
identified according to maximal sensitivity and specificity generated previously by the 
AUC. In addition, we performed multivariate Cox proportional-hazards model survival 
analyses with ER status as covariate. Only breast cancer patients with DNA 
methylation data and overall survival data were included in the analysis. 
 
4.2.7 Roadmap Epigenomics database analysis 
 
Epigenomic data from normal breast myoepithelial cells was analyzed using the 
Roadmap Epigenomics database (Roadmap Epigenomics Consortium et al., 2015) 
and release 9 of the Human Epigenome Atlas from the NIH Roadmap Epigenomics 
Mapping Consortium (http://www.roadmapepigenomics.org/data/). Data including 
DNA methylation levels (MeDIP), histone modification marks (ChIP), and chromatin 
accessibility (ChromHMM) (Ernst & Kellis, 2012) datasets. DNA methylation patterns, 
active histone marks H3K4me3 and H3K4me, repressive histone marks H3K27me3 
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and H3K9me3, and chromatin status (ChromHMM) were mapped for each CpG 
location based on the GRCh37/hg19 genome assembly. 
 
4.2.8 Pan-cancer analysis of gene expression and CpG methylation and 
prognostic potential 
 
We examined 13 cohorts from the TCGA containing both tumor and normal samples 
(≥ 20 samples in each group). All cohorts contained gene expression data and 12 also 
contained methylation and patient survival data. For each gene/CpG, we calculated 
the proportion of cohorts with expression results concordant with the results obtained 
for breast cancer cohort, as well as methylation levels and prognostic ability in these 
cohorts.  
 
4.2.9 Statistical analysis  
 
Preprocessing and normalization of data as well as all statistical analyses were 
performed using the R computing framework, with the exception of Kaplan-Meier 
survival curves, which were generated using GraphPad Prism 5.0 software. 
Differential methylation and expression analyses were performed using the Mann-
Whitney test, while correlation analyses were assessed using Spearman correlations. 
Kaplan-Meier survival curves were compared using the log-rank test. A p-value below 
0.05 was considered statistically significant. 
 
 
4.3 Results and Discussion 
 
4.3.1 Genome-wide DNA methylation analysis reveals 368 differentially 
methylated CpG sites in breast cancer tissue 
 
We set out to investigate the genome-wide DNA methylation profiles in a panel of 780 
breast tumor samples and 83 matched normal samples from The Cancer Genome 
Atlas (TCGA). Although methylation of distal regions, such as enhancers, is relevant 
for gene regulation in breast cancer (Fleischer et al., 2017), we intentionally focused 
on proximal gene regions by limiting our analysis to CpG probes mapping to a known 
gene (n = 251,574) to facilitate the link with the respective target gene. To identify CpG 
sites showing the most significant and relevant tumor-specific changes in methylation, 
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CpGs with a Δβ (between tumors and normal tissues) equal to or greater than 0.4 
were selected. We identified 368 differentially-methylated CpG sites that distinguish 
tumor and normal breast tissues (Δβ ≥ 0.4 and FDR ≤ 5%), mapping to 286 unique 
genes (Figure 4.1A and Supplementary Table 4.1). Hypermethylated CpG sites 
(80.7%) predominated in tumor tissue relative to hypomethylated sites (19.3%) (p< 2.2 
× 10− 16; Figure 4.1B). Hypermethylated and hypomethylated CpG sites also localized 
to different areas within their associated genes (p=0.001). More than 50% of 
hypermethylated CpG sites were localized in upstream regulatory regions including 
the promoter, 5′ untranslated region, and 1st exon (TSS1500, TSS200, 5’UTR and 1st 
exon), while only 30% of hypomethylated CpG sites localized to these regions (Figure 
4.1B). This finding is in agreement with previous studies reporting promoter 
hypermethylation as a mechanism of tumor suppressor gene silencing in breast 
cancer (Kazanets et al., 2016). Conversely, hypomethylated CpG sites were localized 
predominantly in the gene body (66.2%) (Figure 4.1B), a phenomenon that has been 
postulated to contribute to activation of aberrant intragenic promoters, which are 
normally silenced, in other cancers (Kulis et al., 2012; Neri et al., 2017). 
Functional enrichment analysis revealed that genes associated with hypermethylated 
CpG sites are enriched for homeobox genes and transcription factors, while those 
associated with hypomethylated CpG sites are enriched for transmembrane proteins 
and immunoglobulins (Figure 4.1C-D and Supplementary Table 4.2). Homeobox 
genes have previously been reported as differently methylated in breast cancer 
(Tommasi et al., 2009), as well as in other cancer types (Rodrigues et al., 2016).  
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Figure 4.1 Genome-wide DNA methylation alterations in breast cancer. A. Stacked bar 
plot showing localization of the 368 differentially-methylated CpG sites in breast tumor tissue 
relative to their cognate genes. B. Stacked bar plot showing localization of hyper- and 
hypomethylated CpG sites in breast tumor tissue relative to their cognate genes. The 
distributions are significantly different (p<2.2 x 10− 16, Pearson’s chi-squared test). C and D. 
Enriched Gene Ontology categories using DAVID clustering enrichment scores for genes 
hypermethylated (C) or hypomethylated (D) in tumors. TSS1500, within 1500 bp of the 
transcriptional start site; TSS200, within 200 bp of the transcriptional start site; 5’UTR, 5′ 
untranslated region; 3’UTR, 3′ untranslated region. 
 
 
4.3.2 Correlation between DNA methylation and gene expression change in BC 
 
To explore the relationship between DNA methylation and gene expression in BC, we 
compared the direction of CpG methylation change (hyper- vs. hypomethylated) with 
the direction of expression change in the corresponding genes. Among the 368 
differentially-methylated CpG sites, we identified 209 that were associated with 
differentially-expressed genes (FDR < 5%), representing a total of 164 genes. We then 
correlated the direction of methylation change with the direction of expression change 
of the cognate gene. Negative correlations (59%) predominated relative to positive 
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correlations (41%) (p<2.2 × 10−16, Supplementary Figure 4.1), largely represented by 
hypermethylated CpG sites that were associated with downregulated genes 
(Supplementary Table 4.3). When negative and positive correlations were subdivided 
according to CpG location within the associated gene, more than 70% of negative 
correlations involved CpG sites located in the upstream regulatory regions (promoter, 
5’UTR, 1st exon), while 74% of positive correlations involved CpG sites found in the 
gene body (Figure 4.2A). Thus, promoter hypermethylation mostly correlated with 
gene downregulation, while gene body hypermethylation correlated with gene 
upregulation, as previously observed in a separate genome-wide study (Fleischer et 
al., 2014). 
We next analyzed the same 209 CpG sites previously associated with differentially-
expressed genes to ascertain the possible sources of variability at these methylation 
sites. Principal Component Analysis confirmed that sample type (normal breast vs. 
breast tumor) is the primary source of variability underlying the methylation signature, 
accounting for 53.9% of variability (Figure 4.2B). The second component (6.25%) was 
putatively explained by the PAM50 subtypes within the breast tumors, as identified in 
TCGA (Figure 4.2C), with higher Principal Component 2 values associated with basal 
breast tumors and poorer outcomes (p=0.01, Log-rank test, Supplementary Figure 
4.2). Unsupervised hierarchical clustering, using the same 209 CpG probes, revealed 
the existence of two major groups, however, these did not show obvious clustering of 
clinical traits (Supplementary Figure 4.3). 
Functional enrichment analysis of the 164 differentially-methylated and differentially-
expressed genes revealed enrichment for homeobox genes (positively correlated with 
methylation, upregulated expression) as well as transcription factors (negatively 
correlated with methylation, downregulated expression) and cell differentiation genes 
(negatively correlated with methylation change) (Figure 4.2D and Supplementary 
Table 4.2). Further studies are required to elucidate the role of DNA methylation in the 
regulation of this important classes of genes. 
So, altogether our results revealed that the majority of the 209 CpGs are negatively 
correlated with cognate gene expression, confirming that DNA methylation is strongly 
associated with repression of gene expression in breast cancer (Fleischer et al., 2014). 
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Figure 4.2 209 CpG probes are correlated with cognate gene expression. A. Stacked bar 
plot showing localization of differentially-methylated CpG sites within their cognate genes 
subdivided according to the correlation between methylation and gene expression. Negatively-
correlated CpG sites are shown in the first bar, and positively-correlated CpG sites in the 
second bar. The distributions are significantly different (p<2.2 × 10−16, Pearson’s chi-squared 
test). B and C. Principal Component Analyses using the 209 differentially-methylated probes 
located in differentially expressed genes, categorized by sample type (B) or PAM50 subtype 
(C). D. Enriched Gene Ontology categories using DAVID clustering enrichment scores for 
genes with negative (blue) or positive (red) correlations. 
 
 
4.3.3 METABRIC validation and OncoScore analysis reveal 7 new genes related 
to BC 
 
To validate our previous gene expression analyses we used transcriptomic data from 
the METABRIC dataset (Curtis et al., 2012)  which comprises 1992 breast tumor 
samples and 144 normal adjacent tissues. We were able to validate 88 out of 164 
genes (53.7%) as differently expressed in breast tumor tissue relative to normal breast 
tissue, with the direction of expression change being concordant between the datasets 
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(Supplementary Table 4.4). Of the remaining 76 genes, 68 genes did not show 
differential expression in the METABRIC dataset while no data was available for the 
other 8 genes.  
We next determined which of the 96 differentially methylated genes with validated (88) 
or unconfirmed (8) gene expression changes had previously been associated with 
cancer in the medical literature. We used the OncoScore tool (Rocco et al., 2017), a 
text-mining algorithm that ranks genes according to their appearance in the cancer-
related literature, to analyse the 96 genes. The top ranked gene, WT1, had an 
Oncoscore of 77.5, and a total of 81 genes had Oncoscores ≥1, indicating at least one 
citation in a cancer-related article. A total of 7 genes had Oncoscores of 0, indicating 
no prior association with cancer in the medical literature (Figure 4.3 and 
Supplementary Table 4.5). No Oncoscore data was available for 8 genes. 
 
 
 
 
 
 
 
 
 
Figure 4.3 OncoScore of the “top 7” (green) and “bottom 7” (red) genes. The Top and 
Bottom 7 include the 7 genes with the highest and lowest OncoScores, respectively. 
 
 
After OncoScore analysis we selected the top 7 genes (strongly associated with 
cancer: WT1, BCL9, SMYD3, ZNF154, ZNF177, HOXD9, and ITIH5) and the bottom 
7 genes (not previously associated with cancer: TMEM132C, TDRD10, RNF220, 
RIMBP2, PRAC2 (C17orf93), EFCAB1, and ANKRD53) for further analysis regarding 
their diagnostic and prognostic potential (Figure 4.3). 
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4.3.4 Identification of candidate diagnostic and prognostic biomarkers in BC 
 
Within the 14 genes selected for further analysis, 18 differentially-methylated CpGs 
were identified (Table 4.1). These CpG sites were analysed for diagnostic and 
prognostic potential using the area under the ROC curve (AUC) method (Zweig & 
Campbell, 1993) and Kaplan-Meier survival curves, respectively.  
Within the “top 7” genes, there were 9 differentially methylated CpG sites, of which 7 
were hypermethylated and 2 hypomethylated in BC when compared with normal 
breast tissue (Table 4.1). All 9 CpG sites were able to distinguish breast tumor tissue 
from normal tissue (AUC >0.8 and p<0.0001; Table 4.1). Only 2 CpG sites showed an 
association with poor prognosis (Table 4.1). These were both hypermethylated CpG 
sites located in the promoters of the ZNF154 and HOXD9 genes that were negatively 
correlated with gene expression (ZNF154: p=0.0097 and HOXD9: p=0.0266, Table 
4.1 and Supplementary Figure 4.4). When the different ER status were taken into 
account as covariates in a multivariate analysis, only the HOXD9 CpG methylation 
remained significantly associated with poor prognosis (p=0.02, Supplementary Figure 
4.5). These findings suggest that silencing of these genes by DNA methylation may 
have negative implications for prognosis, which is in accordance with previous data 
from triple-negative breast cancer (Stirzaker et al., 2015) and metastatic melanoma 
(Marzese et al., 2014).  
Within the “bottom 7” genes not previously associated with cancer there were nine 
differentially methylated CpG sites, 5 hypermethylated and 4 hypomethylated (Table 
4.1). All 9 CpG sites were able to distinguish breast tumor tissue from normal tissue 
(AUC >0.8 and p<0.0001, Table 4.1). Site cg10216717, located in gene TMEM132C, 
showed the highest discriminative accuracy with an AUC of 0.9920 (Table 4.1). Only 
3 CpG sites showed an association with poor prognosis (Table 4.1 and Figure 4.4). 
Site cg12374721 (PRAC2 gene) was hypermethylated in breast tumor tissue and 
positively correlated with gene expression (p=0.0134, Table 4.1 and Figure 4.4A). 
Sites cg18081940 (TDRD10 gene) and cg04475027 (TMEM132C gene) were also 
hypermethylated but were negatively correlated with gene expression (p=0.0037 and 
p=0.0291 respectively, Table 4.1 and Figures 4.4B and 4.4C). All 3 CpG sites were 
associated with poor prognosis in ER-positive breast cancer samples, but none in ER-
negative (Figure 4.4D-I). The association of TMEM132C CpG site remained significant 
when ER status was taken into account as covariate in a multivariate analysis (p=0.03, 
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Supplementary Figure 4.6). When a combined signature of these 3 CpG sites was 
analysed, patients with a higher hypermethylation index showed poorer prognosis 
(p=0.02; HR: 1.853; Supplementary Figure 4.7). These data suggest a possible role 
for PRAC2, which shows increased expression in tumor tissue, as an oncogene, and 
TDRD10 and TMEM132C, with decreased expression in tumor tissue, as tumor 
suppressor genes. 
 
 
 
 
 
  
 
                                                          
 
 
Table 4.1 List of the Top and Bottom 7-ranking methylation markers selected as potential biomarkers. 
ns, not significant. 
 
 CpG ID Gene 
∆β methylation 
(tumor - normal) 
Correlation 
(methylation vs. expression) 
AUC Overall Survival 
Top 7 
cg10244666 WT1 0.44; p=2.57e-40 r:0.17; p=1.09e-6 0.9430 (CI:0.9279-0.9582); p < 0.0001 ns 
cg03441279 BCL9 -0.41; p=5.8e-25 r:-0.32; p=1.58e-19 0.8434 (CI:0.8184-0.8684); p < 0.0001 ns 
cg25025181 SMYD3 -0.45; p=6.18e-39 r:-0.31; p=2.36e-19 0.9324 (CI:0.9163-0.9486); p < 0.0001 ns 
cg01268824 ZNF154 0.42; p=4.68e-34 r:-0.63; p=1.44e-85 0.9002 (CI:0.8778-0.9226); p < 0.0001 p=0.0097 
cg09578475 
cg08065231 
cg13703871 
ZNF177 
0.51; p=4.87e-40 
0.46; p=9.51e-39 
0.47; p=2.91e-40 
r:0.20; p=2.73e-8 
r:0.23; p=1.54e-10 
r:0.17; p=3.13e-6 
0.9378 (CI:0.9219-0.9537); p < 0.0001 
0.9320 (CI:0.9153-0.9486); p < 0.0001 
0.9410 (CI:0.9257-0.9562); p < 0.0001 
ns 
cg22674699 HOXD9 0.40; p=3.15e-28 r:-0.17; p=1.12e-6 0.8679 (CI:0.8427-0.8931); p < 0.0001 p=0.0266 
cg10119075 ITIH5 0.41; p=1.51e-39 r:-0.26; p=1.73e-13 0.9397 (CI:0.9243-0.9552); p < 0.0001 ns 
Bottom 7 
cg15165122 ANKRD53 0.41; p=2.09e-34 r: -0.48; p=2.34e-46 0.9028 (CI:0.8827-0.9229); p < 0.0001 ns 
cg12743248 EFCAB1 -0.45; p=5.39e-45 r: 0.44; p=8.49e-38 0.9664 (CI:0.9553-0.9775); p < 0.0001 ns 
cg12374721 PRAC2 0.46; p=9.42e-36 r:0.39 ; p=1.63e-30 0.9118 (CI:0.8923-0.9313); p < 0.0001 p=0.0134 
cg27170427 
cg17192862 
RIMBP2 
-0.46; p=1.24e-46 
-0.41; p=1.29e-46 
r:0.35; p=1.79e-24 
r:0.45; p=6.74e-40 
0.9766 (CI:0.9680-0.9851); p < 0.0001 
0.9765 (CI:0.9675-0.9856); p < 0.0001 
ns 
cg10224098 RNF220 0.45; p=1.01e-39 r:-0.09 ; p=1.51e-2 0.9393 (CI:0.9220-0.9566); p < 0.0001 ns 
cg18081940 TDRD10 0.41; p=1.58e-39 r:-0.20 ; p=4.17e-8 0.9360 (CI:0.9189-0.9531); p < 0.0001 p=0.0037 
cg10216717 
cg04475027 
TMEM132C 
-0.45; p=2.02e-49 
0.42; p=1.19e-40 
r:0.46 ; p=3.44e-42 
r:-0.23 ; p=3.24e-11 
0.9920 (CI:0.9872-0.9968); p < 0.0001 
0.9446 (CI:0.9289-0.9604); p < 0.0001 
ns 
p=0.0291 
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Figure 4.4 Kaplan-Meier 
curves for the CpGs 
located in PRAC2, 
TDRD10 and TMEM132C. 
CpGs hypomethylation is 
associated with better 
overall survival for A. 
PRAC2, B. TDRD10 and 
C.TMEM132C gene. 
Hypomethylation of the 3 
CpGs was also associated 
with better prognosis in D-F. 
ER-positive samples, but 
not in G-I. ER-negative 
samples. Based on the 
AUC, a cut-off value was 
established for each probe 
in order to distinguish 
hypomethylated CpG sites 
(blue) from hypermethylated 
ones (red). The following 
cut-offs were used: 0.5503 
(PRAC2-cg12374721) (A, 
D, G); 0.5243 (TDRD10-
cg18081940) (B, E, H); 
0.4014 (TMEM132C-
cg04475027) (C, F,I).
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4.3.5 Roadmap of epigenomic regulatory elements 
 
We used the Roadmap Epigenomics database (Roadmap Epigenomics Consortium 
et al., 2015) to analyse the 5 CpG sites that showed both diagnostic and prognostic 
potential in BC. Using data from normal breast myoepithelial cells, we plotted DNA 
methylation status, histone modification marks and chromatin accessibility 
(ChromHMM) data for these CpG sites and their associated genes.  
Sites cg01268824 (ZNF154), cg22674699 (HOXD9), cg18081940 (TDRD10), and 
cg04475027 (TMEM132C) localized to gene promoter regions, were hypermethylated, 
and negatively correlated with expression in breast tumor tissue, suggesting that DNA 
methylation at these sites may silence gene transcription (Table 4.1). For these 4 CpG 
sites, Roadmap Analysis revealed that in normal breast cells low methylation levels 
was associated with open chromatin and active histone modification marks, namely 
H3K4me1 and H3K4me3 (Figures 4.5B and 4.5C, Supplementary Figure 4.4). 
Conversely, site cg12374721 (PRAC2) was hypermethylated and positively correlated 
with gene transcription in tumor tissue (Table 4.1). Roadmap analysis revealed that 
cg12374721 was located in a polycomb repressive region in normal breast 
myoepithelial cells, which is associated with repressive chromatin marks, including 
enrichment of H3K27me3 marks (facultative heterochromatin) and lack of H3K4me1 
and H3K4me3 (Figure 4.5A).  
The PRAC2 gene is located between the HOXB13 and PRAC genes, both of which 
encode small nuclear proteins. PRAC2 is highly expressed in prostate tissue and has 
been suggested to play a role in prostate growth and development (Olsson et al., 
2003). For this reason PRAC2 was given the name “Prostate Cancer Susceptibility 
Candidate 2” gene. However, it has not previously studied or associated with any type 
of cancer (Rocco et al., 2017). In the TCGA dataset, PRAC2 was highly expressed in 
breast tumor tissue relative to normal tissue (Supplementary Table 4.4). Methylation 
of its associated CpG site, cg12374721, which is located in the gene promoter, was 
positively correlated with gene transcription in tumor tissue. This contradicts one of the 
central paradigms of DNA methylation, namely that promoter methylation results in 
gene silencing (Bert et al., 2013; Esteller, 2008). Analysis of data from the Roadmap 
Epigenetics Atlas shows enrichment of H3K27me3 in this region in normal breast cells, 
a histone mark associated with repressive chromatin. Thus the gain of methylation in 
this CpG site in breast tumor tissue may contribute to PRAC2 transcriptional activation 
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by blocking the binding of transcriptional repressors or altering the repressive 
chromatin conformation in cancer (Portela & Esteller, 2010). Additionally, 
hypermethylation of site cg12374721 was associated with reduced survival (Table 4.1, 
Figure 4.4A). This suggests a potential oncogenic role for PRAC2 in BC, as has been 
suggested in prostate cancer (Olsson et al., 2003). 
Unlike PRAC2, TDRD10 and TMEM132C genes are both downregulated in breast 
tumor tissue when compared to normal tissue (Supplementary Table 4.4). Their 
hypermethylated CpG sites, cg18081940 (TDRD10 5’UTR) and cg04475027 
(TMEM132C gene body), are negatively correlated with gene expression (Table 4.1). 
Methylation of both of these sites is also associated with reduced survival (Figures 
4.4B and 4.4C). Analysis of histone marks in normal breast tissue reveals that 
cg18081940 (TDRD10) and cg04475027 (TMEM132C) both overlap with open 
chromatin and histone modification marks associated with enhancers (H3K4me1 and 
H3K4me3) (Figures 4.5B and 4.5C). Accordingly, hypermethylation of these CpGs 
may hinder the binding of transcription activators leading to gene silencing in breast 
cancer, suggesting a tumor suppressor function for those genes. TDRD10 (Tudor 
domain containing 10) is a member of the TDRD protein family, that binds to 
methylated arginine/lysine residues and plays a crucial role in chromatin and 
transcriptional regulation, genome stability and RNA metabolism (Cong et al., 2014; 
Jiang et al., 2016). Dysregulation of TDRDs has been reported in BC. Surprisingly, a 
negative correlation has been observed between DNA copy number and mRNA 
expression for TDRD10, demonstrating its importance in suppressing carcinogenesis 
(Jiang et al., 2016). Finally, the TMEM132C (Transmembrane Protein 132C) gene 
belongs to a family of five TMEM132 proteins, which are associated with hearing loss, 
panic disorder and cancer (Iwakawa et al., 2015; Sanchez-Pulido & Ponting, 2018). 
However, the biological function of these genes is still under investigation and currently 
there is no scientific literature relative to TMEM132C. 
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Figure 4.5 Epigenetic analysis of CpG sites from PRAC2, TDRD10 and TMEM132C 
(included in the “bottom 7” genes). A. MeDIP-Seq data shows that cg12374721 (PRAC2) 
is hypomethylated in normal breast cells. ChIP-Seq data shows enrichment of H3K27me3 
histone repressive marks (green peaks) and lack of H3K4me1 and H3K4me3 active histone 
marks. ChromHMM classified this region as a poly comb repressive region (grey). B. 
cg18081940 (TDRD10) and C. cg04475027 (TMEM132C) sites are hypomethylated in normal 
cells and overlap with open chromatin and H3K4me1 and H3K4me3 histone modification 
peaks associated with active transcription (green peaks). ChromHMM classified (B) 
cg18081940 (TDRD10) region as an active TSS (red) and (C) cg04475027 (TMEM132C) as 
a bivalent enhancer (dark yellow).  
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4.3.6 Identification of 3 new breast cancer-related genes 
 
Genes PRAC2, TDRD10 and TMEM132C showed both differential methylation and 
expression in breast tumor samples relative to normal breast tissue and also contained 
CpG sites showing diagnostic and prognostic value in breast cancer. None of these 
genes has previously been reported in the cancer-related literature. PRAC2 is 
upregulated in breast tumor tissue whereas TDRD10 and TMEM132C are both 
downregulated. 
We further analyzed expression of these 3 genes in 13 non-breast cancer TCGA 
cohorts including colorectal adenocarcinoma, head and neck cancer, hepatocellular 
carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, prostate 
adenocarcinoma, and thyroid carcinoma (Supplementary Tables 4.6 and 4.7). 
Expression of TMEM132C was downregulated across all 13 non-breast cancer 
cohorts while PRAC2 was upregulated in 77% of cohorts. TDRD10 was 
downregulated in 46% of cohorts (similar to BC) but was upregulated in kidney clear 
cell carcinoma and thyroid carcinoma cohorts (Figure 4.6). We further analysed the 
diagnostic ability of the 3 CpG sites associated with these genes in non-breast cancer 
cohorts. All 3 CpG sites correlated with cancer diagnosis in 10 or more of the 12 TCGA 
cohorts containing methylation data (Figure 4.6). Correlation with survival was 
identified in 50% (TDRD10), 42% (PRAC2), and 25% (TMEM132C) of the 12 TCGA 
cohorts, with no significant opposing results (Figure 4.6). Interestingly, in thyroid 
carcinoma, which is a relatively indolent tumor, none of the 3 CpGs sites showed 
diagnostic or prognostic potential (Supplementary Table 4.7), suggesting that these 
genes are rather not important for the pathogenesis of this particular cancer. Thus, 
PRAC2, TDRD10 and TMEM132C may be more relevant in rapidly growing cancers. 
These genes merit further study to better understand their role in breast cancer 
pathogenesis. Moreover, validation of these and other DNA methylation-based 
diagnostic and prognostic markers may have significant clinical benefits, namely in 
terms of sample stability and cost when compared to the RNA-based tests already 
available (e.g. Oncotype and Mammaprint) (Cardoso et al., 2016; Senkus et al., 2015). 
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Figure 4.6 Pan-cancer analysis of CpGs sites from PRAC2, TDRD10 and TMEM132C. 
Bar plots showing the proportion of cohorts with results concordant with breast cancer (green), 
opposite to breast cancer (red) or non-significant (grey). 
 
 
4.4 Conclusion 
 
We investigated DNA methylation patterns in BC using a genome-wide approach and 
correlated methylation changes with gene expression data from TCGA and 
METABRIC datasets. This work provides a landscape of aberrant DNA methylation 
changes in breast cancer and its association with gene expression regulation. 
Both positive and negative correlations were observed, suggesting that both CpG 
hypermethylation and hypomethylation may be crucial events in breast 
carcinogenesis. Our study reveals seven new genes related to BC that were not 
previously associated with cancer. From these, three novel DNA methylation-gene 
candidate biomarkers for breast cancer were identified and validated in other cancer 
datasets available at TCGA. The methylation status of sites targeted by the probes 
cg12374721 (PRAC2), cg18081940 (TDRD10) and cg04475027 (TMEM132C) may 
be effective as diagnostic and prognostic tools not only in breast cancer but also in 
other cancer types, such as kidney, lung and prostate cancers. Therefore, the present 
study highlights the molecular and clinical importance of DNA methylation changes in 
breast carcinogenesis, identifying novel DNA methylation markers that could be useful 
for breast cancer management. 
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4.5 Supplementary Material 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 4.1 Genome-wide impact of DNA methylation on gene 
expression. Distribution of Spearman correlation coefficients between DNA methylation and 
cognate gene expression levels (59% of negative Spearman correlation coefficients; P < 
2.2x10-16, 1-sample proportions test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 4.2 Higher values of principal component 2 (PC2) are associated 
with poorer survival. Kaplan Meier curve showing patients subdivided by PC2 value with a 
cut off of 0.095 (p=0.01, Log-rank test). 
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Supplementary Figure 4.3 Heatmap showing hierarchical clustering analysis of 209 
differentially-methylated CpG sites associated with 164 differentially-expressed genes. 
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Supplementary Figure 4.4 2 CpGs from ZNF154 and HOXD9 (7-top genes) are 
epigenetically dynamic and predict prognostic. Upper panel- A. cg01268824 (ZNF154) 
and B. cg22674699 (HOXD9) sites are hypomethylated in normal cells, overlapping with open 
chromatin and active histone modification marks (H3K4me1 and H3K4me3, green peaks). 
ChromHMM classified cg01268824 region (A) as an active TSS (red) and cg22674699 (B) as 
a bivalent enhancer (dark yellow). Bottom panel- Kaplan-Meier curves evidenced that 
hypomethylation of CpG probes located in C. ZNF154 and D. HOXD9 are associated with a 
longer overall survival. Based on the AUC, a cut-off value was established for each probe in 
order to distinguish hypomethylated patients (represented in blue) from hypermethylated 
(represented in red). Cut-offs of 0.6188, (corresponding to the 50th percentile of ZNF154-
cg01268824) and 0.6102 (corresponding to the 49th percentile of HOXD9-cg22674699), were 
used.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
Chapter 4.                                                          
153 
 
Supplementary Figure 4.5 Cox multivariate analyses of the 2 CpG sites from “Top 7”  
genes in BC. Forest plot of Cox multivariate survival analyses of methylation values of A. 
ZNF154 and B. HOXD9 CpG probes with ER status as covariate. 
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Supplementary Figure 4.6 Cox multivariate analyses of the 3 CpG sites from “bottom 
7” genes in BC. Forest plot of Cox multivariate survival analyses of methylation values of A. 
PRCA2, B. TDRD10 and C. TMEM132C CpG probes with ER status as covariate. 
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Supplementary Figure 4.7 Prognostic signature of the 3 CpG sites from “bottom 7” 
genes in BC. Kaplan-Meier curve for the combined signature of the 3 CpGs sites 
correspondent to PRAC2 (cg12374721), TDRD10 (cg18081940) and TMEM132C 
(cg04475027). Low methylation levels were significantly associated with better prognosis 
(p=0.02; HR: 1.853). The prognostic index was dichotomized to low or high methylation index 
based on the combination of the cut-offs previously used for each one of the 3 CpGs. 
 
 
 
All the following Supplementary Tables referent to this chapter are available in digital 
support: 
 
Supplementary Table 4.1 List of CpGs differently methylated between breast cancer and 
matched-normal samples. 
 
Supplementary Table 4.2 Results of DAVID clustering Gene Ontology analyses. 
 
Supplementary Table 4.3 List of CpGs located in genes that are differentially expressed 
between breast cancer and matched-normal TCGA samples and whose methylation levels 
are correlated with cognate gene expression. 
 
Supplementary Table 4.4 List of genes differently expressed between normal and tumor 
METABRIC samples and with concordant results with TCGA breast cancer analyses. 
 
Supplementary Table 4.5 Results of OncoScore analyses for the 164 differentially 
methylated and differentially-expressed genes. 
 
Supplementary Table 4.6 Results of pan-cancer analyses of differential gene expression of 
PRAC2, TDRD10 and TMEM132C. 
 
Supplementary Table 4.7 Results of pan-cancer analyses of diagnostic and prognostic 
potential of the CpGs from PRAC2, TDRD10 and TMEM132C. 
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5.1 General Discussion 
 
Breast cancer (BC) is a major public health problem as it remains a leading cause of 
cancer-related death among women worldwide (Bray et al., 2018). Several factors 
have been reported to increase BC risk, however, disease etiology is still not fully 
understood (Subramani & Lakshmanaswamy, 2017). Recent advances have enabled 
a better knowledge about BC heterogeneity and its variability in clinical outcome 
(Cardoso et al., 2016; Malhotra et al., 2010; Sørlie et al., 2001). Nevertheless, despite 
the progresses made in early diagnosis, treatment and patient survival, BC 
management still constitutes a major challenge (Coleman et al., 2008; Torre et al., 
2015). Therefore, the identification of more effective biomarkers that may help predict 
tumor behavior, as well as guide therapy, is an important unmet need in this disease. 
Most cells cannot divide indefinitely due to a powerful tumor suppressor process 
known as cellular senescence (Shay, 2003; Wright et al., 1989). By contrast, cancer 
cells can overcome senescence (M1), and other independent state called crisis (M2). 
Telomeres’ length plays a crucial role in timing and establishing the entrance of cancer 
cells at both states and, by lengthening their telomeres they can emerge from crisis 
becoming immortal. This unlimited self-renewal capacity constitutes one of the 
hallmarks of cancer, being this process mainly dependent on telomerase reactivation 
through human telomerase reverse transcriptase expression (hTERT) in BC (Hanahan 
& Weinberg, 2011; Kulić et al., 2016). Thus, as its activity is absent in most normal 
somatic tissues, telomerase and its regulatory mechanisms have been considered 
attractive BC biomarkers with relevant implications in clinical practice (Poremba et al., 
2002; Rivenbark et al., 2013; Shay et al., 1991).  
hTERT regulation in cancer is complex, and although several regulatory mechanisms 
of hTERT have been associated with increased hTERT expression and telomerase 
activity in BC, the understanding of the mechanisms behind telomerase reactivation is 
still unclear. For instance, hTERT amplifications and hTERT polymorphisms were 
reported to be associated with poor clinical outcome in breast carcinoma (Gay-Bellile 
et al., 2017; Zhang et al., 2000). By contrast, the highly recurrent hTERT promoter 
mutations are usually absent or rarely observed in BC, and thus, it is thought that its 
impact on hTERT regulation is not relevant in BC (Gay-Bellile et al., 2017; Killela et 
al., 2013; Shimoi et al., 2018). Although it is not common, in the present study, we 
detected the C228T mutation in the MDA-MB-231 cell line (Table 3.6). Interestingly, 
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this cell line express more hTERT than the MCF-7 cell line (Figure 3.5B), which is wild-
type for both TERTpMut. Epigenetic mechanisms such as hTERT-targeting miRNAs 
and histone modifications have been identified as key regulators of hTERT (Hrdlickova 
et al., 2014). Additionally, the hypermethylation of a specific region of hTERT 
promoter, termed TERT Hypermethylated Oncological Region (THOR) was recently 
reported as an epigenetic mechanism associated with hTERT upregulation in cancer 
(Castelo-Branco et al., 2013; Faleiro, Apolónio, et al., 2017). However, its precise 
contribution in hTERT gene regulation, as well as its clinical value as a biomarker for 
BC has never been studied. 
Therefore, in this project we aimed to evaluate the role of THOR as a biomarker for 
BC, uncover the mechanism by which THOR may contribute for hTERT upregulation 
in this disease, and also investigate new players in breast tumorigenesis and identify 
other potential biomarkers based on DNA methylation alterations observed in BC.  
In Chapter 2 we described THOR as a candidate clinical biomarker for BC. We found 
that THOR is hypermethylated in malignant breast tissue when compared to benign 
tissue (40.23% vs. 12.81%, Figure 2.4B), distinguishing cancer from normal tissue 
from the earliest stage of disease (AUC > 0.9574; p<0.0001). This finding points THOR 
hypermethylation as an early event in BC tumorigenesis. As previously reported for 
other cancer types (Castelo-Branco et al., 2016; Faleiro, Apolónio, et al., 2017; Leao 
et al., 2019), we demonstrate once again its potential to be used in the clinical setting, 
in particular as a cancer screening tool or early diagnostic biomarker for BC. Indeed, 
several research efforts have been made to identify more robust biomarkers able to 
detect BC at a pre-clinical stage, however, so far the disease screening is limited to 
breast mammography (Ludwig & Weinstein, 2005; Sauter, 2017; Tanos & Thierry, 
2018). 
Surprisingly, when we compared THOR methylation status with the pre-operative 
values of CA 15-3 and CEA tumor markers, 79% of patients diagnosed with stage I of 
disease had THOR hypermethylated, whereas only 15% and 20% of those patients 
had pathological values (above reference value) of CA 15-3 and CEA, respectively 
(Figure 2.8). Therefore, despite in the present study THOR has been assessed in 
tumor tissue, THOR status adds valuable information for those patients, since it 
revealed a higher sensitivity and specificity than the serum-biomarkers CA 15-3 and 
CEA (Khatcheressian et al., 2013). Hence, for future application in a routine follow-up 
context, THOR methylation status could be determined in a non-invasive manner 
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through analysis of circulating cell-free DNA or circulating tumor cells (CTCs) using 
blood samples. Indeed, non-invasive tests has been attracting much attention, and so 
far, several studies have reported that the analysis of tumor cells or DNA released 
from them in the bloodstream constitute a great promise to detect and monitor BC 
treatment (Bidard et al., 2018; Fackler et al., 2014; Tanos & Thierry, 2018). For 
instance, CTCs counts have shown to add significant prognostic value in early breast 
cancer patients, despite the paucity and difficulty in isolating CTCs from blood (Bidard 
et al., 2018). Also, the detection of specific DNA methylation patterns in circulating 
tumor DNA  demonstrated to be a robust assay to detect advanced BC and monitor 
tumor burden in patients with metastatic BC (Fackler et al., 2014; Widschwendter et 
al., 2017). Nevertheless, these early screening tests still require further validation. By 
contrast, for colorectal cancer, is already commercially available a blood screening 
test based on the detection of methylated Septin9, the Epi proColon® (Epigenomics 
AG Corporation, Berlin, Germany) (Tanos & Thierry, 2018). Therefore, as DNA 
methylation marks can be determined from blood samples and may anticipate BC 
detection (Bidard et al., 2018; Tanos & Thierry, 2018), additional studies should be 
performed to evaluate the opportunity to develop a liquid biopsy tool based on THOR 
methylation status. 
In previous studies THOR methylation revealed to be a dynamic process, increasing 
from lower to higher tumor grades and stages, predicting as well clinical outcome 
(Castelo-Branco et al., 2013, 2016). By contrast, in the present study THOR 
hypermethylation has not shown any association with either more advanced stages or 
other clinico-pathological features, such as grade, tumor size and hormone receptor 
status, with the exception of HER2 status (Table 2.3). Interestingly, the HER2- positive 
tumors showed the lowest THOR methylation levels (Figure 2.4D), which may be 
supported by the fact that an alternative mechanism of telomere lengthening may be 
at play (Subhawong et al., 2009; Xu et al., 2014). In addition, while in prostate cancer 
THOR methylation status was able to predict disease prognosis and aid in selecting 
patients that shoud undergo adjuvant treatment (Castelo-Branco et al., 2016), THOR 
status in breast cancer was not associated with clinical outcome (Table 2.2). 
Nevertheless, in the future it would be relevant to evaluate whether THOR could have 
prognostic potential and help in BC management. It is important to mention that the 
validation BC cohort used in the present study was randomly selected, and thus, in 
the upcoming studies, to properly evaluate the ability of THOR to predict disease 
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prognosis and survival, the selection of patients and samples should be more careful: 
for example, a larger number of samples containing follow-up data, recurrence and 
disease progression, should be included. 
Furthermore, it is important to highlight that a DNA methylation-based marker like 
THOR, constitutes a more robust approach than the quantification of telomerase 
activity or hTERT expression, as cancer biomarkers. First, because there are technical 
constraints regarding the TERT antibodies available and the complexity of obtaining 
good quality RNA from tissue samples (Ludyga et al., 2012; Wu et al., 2006). Second, 
as a malignant tumor sample is usually composed by a heterogeneous cell population, 
it may contain normal hTERT-expressing cells, such as activated lymphocytes, which 
can constitute a confounding factor for hTERT quantification in the tumor (Castelo-
Branco et al., 2013). 
Interestingly, we observed that THOR hypermethylation status is different across 
the previously studied cancers, analyzed using the same methods. Specifically, higher 
THOR hypermethylation levels were observed in breast when compared to prostate 
cancer, being those even lower in bladder cancer (Castelo-Branco et al., 2016; Leao 
et al., 2019). These findings may be related to the fact that hTERT promoter mutations 
are not likely to intervene in hTERT upregulation in breast and prostate carcinomas, 
whereas in bladder cancer, both mechanisms, THOR hypermethylation and hTERT 
promoter mutations were detected (Gay-Bellile et al., 2017; Leao et al., 2019). 
Therefore, this fact further suggests that THOR hypermethylation might be one of the 
most relevant mechanisms for hTERT regulation in BC. This point was further clarified 
in Chapter 3, where we demonstrate that unmethylated THOR is a repressive 
regulatory element of hTERT. 
According to the Roadmap Epigenomics database, THOR is localized in a repressive 
chromatin region, upstream to the hTERT core promoter. In normal breast cells, this 
region revealed to be unmethylated and enriched with repressive chromatin marks, in 
particular H3K27me3 histone mark (Figure 3.4). Moreover, the addition of 
unmethylated THOR to the hTERT core promoter induced a significant decrease in 
reporter gene expression (Figure 3.6B). These findings further evidence the repressive 
effects of THOR, suggesting that its hypermethylation during breast carcinogenesis 
may promote constitutive hTERT transcription and telomerase activation in BC.  
The results mentioned above, contradict the central dogma of promoter methylation, 
which is often associated to gene silencing (Bert et al., 2013). Indeed, despite the 
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complexity associated with hTERT regulation in cancer, several studies have reported 
that hTERT promoter methylation plays an essential role in its transcription in 
telomerase-positive cells (Guilleret & Benhattar, 2004; Zinn et al., 2007). In addition, 
some studies have shown that treatment of cells with the demethylating agent 5-
azacitidine, led to hTERT downregulation and reduced telomerase activity (Zinn et al., 
2007). However, demethylating agents lead to genome-wide demethylation, and 
consequently, do not allow to properly evaluate the relationship between specific DNA 
methylation marks within hTERT promoter and hTERT transcription (Hilton et al., 
2015; Jones et al., 2016). Therefore, in the present study we intended to interrogate 
the causative effect of THOR methylation in hTERT gene expression using a targeted 
demethylation approach. We demonstrate that an adapted CRISPR-peptide-repeat-
based system fused with a catalytically inactive Cas9, dCas9, and TET1 demethylase 
enzyme enables significant THOR demethylation (Figure 3.9). Specifically, a decrease 
in methylation levels, from 15% to 70%, was achieved in several CpG sites within 
THOR region. Our results also reveal that the system used in this study was able to 
demethylate both, the CpG sites near to the gRNA-binding site and those located 200-
250 bp away from the target region (Figure 3.9A). These long-range demethylation 
effects were observed even when a single gRNA was used, which is in line with the 
previous observations in other DNA methylation editing studies (Morita et al., 2016; 
Xu et al., 2016). Surprisingly, the co-transfection using both gRNA5 and gRNA7 did 
not enhance the demethylation activity observed within THOR region when compared 
to the single transfection of gRNA7 (Figure 3.9). Although the gRNAs tested have 
shown significant demethylation within THOR region, in contrast to all the negative 
controls (Figure 3.9), hTERT mRNA levels were not significantly reduce (Figure 3.10).  
As previously mentioned, it is thought that promoter methylation may lead to gene 
transcriptional control by preventing the binding of transcriptional factors or through 
chromatin remodeling (Bert et al., 2013; Liu et al., 2016). Based on this, THOR region 
may act as a cis-regulatory element where its hypermethylation prevents the binding 
of transcriptional repressors, such as MZF-2 and WT1, which are known to have 
binding sites within THOR (Avin et al., 2016; Fujimoto et al., 2000; Kyo et al., 2008). 
In this context, since not all the CpG sites within THOR were demethylated with the 
same efficiency, the observed demethylation may not be sufficient to allow the binding 
of transcriptional repressors. Alternatively, even in case of binding, it may not have 
been enough to suppress the activating effects caused by the unmethylated hTERT 
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core promoter, where several transcriptional activators can bind, and by CpG 
methylation within the hTERT first exon, which is known to block CTCF-binding and 
induce hTERT transcriptional activation (Kyo & Inoue, 2002; Zinn et al., 2007). 
Furthermore, another hypothesis is related with the fact that THOR hypermethylation 
can lead to the recruitment of methylated CpG-dependent transcriptional activators. 
For example, the Krüppel-like factor 4 (KLF4) preferentially binds to methylated CpG 
sites, and its binding was reported to induce chromatin remodelling and transcriptional 
activation of their target genes (Wan et al., 2017). Also, DNA methylation within THOR 
may interfere with the looping function of chromatin architecture proteins, bringing 
trans-acting enhancers distally located to the hTERT gene promoter. Indeed, the CpG 
methylation of CTCF-binding sites demonstrated to affect their insulator function, 
increasing the interaction between enhancers and genes in the neighbouring loop, and 
thus causing alterations in their gene expression levels (Kim, Yu, & Kaang, 2015; Liu 
et al., 2016). Furthermore, it is important to mention, that some genomic regions are 
harder to be accessed by the dCas9-guided system components, and therefore 
achieving an efficient targeted DNA modification may be more challenging (Choudhury 
et al., 2016; Xu et al., 2016). 
In the future, several studies should be performed in order to fully elucidate the precise 
mechanism by which THOR hypermethylation affects hTERT transcription in breast 
cancer. First, other gRNAs targeting THOR should be tested in order to evaluate their 
demethylation efficiency and eventual impact on hTERT expression levels. 
Specifically, not only hTERT mRNA levels should be quantified, but also hTERT 
protein and telomerase activity should be measured. Second, it would be relevant to 
identify THOR-binding transcriptional repressors by ChIP-Seq, since it will help to 
clarify whether their binding is hampered by THOR hypermethylation. Third, as our 
results revealed that BT-20 breast cancer cell line exhibit lower levels of THOR 
methylation, along with almost absent hTERT expression when compared to the other 
BC cell lines (Figure 3.5), it would be interesting to evaluate whether targeted THOR 
methylation could increase hTERT expression levels on this cell line. This could be 
achieved by targeting dCas9-DNMT3A constructs to THOR region. Furthermore, it 
was recently reported targeted DNA demethylation using a novel CRISPR/dCas9-
based system, which instead of being fused with TET1 demethylase enzyme, 
promotes passive DNA demethylation by blocking the recruitment of DNMT1 to DNA 
target sites (Lu et al., 2019). Therefore, it would be interesting to test whether this new 
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approach of demethylation is more effective to induce THOR demethylation. Other 
intriguing question, is how DNMTs are specifically targeted to THOR region in cancer, 
however, the mechanisms behind the recruitment of epigenetic machinery to specific 
genomic regions still constitutes an epigenetic mystery (Hervouet et al., 2018; Portela 
& Esteller, 2010). 
The efficacy and accuracy, of CRISPR technology for epigenome editing has been 
notorious, being this proven by the diversity of studies that have emerged in a short 
period of time. Indeed, in vivo manipulation of targeted DNA modifications has already 
been successfully reported, and has relevant clinical implications (Liu et al., 2016; 
Morita et al., 2016). Also, in the present study, despite required validation studies, the 
in vivo pilot study evidenced that cells pre-transfected with the CRISPR-peptide-
dCas9-TET1-based system tend to grow slowly and form smaller tumors in mice, when 
compared to negative controls (Figure 3.11). These observations, although not 
conclusive, suggest that the in vivo application of this system should be tested, since 
DNA demethylation of THOR may affect self-renewal potential of cancer cells, as wells 
as other cancer gene pathways, thus constituting a potential therapeutic target for BC 
and for other telomerase-dependent cancers. Furthermore, as we demonstrated that 
TNBC has THOR hypermethylated, targeted THOR demethylation may constitute a 
new approach to improve the treatment efficacy and patients' survival with this BC 
subtype, which is usually aggressive. Also, the development of a targeted epigenetic 
therapy will allow to overcome the pleiotropic effects of demethylating agents, which 
although being approved or in clinical trials for some malignancies, holds risk of side 
effects in therapeutic use (Jones et al., 2016). Moreover, taking into account the tumor 
heterogeneity that characterizes breast cancer, which is strongly associated with 
treatment resistance, it is extremely important to explore new therapeutic strategies 
and drug-targets to overcome this reality (Turashvili & Brogi, 2017). Based on this, 
CRISPR-dCas9 approaches for epigenome editing offer new opportunities in cancer 
therapeutic applications. 
As previously stated, promoter DNA methylation plays a crucial role in carcinogenesis. 
However, its impact on aberrant gene expression in breast cancer remains poorly 
understood. Therefore, in the last chapter of this thesis, it is reported a genome-wide 
DNA methylation study, where novel players in breast tumorigenesis and potential 
candidate DNA methylation-based markers were identified.  
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Specifically, using the breast invasive carcinoma cohort from TCGA, we identified 368 
individual CpG sites that were differentially methylated between tumor and normal 
breast tissue (Figure 4.1). Hypermethylated CpGs were overrepresented in tumor 
tissue and were found predominantly (56%) in upstream promoter regions, whi le 
hypomethylated CpG sites were found primarily in the gene body (66%). This finding 
is in line with the previous studies in which promoter hypermethylation has been 
associated with silencing of tumor suppressor genes in breast cancer (Shargh et al., 
2014; Zhu et al., 2015). Expression analysis revealed that 209 of the 368 differentially-
methylated CpGs were located in 164 genes that were differently expressed between 
normal and breast tumor tissue (Figure 4.2). Interestingly, both positive and negative 
methylation-expression correlations were observed, being those predominantly 
negative (70%) for promoter CpG sites and positive (74%) for CpG sites within the 
gene body. These findings further support the results obtained by Fleischer et al., in 
which promoter hypermethylation was mostly correlated with gene repression, and 
gene body hypermethylation with gene upregulation (Fleischer et al., 2014). Functional 
enrichment analysis revealed that genes positively correlated were enriched for 
homeobox genes, while the negatively correlated ones were enriched for 
transcriptional factors and cell differentiation genes (Figure 4.2D and Supplementary 
Table 4.2). Nevertheless, further studies are needed to investigate the role of DNA 
methylation in the regulation of this class of genes. 
Among these differentially-methylated and differentially-expressed genes we identified 
7 genes (bottom genes) that had not previously been studied in any cancer type. 
Intriguingly, all of the CpG sites correspondent to those 7 genes, were able to 
accurately distinguish breast cancer tissue from normal tissue (AUC>0.8 and 
p<0.0001, Table 4.1), thus evidencing their diagnostic value. Furthermore, 3 out of 7 
genes, PRAC2, TDRD10 and TMEM132C, contained CpG sites that were able to 
predict breast cancer survival, particularly in estrogen-receptor (ER)-positive patients 
(Figure 4.4). Therefore, these data suggest that these CpG sites have both diagnostic 
and prognostic potential to be used in BC clinical practice.  
Regarding the biological role of their target genes in breast carcinogenesis, PRCA2 is 
suggested to act as an oncogene, since it is upregulated in tumor tissue and the 
methylation of its associated CpG site (cg12374721) was positively correlated with 
gene expression levels. Therefore, as previously described in chapter 3 for THOR 
hypermethylation, the gain of methylation in this CpG site may contribute to PRAC2 
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transcriptional activation by blocking the binding of transcriptional repressors (Bert et 
al., 2013). By contrast, as TDRD10 and TMEM132C, are both downregulated in breast 
tumor tissue when compared to normal tissue and the methylation levels of their CpG 
sites were negatively correlated with gene expression, a tumor suppressor function is 
suggested for those genes. Nevertheless, in the future, their biological function in 
breast carcinogenesis should be addressed. For instance, it would be relevant to 
evaluate whether these genes affect cell proliferation and viability, cell contact 
inhibition, and the acquisition of anchorage-independent growth potential in vitro. In 
addition, if justifiable, the ability to form tumors when injected into NOD/SCID mice 
should also be assessed, since it is a useful indicator of the oncogenic potential of a 
gene (Alvarez, Barisone, & Diaz, 2014; Rampersad, 2012). Furthermore, targeted 
DNA demethylation experiments, as described in Chapter 3, could be performed to 
further evaluate the role of DNA methylation in the transcription control of those genes.  
Moreover, a pan-cancer analysis confirmed differential expression of these genes 
together with diagnostic and prognostic value of their respective CpG sites in other 
cancer types available at TCGA. Therefore, these three novel DNA methylation-gene 
candidate biomarkers are promising diagnostic and prognostic markers in breast 
cancer as well as in other cancer types. Therefore, future validation studies should be 
performed in order to confirm their clinical value.  
 
 
5.2 Concluding Remarks 
 
DNA methylation alterations have emerged as a research area of crucial relevance in 
breast cancer development, representing an asset for future usage as possible 
diagnostic and therapeutic applications in breast cancer.  
In this study, it is demonstrated that a hypermethylated region within hTERT promoter, 
THOR, constitutes an epigenetic mechanism of hTERT regulation, which has relevant 
implications for breast cancer clinical practice. Particularly, THOR hypermethylation 
represents a potential candidate biomarker for breast cancer screening and diagnostic 
in biopsies. Importantly, THOR may constitute an opportunity to develop a non-
invasive test for breast cancer screening and to help in routine follow-up. 
Nevertheless, further studies are required to elucidate this hypothesis, and also their 
value as a prognostic tool. 
Chapter 5.                                                          
168 
 
The results reported in this thesis evidence that THOR acts as a repressive regulatory 
element of hTERT, and that its hypermethylation might be one of the most relevant 
mechanisms for hTERT upregulation in breast cancer. Using an adapted CRISPR-
peptide-repeat-based system we achieved targeted THOR demethylation, although 
hTERT mRNA expression levels were not significantly affected. Though, more 
extensive research is required to fully unravel the molecular mechanism behind THOR 
hypermethylation and hTERT transcription activation in breast cancer. Furthermore, 
as DNA demethylation of THOR may suppress self-renewal potential of cancer cells, 
leading to growth arrest, it might constitute a promising therapeutic target for breast 
cancer, as well as for other telomerase-dependent cancers. 
Also, this study identified novel DNA methylation markers, of which three CpG sites 
located on the following genes PRAC2, TDRD10 and TMEM132C shown promise as 
diagnostic and prognostic markers in breast cancer and in other cancer types. 
Therefore, future validation studies should be performed in order to confirm their 
clinical value.  
Overall, this study highlights the importance of specific DNA methylation marks in 
breast cancer, providing key insights into possible mechanisms regarding the way 
hypermethylated promoter regions can control gene transcription and, more 
importantly, their potential applications in the clinical setting. 
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